<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000024.pub4" GROUP_ID="STROKE" ID="799599072216554010" MERGED_FROM="" MODIFIED="2015-03-10 10:06:58 +0000" MODIFIED_BY="Hazel Fraser" REVIEW_NO="00030001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-03-10 10:06:58 +0000" MODIFIED_BY="Hazel Fraser">
<TITLE>Anticoagulants for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2015-03-10 10:06:58 +0000" MODIFIED_BY="Hazel Fraser"><PERSON ID="8089" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>AG</MIDDLE_INITIALS><LAST_NAME>Sandercock</LAST_NAME><EMAIL_1>peter.sandercock@ed.ac.uk</EMAIL_1><URL>http://www.dcn.ed.ac.uk/csrg/</URL><ADDRESS><DEPARTMENT>Centre for Clinical Brain Sciences (CCBS)</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>The Chancellor's Building</ADDRESS_1><ADDRESS_2>49 Little France Crescent</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH16 4SB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 465 9572</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-03-10 10:06:58 +0000" MODIFIED_BY="Hazel Fraser"><PERSON ID="8089" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>AG</MIDDLE_INITIALS><LAST_NAME>Sandercock</LAST_NAME><EMAIL_1>peter.sandercock@ed.ac.uk</EMAIL_1><URL>http://www.dcn.ed.ac.uk/csrg/</URL><ADDRESS><DEPARTMENT>Centre for Clinical Brain Sciences (CCBS)</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>The Chancellor's Building</ADDRESS_1><ADDRESS_2>49 Little France Crescent</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH16 4SB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 465 9572</PHONE_1></ADDRESS></PERSON><PERSON ID="16452" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carl</FIRST_NAME><LAST_NAME>Counsell</LAST_NAME><POSITION>Reader in Neurology</POSITION><EMAIL_1>carl.counsell@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Applied Health Sciences</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>Polwarth Building</ADDRESS_1><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1224 437119</PHONE_1><FAX_1>+44 1224 551188</FAX_1></ADDRESS></PERSON><PERSON ID="z1403181442106925985183433068966" ROLE="AUTHOR"><FIRST_NAME>Edward</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Kane</LAST_NAME><EMAIL_1>s0902930@sms.ed.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>University of Edinburgh</ORGANISATION><CITY>Edinburgh</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-11-10 09:21:52 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="10" MONTH="11" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1995"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1995"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-02-18 12:01:55 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-02-10 13:47:43 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="18" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>We have searched the literature for new relevant studies to June 2014. We identified one small new ongoing study, but did not identify any new studies for inclusion. We have reformatted and updated the text throughout</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-02-18 12:01:55 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="18" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>The conclusions are unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-20 11:02:43 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2014-11-20 11:02:43 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="9" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>Feedback on the previous version of this review had not been incorporated. This omission has now been rectified in this small revision to the 2008 update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-12 13:43:25 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Duplicate text in 'Updated' event of 11 January 2008 has been deleted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-07 15:51:17 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="17" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-11-07 15:51:21 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="11" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>New co-author: Ayeesha Kamal has replaced Gordon Gubitz. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-07 15:53:33 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="11" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>The searches have been updated to October 2007. Two trials (ARGIS-1 2004; Chaudhary 2002), with 201 participants, were included in this update, bringing the total number of trials to 24 involving 23,547 participants. The text has been extensively revised and updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Edinburgh</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Wellcome Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-03-09 10:41:54 +0000" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2015-03-09 10:06:14 +0000" MODIFIED_BY="Hazel Fraser">
<TITLE>Anticoagulants for acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2015-03-09 10:06:14 +0000" MODIFIED_BY="Hazel Fraser">
<P>Millions of people around the world have strokes every year. Most strokes take place when a blood clot blocks a blood vessel leading to the brain. Without a proper blood supply, the brain quickly suffers damage, which can be permanent. The damage from a stroke can cause arm or leg weakness, or difficulties with language or vision. Strokes are sometimes fatal, but will more often leave the survivor unable to do the things that they used to do. Because strokes are common and cause such damage, researchers are trying to find ways to get rid of the blood clot soon after the stroke happens. One way to do this is with blood thinning drugs called anticoagulants. If anticoagulants work, the bad effects of the stroke might be avoided. The main problem with anticoagulants is that they can cause bleeding, which can sometimes be very serious. This systematic review was designed to find out whether people treated with anticoagulants soon after having a stroke got better or not, and whether they had problems with bleeding. There is a lot of information in this systematic review - 23,748 people with stroke have been involved in 24 included randomised trials to answer this question. People treated with anticoagulants did not have less long-term disability, and experienced more bleeding. Anticoagulant treated patients had less chance of developing blood clots in their legs and in their lungs following their stroke, but these benefits were offset by the increased number of bleeds. This review did not provide any evidence that the early use of anticoagulants is of overall benefit to people with strokes caused by blood clots. More research is needed to find out if there are ways to select the people with stroke who will benefit from anticoagulants without suffering the bleeding complications.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-03-09 10:06:10 +0000" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2015-03-09 10:06:06 +0000" MODIFIED_BY="Hazel Fraser">
<P>Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Clot prevention with anticoagulants might improve outcomes if bleeding risks are low. This is an update of a Cochrane review first published in 1995, with recent updates in 2004 and 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-02-16 14:17:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>To assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) in people with acute presumed or confirmed ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-03-09 10:06:07 +0000" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (June 2014), the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Database of Systematic Reviews (CDSR), the Database of Reviews of Effects (DARE) and the Health Technology Assessment Database (HTA) (<I>The Cochrane Library</I> 2014 Issue 6), MEDLINE (2008 to June 2014) and EMBASE (2008 to June 2014). In addition, we searched ongoing trials registries and reference lists of relevant papers. For previous versions of this review, we searched the register of the Antithrombotic Trialists' (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-02-10 13:48:42 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in people with acute presumed or confirmed ischaemic stroke.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently selected trials for inclusion, assessed trial quality, and extracted the data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-03-09 10:06:08 +0000" MODIFIED_BY="Hazel Fraser">
<P>We included 24 trials involving 23,748 participants. The quality of the trials varied considerably. The anticoagulants tested were standard unfractionated heparin, low-molecular-weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Over 90% of the evidence relates to the effects of anticoagulant therapy initiated within the first 48 hours of onset. Based on 11 trials (22,776 participants) there was no evidence that anticoagulant therapy started within the first 14 days of stroke onset reduced the odds of death from all causes (odds ratio (OR) 1.05; 95% confidence interval (CI) 0.98 to 1.12) at the end of follow-up. Similarly, based on eight trials (22,125 participants), there was no evidence that early anticoagulation reduced the odds of being dead or dependent at the end of follow-up (OR 0.99; 95% CI 0.93 to 1.04). Although early anticoagulant therapy was associated with fewer recurrent ischaemic strokes (OR 0.76; 95% CI 0.65 to 0.88), it was also associated with an increase in symptomatic intracranial haemorrhages (OR 2.55; 95% CI 1.95 to 3.33). Similarly, early anticoagulation reduced the frequency of symptomatic pulmonary emboli (OR 0.60; 95% CI 0.44 to 0.81), but this benefit was offset by an increase in extracranial haemorrhages (OR 2.99; 95% CI 2.24 to 3.99).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-03-09 10:06:10 +0000" MODIFIED_BY="Hazel Fraser">
<P>Since the last version of the review, no new relevant studies have been published and so there is no additional information to change the conclusions. Early anticoagulant therapy is not associated with net short- or long-term benefit in people with acute ischaemic stroke. Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis and pulmonary embolism, but increased bleeding risk. The data do not support the routine use of any of the currently available anticoagulants in acute ischaemic stroke.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-03-09 10:41:54 +0000" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2015-03-09 10:06:21 +0000" MODIFIED_BY="Hazel Fraser">
<CONDITION MODIFIED="2015-03-09 10:06:15 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ischaemic stroke is usually caused by a blood clot blocking flow in an artery supplying parts of the brain and, in Western countries, is approximately 10 times more frequent than haemorrhagic stroke (<LINK REF="REF-Andersen-2009" TYPE="REFERENCE">Andersen 2009</LINK>). Stroke is the second most common cause of death in the world (<LINK REF="REF-Lozano-2012" TYPE="REFERENCE">Lozano 2012</LINK>) and the third most common cause of disability (<LINK REF="REF-Murray-2012" TYPE="REFERENCE">Murray 2012</LINK>). Globally, death and disability that result from stroke have been increasing in absolute numbers, with the greatest burden being in low and middle income countries (<LINK REF="REF-Feigin-2014" TYPE="REFERENCE">Feigin 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-02-18 12:42:57 +0000" MODIFIED_BY="Hazel Fraser">
<P>Anticoagulants are agents acting on the coagulation cascade to reduce fibrin polymerisation and thrombus formation and are distinct from thrombolytic and defibrinogenating agents. Agents included in this review include unfractionated heparin, low-molecular-weight heparins, heparinoids, oral vitamin K antagonists and specific thrombin inhibitors. The control was an inactive intervention, either placebo or no treatment, delivered along with the standard interventions of the respective healthcare systems.</P>
<P>Heparins are administered parenterally (intravenously or subcutaneously) and so have a sufficiently rapid onset to be used in the acute phase of ischaemic stroke whereas oral anticoagulants, such as vitamin K antagonists and direct thrombin inhibitors, have a slower onset of effect and may be of less use. Unfractionated heparin, a sulphated polysaccharide, acts by binding to antithrombin to inhibit factor Xa and deactivate thrombin. Important side-effects include thrombocytopenia and osteopenia. Low molecular weight heparins are depolymerised heparin fragments approximately one third the size of unfractionated heparin and act primarily to inhibit factor Xa. They have a longer half-life, greater bio-availability and more predictable anticoagulant effect than unfractionated heparin. Heparinoids are glycosaminoglycans whose components catalyse the effect of heparin co-factor 2 to inhibit thrombin. All heparins ultimately prevent fibrin formation and subsequent thrombosis.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-03-09 10:06:19 +0000" MODIFIED_BY="Hazel Fraser">
<P>Theoretically, early use of anticoagulants may, by reducing the propagation of a thrombus in an intracerebral artery, decrease the volume of infarcted cerebral tissue and so decrease the neurological deficit, risk of disability and death. Additionally, anticoagulants might inhibit the formation of new arterial and venous thromboses and so reduce the risk of early recurrent thromboembolic stroke, deep vein thrombosis and pulmonary embolism. However, these benefits could be offset by the possibility that anticoagulant therapy increases risk of intracranial and extracranial haemorrhage.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-03-09 10:06:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>This is an update of a Cochrane review first published in 1995, and most recently updated in 2008, encompassing all of the randomised trials of anticoagulants versus control in people with acute presumed or confirmed ischaemic stroke. The aim is to establish the balance of risk and benefit of early anticoagulation for acute ischaemic stroke.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-02-16 14:17:51 +0000" MODIFIED_BY="Hazel Fraser">
<P>To assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) in people with acute presumed or confirmed ischaemic stroke. Our hypotheses were that, compared with a policy of avoiding their use, early anticoagulation would be associated with:</P>
<OL>
<LI>a reduced risk of being dead or dependent in activities of daily living a few months after stroke onset;</LI>
<LI>a reduced risk of early recurrent ischaemic stroke;</LI>
<LI>an increased risk of symptomatic intracranial and extracranial haemorrhage; and</LI>
<LI>a reduced risk of deep vein thrombosis and pulmonary embolism.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2015-03-09 10:07:00 +0000" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2015-03-09 10:06:27 +0000" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES MODIFIED="2015-02-16 14:19:04 +0000" MODIFIED_BY="Hazel Fraser">
<P>We sought all unconfounded, truly randomised trials in which early treatment with anticoagulants was compared with control in people with acute presumed or confirmed ischaemic stroke. People with ischaemic stroke due to cerebral venous thrombosis were not specifically included in these trials, and so are not represented in this review. People with transient ischaemic attacks (TIAs) are also not included in this review. We did not include trials in which allocation to treatment or control group was not truly random or where allocation was not adequately concealed (e.g. allocation by alternation, date of birth, hospital number, day of the week, or open random number list), since foreknowledge of treatment allocation could lead to biased treatment allocation, and thereby overestimate the treatment effect by up to 30% (<LINK REF="REF-Odgaard_x002d_Jensen-2011" TYPE="REFERENCE">Odgaard-Jensen 2011</LINK>). We included trials if it was unclear whether the method of randomisation provided adequate concealment of allocation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-02-16 14:25:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>This review was confined to the early treatment of acute ischaemic stroke, and therefore we excluded the following types of trial: those that randomised participants more than 14 days after stroke onset, those that included only people with TIAs, and those that only included people with intracerebral haemorrhage, confirmed by appropriate brain imaging before entry. We included trials in which the pathological type of stroke was not confirmed by scanning before entry, as the majority of such strokes are ischaemic, at least in the white population (<LINK REF="REF-Bamford-1990" TYPE="REFERENCE">Bamford 1990</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-02-09 16:25:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>Anticoagulants are broadly defined as agents that act on the coagulation cascade to exert an anticoagulant effect, excluding thrombolytic agents (such as alteplase ) and defibrinogenating agents (such as ancrod). The use of thrombolytic agents in acute ischaemic stroke is the subject of a separate Cochrane review (<LINK REF="REF-Wardlaw-2014" TYPE="REFERENCE">Wardlaw 2014</LINK>), as is the use of fibrinogen depleting agents (<LINK REF="REF-Hao-2012" TYPE="REFERENCE">Hao 2012</LINK>). We included the following anticoagulants in this review: subcutaneous and intravenous standard unfractionated heparin, low-molecular-weight heparins, subcutaneous and intravenous heparinoids, oral vitamin K antagonists, factor Xa inhibitors and specific thrombin inhibitors.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-03-09 10:06:27 +0000" MODIFIED_BY="Hazel Fraser">
<P>For each trial, we identified the number of participants originally randomly allocated to each treatment and control group. In both groups, we sought outcome information regarding the number of participants who met the following outcomes.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-02-16 14:27:20 +0000" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>Death or dependency (i.e. people who were either dead, or dependent on help from other people for their activities of daily living), at least one month after their stroke. This minimum interval was used to allow time for recovery from the initial stroke. Comparable definitions of dependency were used in all of the trials assessed in this review.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-03-09 10:06:27 +0000" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>Participants who died from any cause during the scheduled treatment period (generally shorter than the scheduled follow-up period).</LI>
<LI>Participants who died from any cause during the scheduled follow-up period (greater than one month after their stroke).</LI>
<LI>Participants with objective evidence of deep vein thrombosis detected by the systematic use of imaging techniques such as iodine 125 fibrinogen scanning (I-125 scan), ultrasound of the leg, plethysmography, or X-ray contrast venography in all participants during the scheduled treatment period and during scheduled follow up. These methods therefore detected clinically silent deep vein thrombosis as well as confirming or refuting the diagnosis in participants with clinical features suggestive of deep vein thrombosis. The outcome was therefore 'symptomatic or asymptomatic deep vein thrombosis.' Screening of participants by clinical observation alone was not considered adequate.</LI>
<LI>Participants with at least one confirmed symptomatic pulmonary embolus diagnosed during life, or at autopsy (symptomatic or not) within the scheduled treatment period and during scheduled follow-up.</LI>
<LI>Particpants with recurrent stroke during the treatment period and during follow-up, which was either definitely ischaemic (haemorrhage excluded by brain imaging or autopsy), or of unknown type (no brain imaging or autopsy performed).</LI>
<LI>Participants with symptomatic intracranial (intra or extracerebral) haemorrhage, including symptomatic haemorrhagic transformation of the cerebral infarct, during the scheduled treatment period and during follow-up. The haemorrhage must have been confirmed by appropriate brain imaging after clinical deterioration, or by autopsy.</LI>
<LI>Participants with any recurrent stroke or symptomatic intracranial haemorrhage during the treatment period or during long-term follow up (as previously defined).</LI>
<LI>Participants with any major extracranial haemorrhage during the scheduled treatment period. The definition of major haemorrhage was usually taken from the original article but if none was given it was defined as any fatal bleed, or bleeding severe enough to require transfusion or operation.</LI>
</OL>
<P>Although we sought trials that reported the primary outcome (dead or dependent at least one month after stroke), we also included data from trials that only reported data on our secondary outcomes.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-03-09 10:06:53 +0000" MODIFIED_BY="Hazel Fraser">
<P>See the 'Specialized register' section in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A> module. We searched for trials in all languages and arranged translation of relevant papers published in languages other than English .</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-03-09 10:06:53 +0000" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (last searched June 2014) and the following bibliographic databases and trials registers:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2014 Issue 6) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>Cochrane Database of Systematic Reviews (CDSR) (<I>The Cochrane Library</I> 2014 Issue 6) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>Database of Reviews of Effects (DARE) (<I>The Cochrane Library</I> 2014 Issue 6) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>Health Technology Assessment Database (HTA) (<I>The Cochrane Library</I> 2014 Issue 6) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>MEDLINE (Ovid; 2008 to June 2014) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>EMBASE (Ovid; 2008 to June 2014) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI>
<LI>ClinicalTrials.gov (https://clinicaltrials.gov; searched June 2014) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>);</LI>
<LI>Internet Stroke Center Stroke Trials Registry (<A HREF="http://www.strokecenter.org/trials/">http://www.strokecenter.org/trials/</A>; searched June 2014) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>);</LI>
<LI>ISRCTN Registry (http://www.isrctn.com/; searched June 2014) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
<P>Using a comprehensive search strategy the Cochrane Stroke Group Trials Search Co-ordinator has already completed a retrospective search of MEDLINE and EMBASE for all stroke trials to January 2008 and added all relevant trials to the Cochrane Stroke Group Trials Register. To avoid duplication of effort we have limited the search of these two databases from January 2008 onwards.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-02-10 14:08:30 +0000" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>We scanned the reference lists of all relevant papers.</LI>
<LI>For previous versions of this review:</LI>
<OL>
<LI>we contacted the following anticoagulant manufacturers in an effort to identify unpublished trials (last contact 1999): Alfa Wasserman (parnaparin and dermatan sulphate), Kabi (dalteparin), Knoll (reviparin), Leo (tinzaparin), Mediolanum (dermatan sulphate), Mitsubishi Chemical (argatroban/MD-805), Novo (tinzaparin), Organon (danaparoid), Rhone-Poulenc Rorer (enoxaparin), Sandoz (Sandoz LMWH), Sanofi Winthrop (nadroparin and CY 222);</LI>
<LI>we consulted a comprehensive guide to pharmaceutical development in the field of stroke (MedStrategy 1995) but have not updated the search, as relevant trials contained within it are in the Cochrane Stroke Group Trials Register;</LI>
<LI>we searched the trials register held by the Antithrombotic Trialists' (ATT) Collaboration in August 1998, but this is no longer available and relevant trials from the register are now in the Cochrane Stroke Group Trials Register.</LI>
</OL>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-03-09 10:07:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>For this update EK performed the searches following advice from Brenda Thomas (Cochrane Stroke Group Trials Search Co-ordinator). EK and PS then independently screened all the titles and abstracts of the identified references and excluded obviously irrelevant studies. EK obtained the full-text articles of the remaining studies and both EK and PS independently assessed these for inclusion or exclusion. We resolved any disagreements by discussion.<BR/>
</P>
<STUDY_SELECTION MODIFIED="2015-03-09 10:07:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>Two review authors (PS &amp; CC, for the trials included in the first version of this review; PS &amp; Gordon Gubitz for the proceeding two updates following the original review, Ayeesha Kamal &amp; PS for the most recent update and PS &amp; EK for this review) independently selected trials for inclusion in the review. We resolved disagreements through discussion. The same two review authors assessed the methodological quality of each trial.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-02-18 12:43:43 +0000" MODIFIED_BY="Hazel Fraser">
<P>Two review authors independently extracted and cross-checked the data. We sought data on the number of participants with each outcome event, by allocated treatment group, irrespective of compliance, and whether or not the participant was subsequently deemed ineligible or otherwise excluded from treatment or follow-up, to allow an intention-to-treat (ITT) analysis. We also sought data on the use of brain imaging prior to randomisation, the delay from stroke onset to trial entry, the type of patients included, and the type of anticoagulant regimen used. If any of the above data were not available in the publications, we sought further information by correspondence with the trialists.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-02-18 12:43:48 +0000" MODIFIED_BY="Hazel Fraser">
<P>For the previous versions of this review, two authors assessed the methodological quality of each trial. We did not use a scoring system to assess trial quality, but simply recorded details of randomisation and concealment methods, blinding, if ITT analyses were possible from the published data (that is, if there were any exclusions from the trial after randomisation) and if any participants were lost to follow-up. We sought data on the number of participants with each outcome event, by allocated treatment group, irrespective of compliance, and whether or not the participant was subsequently deemed ineligible or otherwise excluded from treatment or follow-up, to allow an ITT analysis.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-02-16 14:50:25 +0000" MODIFIED_BY="Hazel Fraser">
<P>The results reported in the text are odds ratios (OR: that is, the ratio of the odds of an unfavourable outcome among treatment-allocated participants to the corresponding odds amongst controls), which we calculated using the Peto fixed-effect method (<LINK REF="REF-APT-1994" TYPE="REFERENCE">APT 1994</LINK>). We calculated the significance of any differences between ORs (in relation to subgroup analyses) using a standard method (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Where relevant, the absolute effects of treatment on each outcome are expressed as the number needed to treat to benefit (NNTB) i.e. to avoid one bad outcome event. For events that are adverse (such as intracranial haemorrhage), this is calculated as the number needed to treat to harm (NNTH). To calculate NNTBs or NNTHs, we used the NNT calculator at http://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp. This applies the point estimate of relative effect and its 95% confidence interval (CI), and then calculates the NNTB or NNTH for a specified control event rate.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-02-16 14:51:14 +0000" MODIFIED_BY="Hazel Fraser">
<P>All the included studies were trials in which individuals were randomised, and follow-up was generally to a prespecified and fixed time point, and all analyses were by ITT where possible (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>). For outcomes where more than one event could occur during follow-up, such as non-fatal recurrent stroke, we counted only the first event.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-02-18 12:43:53 +0000" MODIFIED_BY="Hazel Fraser">
<P>For some outcomes (such as deep vein thrombosis and any intracranial haemorrhage), ITT analyses were not possible because all participants did not have the relevant investigation performed to detect the event. In these analyses, we used the number of participants in each group who had the appropriate investigation as the denominator for the main analyses. However, if we found statistically significant results we also analysed best and worst case scenarios: the best-case scenario (with regards to treatment) assumed that none of the participants excluded from the analysis in the treatment group had an adverse outcome, whilst all those excluded from the control group did, and vice versa for the worst-case analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-02-16 14:53:16 +0000" MODIFIED_BY="Hazel Fraser">
<P>We tested for heterogeneity between trial results with the I² test. We used the method described in <LINK REF="REF-Bland-2003" TYPE="REFERENCE">Bland 2003</LINK> to test for interaction between the effect in a specified subgroup and the overall effect.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>We sought evidence of publication bias with funnel plots for three outcomes: deep vein thrombosis, death from all causes within the scheduled treatment period and death from all causes by the end of follow-up.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-02-18 13:12:33 +0000" MODIFIED_BY="Hazel Fraser">
<P>We used <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK> for the analyses, in which we grouped together trials of each type of anticoagulant (e.g. unfractionated heparin, low-molecular-weight heparins, heparinoids, oral vitamin K antagonists, thrombin inhibitors) to assess whether there were any significant differences between classes of anticoagulant agent. It should be noted that this was an indirect rather than a direct randomised comparison.</P>
<P>We also specified the following classification of anticoagulant dosing regimens.</P>
<OL>
<LI>Low fixed-dose anticoagulant, that is a dose intended to be sufficient for the prevention of deep vein thrombosis and pulmonary embolism.</LI>
<LI>Medium fixed-dose anticoagulant, that is a dose intended to have effects on the arterial circulation, but not enough to require monitoring.</LI>
<LI>Adjusted-dose anticoagulant, that is a dose adjusted by blood testing or body weight to meet a specific target.</LI>
</OL>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-02-10 14:09:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>For this update, we performed subgroup analyses of:</P>
<UL>
<LI>the type of anticoagulant agent used; and</LI>
<LI>the dose of anticoagulant used, applying the classification above.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-02-16 14:56:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>For this update, we performed the following sensitivity analyses, restricting analyses to:</P>
<UL>
<LI>trials in which the method of randomisation ensured adequate concealment of treatment allocation;</LI>
<LI>trials in which all participants were recruited within 48 hours of stroke onset; and</LI>
<LI>trials except <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, as this trial contained most of the data for the review.</LI>
</UL>
<P>In the previous version of this review we performed numerous sensitivity analyses to investigate whether the exclusion or inclusion of trials with particular characteristics would alter the overall conclusions. These characteristics included: trials that had intracerebral haemorrhages excluded by neuroimaging prior to trial entry, time from stroke onset (less than 48 hours versus more than 48 hours) to randomisation, concomitant unconfounded treatment with antiplatelet agents, trials in which stroke was of suspected cardioembolic origin versus non-cardioembolic origin, and trials that evaluated different anticoagulant doses. These analyses were not informative and we have excluded them from this updated review for brevity and clarity. In future updates of the review, we do not plan to repeat these analyses unless substantial new trial data had been added.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-03-09 10:08:59 +0000" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2015-03-09 10:07:40 +0000" MODIFIED_BY="Hazel Fraser">
<SEARCH_RESULTS MODIFIED="2015-03-09 10:07:06 +0000" MODIFIED_BY="Hazel Fraser">
<P>For this update we searched the Cochrane Stroke Group Trials Register and performed additional new comprehensive searches of The Cochrane Library databases, MEDLINE and EMBASE. After removal of duplicate records we screened the titles and abstracts of 8913 records from these electronic bibliographic databases and obtained the full text of six studies, all of which we excluded leaving no new trials for inclusion. The total number of included studies remains unchanged from the last update at 24 trials. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>We identified one new ongoing trial from searches of the trials registers (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-03-09 10:07:40 +0000" MODIFIED_BY="Hazel Fraser">
<P>We included 24 trials with a total of 23,748 participants in this review. Summary details of the trials are given in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table. Of the 24 included studies, one enrolled participants within 12 hours of stroke onset (<LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>), two enrolled participants within 24 hours of stroke onset (<LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK>; <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>), 10 enrolled participants within 48 hours of stroke onset (<LINK REF="STD-Cazzato-1989" TYPE="STUDY">Cazzato 1989</LINK>; <LINK REF="STD-CESG-1983" TYPE="STUDY">CESG 1983</LINK>; <LINK REF="STD-Duke-1983" TYPE="STUDY">Duke 1983</LINK>; <LINK REF="STD-Duke-1986" TYPE="STUDY">Duke 1986</LINK>; <LINK REF="STD-Elias-1990" TYPE="STUDY">Elias 1990</LINK>; <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>; <LINK REF="STD-Kwiecinski-1995" TYPE="STUDY">Kwiecinski 1995</LINK>; <LINK REF="STD-McCarthy-1977" TYPE="STUDY">McCarthy 1977</LINK>; <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>), and the rest enrolled participants within 14 days. The age of participants in the included studies ranged from 28 to 92 years. A significant proportion of participants were over 70 years old. For example, 61% of participants enrolled in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> were aged 70 or older. Most trials included slightly more males than females. Most trials excluded people thought to be at high risk of bleeding (e.g. clotting disorders, hepatic or renal failure). In addition, 10 trials excluded people with significant degrees of hypertension (generally diastolic pressures greater than 120 mmHg or systolic pressures greater than 180 mmHg), and nine trials excluded comatose people.</P>
<P>The scheduled period of anticoagulant treatment in the included trials was one to two weeks in 20 trials and one month in four trials. The anticoagulants used were:<BR/>
</P>
<UL>
<LI>standard unfractionated subcutaneous heparin (six trials);</LI>
<LI>standard unfractionated intravenous heparin (two trials);</LI>
<LI>low-molecular-weight heparins (eight trials: two dalteparin, two nadroparin, one tinzaparin, one fraxiparin, one parnaparin, and one CY 222);</LI>
<LI>subcutaneous heparinoid (two trials: one danaparoid and one mesoglycan);</LI>
<LI>intravenous heparinoid (one danaparoid trial);</LI>
<LI>oral vitamin K antagonists (two trials); and</LI>
<LI>thrombin inhibitors (three trials: two MD805 trials, one argatroban).</LI>
</UL>
<P>In the trials using oral vitamin K antagonists, heparin was given intravenously for the first few days to provide rapid anticoagulation (<LINK REF="STD-Marshall-1960" TYPE="STUDY">Marshall 1960</LINK>; <LINK REF="STD-NAT_x002d_COOP-1962" TYPE="STUDY">NAT-COOP 1962</LINK>). Three trials randomised between two doses of anticoagulant as well as control (<LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK>; <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>); for the main analyses in this review we combined the two anticoagulant groups for these trials.</P>
<P>Fifteen trials routinely performed a CT head scan in all patients to rule out haemorrhage before randomisation (<LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>; <LINK REF="STD-Cazzato-1989" TYPE="STUDY">Cazzato 1989</LINK>; <LINK REF="STD-CESG-1983" TYPE="STUDY">CESG 1983</LINK>; <LINK REF="STD-Duke-1986" TYPE="STUDY">Duke 1986</LINK>; <LINK REF="STD-Elias-1990" TYPE="STUDY">Elias 1990</LINK>; <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK>; <LINK REF="STD-Kwiecinski-1995" TYPE="STUDY">Kwiecinski 1995</LINK>; <LINK REF="STD-Pambianco-1995" TYPE="STUDY">Pambianco 1995</LINK>; <LINK REF="STD-Prins-1989" TYPE="STUDY">Prins 1989</LINK>; <LINK REF="STD-Sandset-1990" TYPE="STUDY">Sandset 1990</LINK>; <LINK REF="STD-Tazaki-1986" TYPE="STUDY">Tazaki 1986</LINK>; <LINK REF="STD-Tazaki-1992" TYPE="STUDY">Tazaki 1992</LINK>; <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>; <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>). Three trials performed CT in most patients (<LINK REF="STD-Duke-1983" TYPE="STUDY">Duke 1983</LINK>; <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>; <LINK REF="STD-Vissinger-1995" TYPE="STUDY">Vissinger 1995</LINK>): eighty-one per cent of participants in <LINK REF="STD-Duke-1983" TYPE="STUDY">Duke 1983</LINK> were scanned; in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, 67% were scanned before randomisation, and 29% after randomisation, so that overall, 96% of participants were scanned; in <LINK REF="STD-Vissinger-1995" TYPE="STUDY">Vissinger 1995</LINK>, 66% of participants were scanned, and the remainder had cerebral scintigraphy to exclude haemorrhage. Three trials performed almost no CT scans (<LINK REF="STD-McCarthy-1977" TYPE="STUDY">McCarthy 1977</LINK>; <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>; <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK>), and two trials were undertaken before CT scanning was introduced (<LINK REF="STD-Marshall-1960" TYPE="STUDY">Marshall 1960</LINK>; <LINK REF="STD-NAT_x002d_COOP-1962" TYPE="STUDY">NAT-COOP 1962</LINK>). It is therefore likely that some people with intracerebral haemorrhage were inadvertently included in the main analyses of this review. This may have biased the results against anticoagulation if the risks of anticoagulation are greater in those with intracerebral haemorrhage, although such a bias is unlikely given the relatively small numbers of people with intracerebral haemorrhage involved in these trials, and because <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> provided well over 80% of the overall data.</P>
<P>Two trials included only participants with presumed cardioembolic stroke (<LINK REF="STD-CESG-1983" TYPE="STUDY">CESG 1983</LINK>; <LINK REF="STD-NAT_x002d_COOP-1962" TYPE="STUDY">NAT-COOP 1962</LINK>). One trial enrolled a subset of people with atrial fibrillation (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>) and detailed information on the effect of heparin in this subgroup was reported in a paper published in 2001 (<LINK REF="REF-Saxena-2001" TYPE="REFERENCE">Saxena 2001</LINK>).</P>
<P>The duration of follow-up in the trials was generally short, although this was mainly a characteristic of the smaller trials, which contributed less to the overall analysis. Four trials in which the primary outcome of interest was deep vein thrombosis did not follow the participants beyond 14 days (<LINK REF="STD-Elias-1990" TYPE="STUDY">Elias 1990</LINK>; <LINK REF="STD-McCarthy-1977" TYPE="STUDY">McCarthy 1977</LINK>; <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK>; <LINK REF="STD-Prins-1989" TYPE="STUDY">Prins 1989</LINK>), and only 11 trials followed participants for longer than one month (<LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>; <LINK REF="STD-Chaudhary-2002" TYPE="STUDY">Chaudhary 2002</LINK>; <LINK REF="STD-Duke-1986" TYPE="STUDY">Duke 1986</LINK>; <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK>; <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>; <LINK REF="STD-Kwiecinski-1995" TYPE="STUDY">Kwiecinski 1995</LINK>; <LINK REF="STD-Marshall-1960" TYPE="STUDY">Marshall 1960</LINK>; <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>; <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>; <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>). This lack of long-term follow-up is a weakness of many of the smaller studies, as a significant proportion of deaths after one month could have been due to stroke-related thromboembolic events and might therefore have been prevented by early anticoagulation. Similarly, disability is best assessed when most of the recovery has taken place (that is between three to six months), rather than in the first week or so.</P>
<P>Relatively few trials assessed the clinically most important outcome of long-term functional status. Treatments that prevent death from stroke may lead to survival in a disabled state - an outcome considered by many to be worse than death. The composite outcome of 'dead or dependent at follow-up' is therefore the most important outcome in acute stroke trials. Eight trials assessed this composite outcome. These trials contain data from well over 90% of the participants included in this review, and evaluated the outcomes of death and dependency adequately (<LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>; <LINK REF="STD-Cazzato-1989" TYPE="STUDY">Cazzato 1989</LINK>; <LINK REF="STD-Chaudhary-2002" TYPE="STUDY">Chaudhary 2002</LINK>; <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK>; <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>; <LINK REF="STD-Kwiecinski-1995" TYPE="STUDY">Kwiecinski 1995</LINK>; <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>). Other important outcomes, including recurrent stroke or intracranial haemorrhage, were assessed but, once again, only by the more recent trials that included large numbers of participants. Quality of life assessments were not undertaken in any of these trials.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-02-16 15:10:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>We excluded 31 studies for a variety of reasons (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-02-18 12:44:05 +0000" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Randomisation</HEADING>
<P>There was marked variation in the quality of the trials. In 14 trials, the method of randomisation adequately prevented foreknowledge of treatment allocation. <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> used a central telephone randomisation service. <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK> used permuted blocks to generate a randomisation list controlled by the hospital pharmacy. Eight trials utilised numbered or coded containers administered sequentially to enrolled participants (<LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK>; <LINK REF="STD-Prins-1989" TYPE="STUDY">Prins 1989</LINK>; <LINK REF="STD-Sandset-1990" TYPE="STUDY">Sandset 1990</LINK>; <LINK REF="STD-Tazaki-1986" TYPE="STUDY">Tazaki 1986</LINK>; <LINK REF="STD-Tazaki-1992" TYPE="STUDY">Tazaki 1992</LINK>; <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>; <LINK REF="STD-Vissinger-1995" TYPE="STUDY">Vissinger 1995</LINK>). Three trials used random-number tables controlled by an independent party (<LINK REF="STD-Cazzato-1989" TYPE="STUDY">Cazzato 1989</LINK>; <LINK REF="STD-Duke-1983" TYPE="STUDY">Duke 1983</LINK>; <LINK REF="STD-Duke-1986" TYPE="STUDY">Duke 1986</LINK>). The 2:1 treatment-to-control allocation ratio in <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>, <LINK REF="STD-Tazaki-1986" TYPE="STUDY">Tazaki 1986</LINK>, <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>, and <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK> was deliberate. <LINK REF="STD-CESG-1983" TYPE="STUDY">CESG 1983</LINK> used opaque sequentially-numbered envelopes. The method of randomisation was unclear in nine trials. Six trials stated that sealed envelopes were used but in five of these it was not clear whether or not the envelopes were opaque and sequentially numbered (<LINK REF="STD-Elias-1990" TYPE="STUDY">Elias 1990</LINK>; <LINK REF="STD-McCarthy-1977" TYPE="STUDY">McCarthy 1977</LINK>; <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>; <LINK REF="STD-NAT_x002d_COOP-1962" TYPE="STUDY">NAT-COOP 1962</LINK>; <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK>). In <LINK REF="STD-Pambianco-1995" TYPE="STUDY">Pambianco 1995</LINK> the envelopes were not numbered. The exact method of randomisation was unknown in <LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>, <LINK REF="STD-Chaudhary-2002" TYPE="STUDY">Chaudhary 2002</LINK>, <LINK REF="STD-Kwiecinski-1995" TYPE="STUDY">Kwiecinski 1995</LINK>, and <LINK REF="STD-Marshall-1960" TYPE="STUDY">Marshall 1960</LINK>.</P>
</SUBSECTION>
<ALLOCATION MODIFIED="2015-02-16 15:28:37 +0000" MODIFIED_BY="Hazel Fraser">
<P>Allocation concealment for the following small trials was unclear: <LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>, <LINK REF="STD-Chaudhary-2002" TYPE="STUDY">Chaudhary 2002</LINK>, <LINK REF="STD-Elias-1990" TYPE="STUDY">Elias 1990</LINK>, <LINK REF="STD-Kwiecinski-1995" TYPE="STUDY">Kwiecinski 1995</LINK>, <LINK REF="STD-Marshall-1960" TYPE="STUDY">Marshall 1960</LINK>, <LINK REF="STD-McCarthy-1977" TYPE="STUDY">McCarthy 1977</LINK>, <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>, <LINK REF="STD-Pambianco-1995" TYPE="STUDY">Pambianco 1995</LINK>, and <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK>. In the remainder we deemed allocation concealment adequate, with low risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-02-18 12:44:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Adequate blinding may be important to reduce bias in the detection of deep vein thrombosis, pulmonary embolism, symptomatic intracranial haemorrhage, recurrent stroke and functional outcome. Twelve trials were double-blind, that is treatment allocation was concealed from participants, physicians and outcome assessors (<LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>; <LINK REF="STD-Duke-1983" TYPE="STUDY">Duke 1983</LINK>; <LINK REF="STD-Duke-1986" TYPE="STUDY">Duke 1986</LINK>; <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK>; <LINK REF="STD-Prins-1989" TYPE="STUDY">Prins 1989</LINK>; <LINK REF="STD-Sandset-1990" TYPE="STUDY">Sandset 1990</LINK>; <LINK REF="STD-Tazaki-1986" TYPE="STUDY">Tazaki 1986</LINK>; <LINK REF="STD-Tazaki-1992" TYPE="STUDY">Tazaki 1992</LINK>; <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>; <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>; <LINK REF="STD-Vissinger-1995" TYPE="STUDY">Vissinger 1995</LINK>), and in two other trials the assessment of deep vein thrombosis was made by radiologists blinded to treatment allocation (<LINK REF="STD-McCarthy-1977" TYPE="STUDY">McCarthy 1977</LINK>; <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>). <LINK REF="STD-Cazzato-1989" TYPE="STUDY">Cazzato 1989</LINK> had a blinded outcome assessor only. <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> was not designed as a blinded study. However, an analysis of 207 participants from the UK enrolled in the IST pilot study showed that, at the six-month follow-up, the majority of participants could not remember whether or not they had been treated, and so these participants were effectively 'blinded' (<LINK REF="REF-Lindley-1993" TYPE="REFERENCE">Lindley 1993</LINK>). In <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, follow-up data were collected by self-completed questionnaire mailed to the participant six months after randomisation, or by telephone interview by a person blinded to treatment allocation. The remainder of the trials did not appear to use any form of blinded assessment.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-02-16 15:32:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>In total, only 218 participants (0.9% overall) were reported to be excluded from analysis after randomisation or were lost to follow-up, with the vast majority of participants enrolled in studies in which an ITT analysis was performed. However, a number of participants in the smaller trials that did not report an ITT analysis may have been omitted from the analysis.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-02-16 15:32:22 +0000" MODIFIED_BY="Hazel Fraser">
<P>We were only able to assess this for <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> and did not have access to the original protocols of the remaining studies. There was no evidence of reporting bias for <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-02-16 16:10:38 +0000" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="4">Long-term use of antiplatelet agents</HEADING>
<P>In trials with follow-up, differences in the long-term use of antiplatelet treatment between the anticoagulant and control groups after hospital discharge may have biased the results, as antiplatelet treatment has been shown to reduce the risk of further vascular events by about 25% (<LINK REF="REF-ATC-2002" TYPE="REFERENCE">ATC 2002</LINK>). Aspirin was given to all survivors in <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>. Long-term treatment with aspirin was encouraged, but optional in several other trials, including <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, <LINK REF="STD-FISS_x002d_bis-1998" TYPE="STUDY">FISS-bis 1998</LINK> and <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>. Aspirin (81 mg to 325 mg) was also used in both arms of the <LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK> trial of the direct thrombin inhibitor argatroban.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Imbalance at baseline</HEADING>
<P>None of the trials reported significant imbalances in important baseline prognostic variables, although the small size of many suggests that they might only be ruling out substantial differences.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-03-09 10:08:59 +0000" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.1: Dead or dependent at end of follow up more than one month after randomisation</HEADING>
<P>Eight trials including randomised data from 22,125 participants (93.2% of participants included in the overall review) evaluated death and long-term disability. The degree of dependence was determined by noting whether the participants required help from other people for their activities of daily living at the time of final follow-up. Treatment with early anticoagulation was not associated with a significant reduction in the odds of being dead or dependent at final follow up (odds ratio (OR) 0.99; 95% confidence interval (CI) 0.93 to 1.04, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was, however, substantial heterogeneity of treatment effect (I² = 47.7%) between the different regimens included.</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">By the type of anticoagulant agent used</HEADING>
<P>The heterogeneity in the overall estimate was attributable to the non-significant trends to benefit associated with low-molecular-weight heparins and subcutaneous heparinoid regimens, and trend to harm associated with direct thrombin inhibitor (OR 1.28; 95% CI 0.62 to 2.62).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">By the dose of anticoagulant agent</HEADING>
<P>There was no statistically significant difference in death or dependence at final follow-up between trials in which low fixed-dose anticoagulants were compared with control (OR 1.00; 95% CI 0.92 to 1.08), or in which medium fixed-dose anticoagulants (OR 0.98; 95% CI 0.91 to 1.06) or adjusted-dose anticoagulants were compared with control (OR 0.95; 95% CI 0.75 to 1.20).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<P>Sensitivity analyses restricted to:</P>
<UL>
<LI>trials in which the method of randomisation ensured adequate concealment of treatment allocation showed that all of the trials evaluating death and dependence at final follow-up had adequate concealment of the randomisation process;</LI>
<LI>trials that restricted entry to the study to less than 48 hours of stroke onset showed that all trials evaluating death or dependence at final follow-up enrolled participants within 48 hours of stroke onset. Within <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> there was no evidence that the effect of treatment increased or decreased with increasing delay to randomisation up to 48 hours;</LI>
<LI>trials other than <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> (since it contained most of the data for the review) showed no apparent difference in the effect of treatment on death or dependence at final follow-up if data from IST were included (OR 0.99; 95% CI 0.94 to 1.05) or excluded (OR 0.92; 95% CI .78 to 1.09).</LI>
</UL>
<P>In a post-hoc sensitivity analysis to assess the impact of duration of follow-up on the estimate of effect for the primary outcome, exclusion of the trial with assessment of the primary outcome after only one month (<LINK REF="STD-Cazzato-1989" TYPE="STUDY">Cazzato 1989</LINK>) had no impact on the overall estimate of effect (OR 0.99; 95% CI 0.94, 1.04) or the degree of heterogeneity (I² = 55%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.2: Death from all causes during the scheduled treatment period</HEADING>
<P>Data from 21 trials, which included randomised data from 22,562 participants (95% of participants included in the review) were available for this outcome. Anticoagulants were not associated with a significant reduction in death at the end of the treatment period (OR 0.99; 95% CI 0.90 to 1.09, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was no significant heterogeneity (I² = 15.8%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.3: Death from all causes at final follow-up more than one month after randomisation</HEADING>
<P>Data were available for 11 trials, which included 22,776 participants (95.9 % of participants included in the overall review). Anticoagulants were not associated with any significant reduction in the odds of death at final follow-up of greater than one month (OR 1.05; 95% CI 0.98 to 1.12, I² = 28.5%, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.4: Deep vein thrombosis during the treatment period</HEADING>
<P>Ten trials, which included randomised data from 916 participants (only 3.9% of participants included in the overall review), sought to systematically determine the effect of anticoagulants on the occurrence of 'symptomatic or asymptomatic deep vein thrombosis' at the end of the treatment period, as detected by:<BR/>
</P>
<UL>
<LI>I-125 fibrinogen scanning (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Duke-1983">Duke 1983</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Elias-1990">Elias 1990</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-McCarthy-1977">McCarthy 1977</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-McCarthy-1986">McCarthy 1986</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Pince-1981">Pince 1981</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Prins-1989">Prins 1989</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Turpie-1987">Turpie 1987</A>);</LI>
<LI>B-mode and Doppler ultrasound (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Pambianco-1995">Pambianco 1995</A>); or</LI>
<LI>X-ray contrast venography (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Sandset-1990">Sandset 1990</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Vissinger-1995">Vissinger 1995</A>).</LI>
</UL>
<P>Despite the small numbers of participants studied, anticoagulation was associated with a highly significant reduction in the odds of deep vein thrombosis (OR 0.21; 95% CI 0.15 to 0.29, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), although the majority of deep vein thromboses detected were subclinical and asymptomatic. Assuming a control event rate of 15%, this would be equivalent to an NNTB of 9 (95% CI 9 to 10). To calculate NNTBs for different control event rates, we used the NNT calculator at <A HREF="http://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp">http://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp</A>. Fifteen participants (10 in the treatment group, five in the control group) did not have an adequate assessment of deep vein thrombosis and therefore we excluded them from this analysis, however even if we included these participants under a worst-case scenario the results did not change significantly (OR 0.23).</P>
<P>There was significant heterogeneity between the trial results (I² = 71.5%), which appeared to be due to three trials that did not show any clear effect of anticoagulation on the odds of deep vein thrombosis (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Pambianco-1995">Pambianco 1995</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Sandset-1990">Sandset 1990</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Vissinger-1995">Vissinger 1995</A>) and two trials that did (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Elias-1990">Elias 1990</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-McCarthy-1986">McCarthy 1986</A>). The three negative trials were the only ones that did not use I-125 fibrinogen scanning. One used ultrasound assessment (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Pambianco-1995">Pambianco 1995</A>) while the other two used venography (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Sandset-1990">Sandset 1990</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Vissinger-1995">Vissinger 1995</A>). In addition, in one of these trials, participants were randomised up to 14 days after their initial stroke (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Pambianco-1995">Pambianco 1995</A>) whereas the other trials all randomised participants within seven days. The two most positive trials had very small numbers of participants, with the resultant possibility that the results may have been due to chance. In addition, <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK> (the most positive trial) was poorly concealed, introducing another potential source of bias.</P>
<P>Sensitivity analyses showed that there was no significant difference in the reduction in deep vein thrombosis from the above result if the analysis was restricted to trials where the concealment of allocation was secure (OR 0.45; 95% CI 0.26 to 0.78) or to trials in which radiographic assessment was blinded (OR 0.21; 95% CI 0.15 to 0.29). One of the trials excluded from this review did provide data on the numbers of deep vein thromboses in the participants by allocated treatment group (1/19 heparin, 3/27 placebo), but inclusion of these results did not significantly alter the analysis (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1502161611272582509295914950303&amp;format=REVMAN#STD-Dahan-1986">Dahan 1986</A>). No trials systematically sought to assess deep vein thrombosis after the end of the treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.5: Symptomatic pulmonary embolism during the treatment period</HEADING>
<P>Fourteen trials, which included data from 22,544 participants (95.7% of participants included in the overall review), assessed reported fatal and non-fatal symptomatic pulmonary embolism, but no trial had systematically sought asymptomatic pulmonary embolism by performing ventilation-perfusion scans in all participants at the end of the treatment period. Anticoagulation was associated with a significant reduction in the odds of pulmonary embolism (OR 0.60; 95% CI 0.44 to 0.81, I² = 13.7%, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>In the trials described, the frequency of pulmonary embolism during the treatment period was variable, but quite low (1% in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> versus 7% in <LINK REF="STD-Elias-1990" TYPE="STUDY">Elias 1990</LINK> and <LINK REF="STD-Prins-1989" TYPE="STUDY">Prins 1989</LINK>). Although not reported systematically, and thereby potentially under-reported, the rate of pulmonary embolism in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> in participants not receiving heparin was only 0.8%. This observation is supported by data from prospective hospital-based studies that have reported symptomatic pulmonary embolism as a complication in between 1% and 3% of patients with acute stroke (<LINK REF="REF-Davenport-1996" TYPE="REFERENCE">Davenport 1996</LINK>). Applying the observed odds reduction in pulmonary embolism and assuming a control event rate of 2%, this effect translated into an NNTB of 127 (95% CI 91 to 268), although this may be an underestimate of the reduction in risk due to incomplete ascertainment.</P>
<P>Patients may continue to be at risk of pulmonary embolism after the early treatment period. This was suggested by data from three trials that continued to seek events systematically during the follow-up period (<LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>; <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>). Eight further pulmonary emboli were recorded, six of which were in the control group. The potential use of antiplatelet or anticoagulant agents after the trial period may have influenced the results of several trials (<LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-TOAST-1998" TYPE="STUDY">TOAST 1998</LINK>; <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>). One trial, with an 80% autopsy rate, did show a significant reduction in the risk of symptomatic and asymptomatic pulmonary embolism detected at autopsy in the anticoagulation group (7/24 versus 33/47, OR 0.19; 95% CI 0.07 to 0.52) (<LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.6: Recurrent ischaemic stroke or recurrent stroke of unknown pathological type during the treatment period</HEADING>
<P>Eleven trials, which included 21,605 participants (90.9% of participants included in the overall review) systematically sought to record early recurrent strokes that were definitely ischaemic (CT scan excluded haemorrhage) or probably ischaemic, that is in which the cerebral pathology was unknown because a CT scan had not been performed. Anticoagulation was associated with a statistically significant reduction in recurrent ischaemic stroke (OR 0.76; 95% CI 0.65 to 0.88, I² = 0, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) which, assuming a control event rate of 4%, translated into an NNTB of 108 (95% CI 74 to 266). The majority of the data (95%) were obtained from one trial (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.7: Symptomatic intracranial haemorrhage during the treatment period</HEADING>
<P>Sixteen trials, which included randomised data from 22,943 participants (96.6% of participants included in the overall review) reported data on symptomatic (fatal and non-fatal) intracranial haemorrhage confirmed by CT scanning or autopsy. Early anticoagulation significantly increased symptomatic intracranial haemorrhages by more than twofold (OR 2.55; 95% CI 1.95 to 3.33, I² = 0, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). Assuming a control event rate of 0.5%, this is equivalent to a NNTH of 131 (95% CI 88 to 213). The majority of data (76%) were contributed by one trial (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>).</P>
<P>There was no significant heterogeneity in the excess of haemorrhages with different types of heparin. However, within <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, intracranial haemorrhage significantly increased with increasing heparin dose. Participants allocated to avoid heparin, low-dose heparin, and medium-dose heparin had rates of intracranial haemorrhage of 0.3%, 0.7% and 1.8% respectively.</P>
<P>There is the possibility of some bias within these data, as there may have been a lower threshold for rescanning participants who had deteriorated clinically if they were known to be receiving anticoagulants (for example in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, which was not blinded). In addition, even in blinded trials, a physician is likely to be unblinded if bruising is observed at heparin injection sites. An unbiased assessment of the effect of anticoagulants on the occurrence of intracranial haemorrhage would come from systematic studies, in which all participants undergo a CT scan before the beginning of treatment to exclude haemorrhage, and all survivors have a repeat CT scan at the end of the scheduled treatment period, regardless of their clinical status. In such an unbiased assessment, all participants who died during the study would also have to undergo an autopsy. Unfortunately, it is rarely possible to achieve repeat CT scans in all survivors, or autopsies in all deaths. Five trials in this review made a systematic attempt to detect both symptomatic and asymptomatic intracranial haemorrhage in this way (<LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>; <LINK REF="STD-CESG-1983" TYPE="STUDY">CESG 1983</LINK>; <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-Prins-1989" TYPE="STUDY">Prins 1989</LINK>; <LINK REF="STD-Sandset-1990" TYPE="STUDY">Sandset 1990</LINK>). All of the confirmed intracranial haemorrhages were intracerebral. In <LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK> the use of systematic CT scanning was introduced during the trial and so not all participants were eligible for this analysis. However, the numbers of participants and events in this analysis were small (symptomatic plus asymptomatic haemorrhages occurring in 20/266 participants (7.5%) allocated anticoagulant versus 27/264 control participants (10.2%)) so the estimate of risk of 'symptomatic plus asymptomatic' haemorrhage is imprecise (OR 0.76; 95% CI 0.38 to 1.52). In these trials, 25 participants (5% overall, 15 treated versus 10 control) did not have a repeat CT scan or autopsy. Including these 25 participants in hypothetical best and worst-case analyses changed the odds ratio significantly (OR 0.44 and 1.44 respectively), which suggests that the results are compatible with either substantial reductions or increases in the risk of 'symptomatic plus asymptomatic' intracranial haemorrhages with treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.8: Any recurrent stroke or symptomatic intracranial haemorrhage during the treatment period and during long-term follow-up</HEADING>
<P>Early anticoagulation reduces the odds of ischaemic stroke but also increases the odds of symptomatic intracranial haemorrhage. An outcome that combines these two (without double counting - that is, each participant is counted only once, even if both events occurred, with the first event being the one which is included) is useful for assessing the net short-term effects of anticoagulants. Eleven trials, which included randomised data from 21,605 participants (96.0% of participants included in the overall review), evaluated the occurrence of 'any recurrent stroke or symptomatic intracranial haemorrhage' during the treatment period. Anticoagulation was not associated with a net reduction in the odds of this outcome (OR 0.97; 95% CI 0.85 to 1.11, I² = 31.3%, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The majority of the data (93.6%) were obtained from <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>. An analysis of the recurrent strokes or intracranial haemorrhages during the follow-up period could only include data from three small studies (<LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>; <LINK REF="STD-Marshall-1960" TYPE="STUDY">Marshall 1960</LINK>; <LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>). There were far too few events for a reliable analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome 1.9: Major extracranial haemorrhage during the treatment period</HEADING>
<P>Eighteen trials, which included randomised data from 22,255 participants (93.7 % of participants included in the overall review), reported data on major extracranial haemorrhage (defined as bleeding serious enough to cause death or require hospitalisation or transfusion). Anticoagulation was associated with a significant three-fold increase in major extracranial haemorrhage (OR 2.99; 95% CI 2.24 to 3.99, I² = 4%, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Assuming a control event rate of 0.4%, this is equivalent to an NNTH of 128 (95% CI 85 to 204).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Publication bias</HEADING>
<P>To determine whether or not we might have missed an important number of small negative trials (these are the trials most likely to remain unpublished) we undertook a funnel plot analysis (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). The analyses with the most number of trials included (and hence the greatest statistical power) were the effects of treatment on death during the treatment period (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), death from all causes at final follow-up (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) and deep vein thrombosis (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). For these outcomes, a plot of the sample size for each trial versus the odds ratio for that trial showed an approximate 'funnel distribution' with 'tails' in both the positive and negative treatment effect directions (except in the outcome of deep vein thrombosis) indicating that we were unlikely to have missed a substantial number of negative trials.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-03-09 10:41:54 +0000" MODIFIED_BY="Hazel Fraser">
<P>The evidence provided in this updated systematic review has not changed any of the conclusions of the previous review published in 2008, and can be summarised as follows.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-03-09 10:41:54 +0000" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Net effect of early anticoagulants in acute ischaemic stroke</HEADING>
<P>Acute stroke treatments should aim to prevent disability as well as death, lest patients survive their acute stroke only to remain severely disabled. The currently available evidence from randomised trials indicates that routine early anticoagulation does not provide any significant net short or long-term reduction in death or disability. Although early anticoagulation leads to fewer recurrent ischaemic strokes (NNTB 108), this benefit is entirely offset by a similar-sized increase in intracranial haemorrhages (NNTH 131). The net result is no short or long-term benefit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hazards of early anticoagulants in acute ischaemic stroke</HEADING>
<P>In order to be useful, a medical therapy must be safe. The current evidence from randomised trials demonstrates a clinically and statistically significant risk of major intra and extracranial haemorrhage with the early use of anticoagulants in people with acute ischaemic stroke.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Different anticoagulant agents, doses and routes of administration</HEADING>
<P>The present evidence from randomised trials does not suggest that any one anticoagulant regimen is superior to any other. Indirect comparisons of unfractionated heparin, low-molecular-weight heparin, heparinoids and specific thrombin inhibitors have shown no significant net benefit in terms of reducing death during the treatment period, or death or dependency after follow-up greater than one month. Direct comparisons of different anticoagulants show no clear benefit of heparinoids versus unfractionated heparin (<LINK REF="REF-Sandercock-2008" TYPE="REFERENCE">Sandercock 2008</LINK>). The available evidence does not support the routine use of adjusted-dose intravenous heparin (or heparinoid) regimens, or of more intensive fixed-dose regimens.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prevention of deep vein thrombosis and pulmonary embolism in acute ischaemic stroke with anticoagulants</HEADING>
<P>In participants with presumed or confirmed ischaemic stroke, allocation to early anticoagulation was associated with a highly significant 79% reduction in the odds of deep vein thrombosis during the treatment period, similar to that seen with the use of prophylactic heparin in people undergoing different types of surgery (<LINK REF="REF-Collins-1988" TYPE="REFERENCE">Collins 1988</LINK>). In this review, the reductions in deep vein thrombosis with acute anticoagulation were statistically significant, though this estimate is based on relatively small numbers of participants, and most of the deep vein thromboses detected were asymptomatic. There was also significant heterogeneity in the effects of treatment, which renders the overall estimate less reliable.</P>
<P>The clinical significance of this reduction depends critically on the control event rate. In the included studies, there was substantial variation in the control event rate from 13% in <LINK REF="STD-Vissinger-1995" TYPE="STUDY">Vissinger 1995</LINK> to 73% in <LINK REF="STD-McCarthy-1986" TYPE="STUDY">McCarthy 1986</LINK>. The rate will depend on many factors such as the severity of the stroke, the presence of leg paralysis and a history of previous deep vein thrombosis (<LINK REF="REF-Warlow-2008" TYPE="REFERENCE">Warlow 2008</LINK>). The odds of pulmonary embolism were reduced significantly with the use of anticoagulants by 40%. In the included trials, pulmonary embolism was uncommon, so assuming the 0.8% control rate seen in the largest trial with the most representative sample of participants (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>), the NNTB was 315, though with a perhaps more realistic control event rate of 2% it would be 127. The overall risk of pulmonary embolism appeared to be low, and the absolute benefit was small, and so the apparent reduction in deep vein thrombosis may have little clinical relevance if there is not a correspondingly large reduction in pulmonary embolism. However, there may well have been under-ascertainment of pulmonary embolism in all of the trials, since data on pulmonary emboli were not sought systematically. In addition, deep vein thrombosis can lead to morbidity (such as post-phlebitic leg and varicose ulcers), but data on these outcomes were not available from the trials. Finally, it is possible that once anticoagulants are stopped, rebound thrombosis could occur, and deep vein thromboses may begin to develop. We were unable to exclude this possibility because no trials sought data on deep vein thrombosis systematically after the treatment period.</P>
<P>If anticoagulants result in no net increase or decrease in long-term death or disability, but do lead to a reduction in the number of deep vein thromboses and pulmonary emboli (albeit in immobile patients at higher risk), then the benefit of fixed heparin regimens associated with a low risk of bleeding (for example low fixed-dose unfractionated or low-molecular weight heparin) may yet outweigh the increased risk of haemorrhage. A low deep vein thrombosis risk reduces the justification for unselective thromboprophylaxis with heparin. In <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> the frequency of fatal and non-fatal symptomatic pulmonary embolism (perhaps a surrogate for the occurrence of deep vein thrombosis) was very similar among participants allocated low-dose subcutaneous heparin alone (0.8%) and aspirin alone (0.7%). Aspirin alone may therefore be an adequate antithrombotic agent to be used for routine deep vein thrombosis prophylaxis in some people with acute ischaemic stroke, as antiplatelet drugs, when used for prophylaxis of deep vein thrombosis and pulmonary embolism prophylaxis in other categories of high-risk patients are of modest benefit (<LINK REF="REF-ATC-2002" TYPE="REFERENCE">ATC 2002</LINK>). The recent <LINK REF="REF-CLOTS_x002d_3-2013" TYPE="REFERENCE">CLOTS-3 2013</LINK> study has demonstrated that for people with ischaemic and haemorrhagic stroke, intermittent pneumatic compression reduces the risk of deep vein thrombosis after stroke, without any increased bleeding risk, and is effective both in the presence and absence of background heparin therapy.</P>
<P>The effects observed on deep vein thrombosis and pulmonary embolism in the present review indicate there might be a net benefit of low-dose heparin regimens among patients who are at high risk of venous thromboembolism, but at relatively low risk of intracranial or major extracranial bleeding. <LINK REF="REF-PREVAIL-2007" TYPE="REFERENCE">PREVAIL 2007</LINK> illustrates some of the difficulty in identifying subgroups who might have a favourable balance of risk and benefit. In that study, although the risk of venous thromboembolism (VTE) (symptomatic plus asymptomatic) was significantly lower among participants allocated enoxaparin, the study could not exclude a 69% increase in the risk of death up to day 14 and a 134% increase in the risk of intracranial haemorrhage with enoxaparin. This was because the event rates for the more major clinical outcomes were low: among the participants allocated unfractionated heparin, pulmonary embolism occurred in 1% and intracerebral haemorrhage in 1%. With such low event rates, conducting randomised trials large enough to reliably determine the balance of risk and benefit on these major clinical outcomes is challenging. In conclusion, the data from the present review were insufficient to reliably identify a subgroup that might benefit from heparin for thromboprophylaxis.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-03-09 10:09:56 +0000" MODIFIED_BY="Hazel Fraser">
<P>This systematic review provides information about the use of anticoagulants in unselected people with ischaemic stroke as well as limited information about various subgroups. Given that many of the trials were conducted more than 20 years ago, are these results still relevant to clinical practice in the 21st century? In the sense that they represent the totality of evidence comparing treatment with control, they remain relevant to current practice in many parts of the world and continue to be cited in stroke treatment guidelines. The pattern of background treatment has changed, with many patients now being treated within organised stroke units (in the developed world at least). This might have an impact on the absolute risks and benefit of anticoagulation, but is less likely to influence the estimates of relative effect, and hence - in our view - the results remain relevant. Anticoagulants are also sometimes advocated for the treatment of acute carotid dissection and cerebral venous thrombosis. Separate Cochrane reviews have been prepared for these topics (<LINK REF="REF-Lyrer-2010" TYPE="REFERENCE">Lyrer 2010</LINK>; <LINK REF="REF-Coutinho-2011" TYPE="REFERENCE">Coutinho 2011</LINK>). We were reluctant to pursue further subgroup analysis, since it is hazardous to explore subgroup effects when there is no significant overall effect of an intervention on major outcomes and we only had access to major outcomes. A more detailed assessment of the effects of anticoagulants in other categories of patient (for example patients treated within three hours, patients with large-artery strokes, patients with carotid stenosis) would however, be possible with an individual patient data meta-analysis.</P>
<P>The stroke patients included in the trials of anticoagulants to prevent deep vein thrombosis generally had quite severe strokes, and paralysis of one leg (with the attendant high risk of deep vein thrombosis) was almost invariably present at randomisation. If, however, one accepts the estimate of treatment effect from these trials in the 1980s and 1990s, it is then difficult to assess the extent to which it may be generalisable to clinical practice from 2000 onwards. In current practice, the risk of deep vein thrombosis may well be low, since many patients are admitted to stroke units, receive aspirin, maintain good hydration, and are generally mobilised early.</P>
<P>With that qualification in mind, the small amounts of (randomised) subgroup data evaluated here do not provide any evidence to support the routine use of anticoagulants in any specific category of stroke patient.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-03-09 10:10:19 +0000" MODIFIED_BY="Hazel Fraser">
<P>The bulk of the evidence in this review comes from trials with adequate allocation concealment, which is a strength. However, <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> - by far the largest trial - was unblinded - which may well have led to ascertainment bias especially for the early outcomes. The final outcome, however, was assessed at a time when patients could not accurately recall their treatment allocation, so in all likelihood the assessment of the primary outcome was probably not materially biased.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-03-09 10:10:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>This review is based on an analysis of tabular data, which limits the extent to which effects in subgroups can be explored. However, an individual patient data meta-analysis has been performed. The included trials measured the primary outcome at differing times after randomisation, ranging from one to six months after randomisation, as we did not have access to individual patient level data to calculate person-days or hazard ratios. In considering the impact of differing lengths of follow-up on the primary outcome, a post hoc-sensitivity analysis excluding the study with less than three months follow-up did not alter the overall estimate of effect or reduce the heterogeneity.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-03-09 10:10:30 +0000" MODIFIED_BY="Hazel Fraser">
<P>
<LINK REF="REF-Lederle-2011" TYPE="REFERENCE">Lederle 2011</LINK> is a systematic review of venous thromboembolism prophylaxis in hospitalised medical patients and those with stroke, and concluded "Heparin prophylaxis had no significant effect on mortality, may have reduced PE (pulmonary embolism) in medical patients and all patients combined, and led to more bleeding and major bleeding events, thus resulting in little or no net benefit. No differences in benefits or harms were found according to type of heparin used." Similarly, there was no clear difference in effects between people with stroke and with other non-surgical causes for hospital admission. A number of guideline statements have since been developed; the most recent American Stroke Association Guidelines (<LINK REF="REF-AHA-Guidelines-2012" TYPE="REFERENCE">AHA Guidelines 2012</LINK>) include two specific recommendations that are supported by the evidence provided in this systematic review. These are as follows.<BR/>
</P>
<UL>
<LI>Urgent anticoagulation, with the goal of preventing early recurrent stroke, halting neurological worsening, or improving outcomes after acute ischaemic stroke, is not recommended for treatment of patients with acute ischaemic stroke.</LI>
</UL>
<UL>
<LI>At present, the usefulness of argatroban or other thrombin inhibitors for treatment of patients with acute ischaemic stroke is not well established.</LI>
</UL>
<P>An individual patient data meta-analysis of the large trials of heparin in acute ischaemic stroke was recently able to explore subgroup effects in greater detail, with the aim of identifying the subgroup of patients most likely to derive net benefit from heparin. However, the authors concluded: "There was no evidence that patients with ischaemic stroke who were at higher risk of thrombotic events or lower risk of haemorrhagic events benefited from heparins. We were, therefore, unable to define a targeted approach to select the patients who would benefit from treatment with early anticoagulant therapy." (<LINK REF="REF-Whiteley-2013" TYPE="REFERENCE">Whiteley 2013</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-03-09 10:10:35 +0000" MODIFIED_BY="Hazel Fraser">
<IMPLICATIONS_PRACTICE MODIFIED="2015-03-09 10:10:33 +0000" MODIFIED_BY="Hazel Fraser">
<P>Evidence from this systematic review indicates that, compared with control, the types of anticoagulants tested in people with acute ischaemic stroke have no effect in terms of death in the short term, or death or dependency after follow-up of at least one month. A reduction in recurrent ischaemic stroke during the treatment period is exactly offset by an increase in intracranial haemorrhage. Although anticoagulants decrease deep vein thrombosis and pulmonary embolus, these benefits are once again offset by similar-sized increases in extracranial haemorrhage.</P>
<P>The data do not support the routine use of early high-dose intravenous or subcutaneous anticoagulants in any form for people with acute ischaemic stroke. Low-dose subcutaneous regimens will prevent deep vein thrombosis, but with a small but definite increased risk of major haemorrhage. It may therefore be advisable to consider safer alternatives in immobile patients (such as aspirin, compression stockings, or early mobilisation).</P>
<P>The data reviewed from trials comparing these agents with control do not support the use of low-molecular-weight heparins, heparinoids or thrombin inhibitors in the treatment of acute ischaemic stroke.</P>
<P>The analysis performed did not identify any category of patient where there was clear net benefit. Clinicians who feel compelled to use early anticoagulants for specific categories of patients following acute ischaemic stroke should weigh any potential theoretical benefits with the known risk of bleeding. Aspirin is an effective antithrombotic alternative to anticoagulation that is safe when used in the acute phase of ischaemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-03-09 10:10:35 +0000" MODIFIED_BY="Hazel Fraser">
<P>This review has not provided reliable evidence on a number of important categories of patient with acute cerebrovascular disease who might plausibly derive net benefit from early anticoagulation (very recent transient ischaemic attacks (within hours or days of onset), crescendo transient ischaemic attacks and progressing ischaemic stroke are a few examples) and further trials targeted at these groups (perhaps with new agents) may be warranted. The choice of comparator agent against which to test any anticoagulant will depend on a number of factors, but further trials comparing anticoagulants against control seem unlikely.</P>
<P>Those clinicians who wish to continue to use intensive intravenous dose-adjusted heparin regimens routinely to treat specific categories of stroke patient should provide convincing evidence from new randomised controlled trials to support such practices.</P>
<P>This review has not provided clear evidence about the optimum antithrombotic regimen for the prevention of deep vein thrombosis and pulmonary embolism in stroke patients. Aspirin alone, low-dose subcutaneous heparin, and the use of graded compression stockings are all promising possibilities, but a very large scale randomised trial with several tens of thousands of participants would be required to determine which (or which combination) has the most favourable balance of risk and benefit on overall clinical outcome.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-03-09 10:10:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>We would like to thank individual trialists for supplying additional information: Professor B Boneu for providing us with a copy of Dr Pince's thesis; Dr Duke and Dr R Kay (<LINK REF="STD-FISS-1995" TYPE="STUDY">FISS 1995</LINK>); Dr G Pambianco and Dr H Magnani from Organon International for supplying additional information on the trial using danaparoid (<LINK REF="STD-Turpie-1987" TYPE="STUDY">Turpie 1987</LINK>); Dr L Antonutti and Dr M Zorzon (<LINK REF="STD-Cazzato-1989" TYPE="STUDY">Cazzato 1989</LINK>); Dr Ewa Lindenstrom from Leo Pharmaceuticals for data on tinzaparin (<LINK REF="STD-Vissinger-1995" TYPE="STUDY">Vissinger 1995</LINK>); Dr M Lamonte who provided additional data on the ARGIS study (<LINK REF="STD-ARGIS_x002d_1-2004" TYPE="STUDY">ARGIS-1 2004</LINK>); H Willems who helped identify many of the early trials; Dr E Dick for supplying us with a copy of the MedStrategy document 'Stroke: A focus on opportunity'; Dr AGM van den Belt and Dr RI Lindley who helped produce the previously published version of this review (<LINK REF="REF-Sandercock-1993" TYPE="REFERENCE">Sandercock 1993</LINK>); and Hazel Fraser for supplying regular lists of trials identified by the Cochrane Stroke Group's search strategy. David Signorini was a co-author of an earlier version of the review. Dr Gord Gubitz contributed to earlier versions of this review. We also acknowledge the help given by the secretariat of the Antithrombotic Trialists' Collaboration (Dr C Baigent, Dr C Sudlow). We would like to acknowledge Brenda Thomas, Steff Lewis and Hazel Fraser of the Cochrane Stroke Group for their input and expertise in completing the update of this review.</P>
<SUBSECTION>
<HEADING LEVEL="2">Ongoing trials</HEADING>
<P>Anyone who knows of additional trials that we have omitted, please write to Dr Peter Sandercock.</P>
</SUBSECTION>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-02-18 12:00:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>Dr Sandercock was the principal investigator of the International Stroke Trial and Dr Counsell was also on the Steering Committee of this trial (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>). Edward Kane has no conflicts of interest to declare.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>Peter Sandercock designed the original 1993 review of anticoagulant versus control, double-checked the data and supervised the analysis and writing of this report. Edward Kane did the new literature searches and helped reformat and rewrite this update.<BR/>Ayeesha Kamal did the new literature searches, extracted the new data , performed the analysis and helped rewrite the text of the 2008 update. <BR/>Carl Counsell prepared the first version of the review and helped with the analysis and text of subsequent updates.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-03-09 10:23:13 +0000" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2015-03-09 10:23:13 +0000" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2015-03-09 10:23:13 +0000" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="MIX" ID="STD-ARGIS_x002d_1-2004" MODIFIED="2015-02-09 16:27:39 +0000" MODIFIED_BY="Hazel Fraser" NAME="ARGIS-1 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-02-09 16:27:39 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schulz J, Hursting MJ, et al</AU>
<TI>Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1)</TI>
<SO>Stroke</SO>
<YR>2004</YR>
<VL>35</VL>
<PG>1677-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cazzato-1989" MODIFIED="2015-02-09 16:27:49 +0000" MODIFIED_BY="Hazel Fraser" NAME="Cazzato 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-02-09 16:27:49 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cazzato G, Zorzon M, Mase G, Antonutto L, Iona LG</AU>
<TI>Mesoglycan in the treatment of acute cerebral infarction</TI>
<TO>Il mesoglicano nelle ischemie cerebrali acute a focolaio</TO>
<SO>Rivista di Neurologia</SO>
<YR>1989</YR>
<VL>59</VL>
<PG>121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-CESG-1983" NAME="CESG 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hakim AM, Furlan AJ, Hart RG</AU>
<TI>Immediate anticoagulation of embolic stroke: a randomized trial. The Cerebral Embolism Study Group</TI>
<SO>Stroke</SO>
<YR>1983</YR>
<VL>14</VL>
<PG>668-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim AM, Ryder-Cooke A, Melanson D</AU>
<TI>Sequential computerized tomographic appearances of strokes</TI>
<SO>Stroke</SO>
<YR>1983</YR>
<VL>14</VL>
<PG>893-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhary-2002" MODIFIED="2015-02-09 16:28:16 +0000" MODIFIED_BY="Hazel Fraser" NAME="Chaudhary 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-09 16:28:16 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhry HR, Arora H, Yadav K, Dubey S, Gupta R, Jain R</AU>
<TI>Low molecular weight heparin In acute ischemic stroke</TI>
<SO>The Antiseptic</SO>
<YR>2002</YR>
<VL>99</VL>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Duke-1983" NAME="Duke 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duke RJ, Turpie AGG, Bloch RF, Derby IR, Kronby MH, Bayer NH</AU>
<TI>Clinical trial of low-dose heparin for the prevention of stroke progression</TI>
<SO>Circulation</SO>
<YR>1980</YR>
<VL>Suppl III</VL>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Duke RJ, Turpie AGG, Bloch RF, Trebilcock RG</AU>
<TI>Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution</TI>
<SO>Cerebrovascular Disease</SO>
<YR>1983</YR>
<PG>399-405</PG>
<ED>Reivich M, Hurtig HI</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Duke-1986" MODIFIED="2015-03-09 10:11:26 +0000" MODIFIED_BY="Hazel Fraser" NAME="Duke 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Duke RJ, Bloch RF, Turpie AGG, Trebilcock RG, Bayer N</AU>
<TI>Intravenous heparin for the prevention of stroke progression in acute partial stable stroke</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1986</YR>
<VL>105</VL>
<PG>825-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duke RJ, Bloch RF, Turpie AGG</AU>
<TI>Heparin in acute partial stable stroke</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<PG>782</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Easton JD, Sherman DG, Hart RG</AU>
<TI>Heparin in acute partial stable stroke</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<PG>781</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-09 10:11:26 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loeliger EA</AU>
<TI>Heparin in acute partial stable stroke</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<PG>781-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Elias-1990" MODIFIED="2015-02-09 16:28:58 +0000" MODIFIED_BY="Hazel Fraser" NAME="Elias 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-02-09 16:28:58 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elias A, Milandre L, Lagrange G, Aillaud MF, Alonzo B, Toulemonde F, et al</AU>
<TI>Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)</TI>
<SO>Revue de Medecine Interne</SO>
<YR>1990</YR>
<VL>11</VL>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-FISS-1995" MODIFIED="2015-03-09 10:23:13 +0000" MODIFIED_BY="Hazel Fraser" NAME="FISS 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kay R, Wong KS, Lu YL, Chan YW, Tsoi TH, Ahuja AT, et al</AU>
<TI>Low-molecular-weight heparin for the treatment of acute ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>1588-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-09 10:23:13 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kay R</AU>
<TI>Fraxiparin in stroke study</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>253</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FISS_x002d_bis-1998" MODIFIED="2015-02-09 16:29:13 +0000" MODIFIED_BY="Hazel Fraser" NAME="FISS-bis 1998" YEAR="">
<REFERENCE MODIFIED="2015-02-09 16:29:13 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hommel M, for the FISS-bis Investigators Group</AU>
<TI>Fraxiparine in Ischaemic Stroke Study (FISS bis)</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1998</YR>
<VL>8 Suppl 4</VL>
<PG>19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IST-1997" NAME="IST 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>International Stroke Trial Collaborative Group</AU>
<TI>The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1569-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>International Stroke Trial Pilot Study Collaborative Group</AU>
<TI>Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1996</YR>
<VL>60</VL>
<PG>371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saxena R, Lewis S, Berge E, Sandercock P, Koudstaal P, for the International Stroke Trial Collaborative Group</AU>
<TI>Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>2333-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kwiecinski-1995" NAME="Kwiecinski 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kwiecinski H, Pniewski J, Kaminska A, Szyluk B</AU>
<TI>A randomized trial of fraxiparine in acute ischaemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>234</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marshall-1960" NAME="Marshall 1960" YEAR="1960">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marshall J, Shaw DA</AU>
<TI>Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial</TI>
<SO>Lancet</SO>
<YR>1960</YR>
<VL>1</VL>
<PG>995-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marshall J, Shaw DA</AU>
<TI>Anticoagulant therapy in cerebrovascular disease</TI>
<SO>Proceedings of the Royal Society of Medicine</SO>
<YR>1960</YR>
<PG>547-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-McCarthy-1977" MODIFIED="2015-02-09 16:29:53 +0000" MODIFIED_BY="Hazel Fraser" NAME="McCarthy 1977" YEAR="1977">
<REFERENCE MODIFIED="2015-02-09 16:29:53 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ</AU>
<TI>Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>ii</VL>
<PG>800-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-McCarthy-1986" MODIFIED="2015-02-09 16:30:05 +0000" MODIFIED_BY="Hazel Fraser" NAME="McCarthy 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-02-09 16:30:05 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy ST, Turner J</AU>
<TI>Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke</TI>
<SO>Age and Ageing</SO>
<YR>1986</YR>
<VL>15</VL>
<PG>84-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NAT_x002d_COOP-1962" NAME="NAT-COOP 1962" YEAR="1962">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baker RN, Broward JA, Fang HC, Fisher CM, Groch SN, Heyman A, et al</AU>
<TI>Anticoagulant therapy in cerebral infarction. Report on co-operative study</TI>
<SO>Neurology</SO>
<YR>1962</YR>
<VL>12</VL>
<PG>823-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller Fisher C</AU>
<TI>Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report</TI>
<SO>Neurology</SO>
<YR>1961</YR>
<VL>11</VL>
<PG>119-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pambianco-1995" NAME="Pambianco 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desmukh M, Bisignani M, Landau P, Orchard TJ</AU>
<TI>Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>1991</YR>
<VL>70</VL>
<PG>313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pambianco G, Orchard T, Landau P</AU>
<TI>Deep vein thrombosis: prevention in stroke patients during rehabilitation</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1995</YR>
<VL>76</VL>
<PG>324-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pince-1981" MODIFIED="2015-02-09 16:30:35 +0000" MODIFIED_BY="Hazel Fraser" NAME="Pince 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-02-09 16:30:35 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK">
<AU>Pince J</AU>
<SO>Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparitif de traitement preventif (These pour le doctorat d'etat en medecine)</SO>
<YR>1981</YR>
<PB>Universite Paul Sabatier</PB>
<CY>Toulouse</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Prins-1989" NAME="Prins 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJ</AU>
<TI>Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients</TI>
<SO>Haemostasis</SO>
<YR>1989</YR>
<VL>19</VL>
<PG>245-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prins MH, den Ottolander GJH, Gelsema R, van Woerkom TCM, Sing AK, Heller I</AU>
<TI>Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1987</YR>
<VL>58</VL>
<PG>117</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sandset-1990" NAME="Sandset 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandset PM, Dahl T, Abildgaard U</AU>
<TI>Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial</TI>
<SO>Acta Neurologia Scandinavica</SO>
<YR>1987</YR>
<VL>76</VL>
<PG>392</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U</AU>
<TI>A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>1990</YR>
<VL>16 Suppl</VL>
<PG>25-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tazaki-1986" MODIFIED="2015-02-09 16:31:23 +0000" MODIFIED_BY="Hazel Fraser" NAME="Tazaki 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-02-09 16:31:23 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tazaki Y, Kobayashi S, Togi H, Ohtomo E, Goto F, Araki G, et al</AU>
<TI>Therapeutic effect of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - Phase II double-blinded clinical trial (English translation)</TI>
<SO>Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine)</SO>
<YR>1986</YR>
<VL>63</VL>
<PG>3047-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tazaki-1992" MODIFIED="2015-02-09 16:31:34 +0000" MODIFIED_BY="Hazel Fraser" NAME="Tazaki 1992" YEAR="19921">
<REFERENCE MODIFIED="2015-02-09 16:31:34 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tazaki Y, Kobayashi S, Togi H, Ohtomo E, Goto F, Araki G, et al</AU>
<TI>Clinical usefulness of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - double blinded comparative study using placebo as a control (English translation)</TI>
<SO>Igaku no Ayumi (Journal of Clinical and Experimental Medicine)</SO>
<YR>1992</YR>
<VL>161</VL>
<PG>887-907</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-TOAST-1998" NAME="TOAST 1998" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adams JHP</AU>
<TI>Trial of Org 10172 in Acute Stroke Treatment (TOAST)</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>545</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>TOAST Investigators</AU>
<TI>Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>279</VL>
<PG>1265-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Turpie-1987" NAME="Turpie 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al</AU>
<TI>A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1987</YR>
<VL>58</VL>
<PG>123</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al</AU>
<TI>Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>523-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turpie AGG</AU>
<TI>Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke</TI>
<SO>Acta Chirurgica Scandinavica Supplementum</SO>
<YR>1988</YR>
<VL>543</VL>
<PG>85-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Vissinger-1995" MODIFIED="2015-02-09 16:32:20 +0000" MODIFIED_BY="Hazel Fraser" NAME="Vissinger 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-02-09 16:32:20 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Vissinger H, Husted S</AU>
<TI>Trial of tinzaparin versus placebo in ischaemic stroke</TI>
<SO>Unpublished work</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-02-18 12:38:02 +0000" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Bradshaw-1975" NAME="Bradshaw 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradshaw P, Brennan S</AU>
<TI>Trial of long-term anticoagulant therapy in the treatment of small stroke associated with a normal carotid angiogram</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1975</YR>
<VL>38</VL>
<PG>642-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camerlingo-2005" MODIFIED="2015-02-09 16:32:34 +0000" MODIFIED_BY="Hazel Fraser" NAME="Camerlingo 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-02-09 16:32:34 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A</AU>
<TI>Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute non lacunar hemispheric cerebral infarctions</TI>
<SO>Stroke</SO>
<YR>2005</YR>
<VL>36</VL>
<PG>2415-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1961" MODIFIED="2015-02-09 16:32:55 +0000" MODIFIED_BY="Hazel Fraser" NAME="Carter 1961" YEAR="1961">
<REFERENCE MODIFIED="2015-02-09 16:32:55 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carter AB</AU>
<TI>Anticoagulant treatment in progressing stroke</TI>
<SO>BMJ</SO>
<YR>1961</YR>
<VL>II</VL>
<PG>70-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter AB</AU>
<TI>Use of anticoagulants in patients with progressive cerebral infarction</TI>
<SO>Neurology</SO>
<YR>1961</YR>
<VL>11</VL>
<PG>601-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-COU-9116" NAME="COU 9116" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Oczkowski WJ</AU>
<TI>A randomised trial of fixed low dose warfarin in the prevention of deep vein thrombosis in patients undergoing rehabilitation after stroke (Cou 9116)</TI>
<SO>Unpublished protocol</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czechanowski-1981" NAME="Czechanowski 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czechanowski B, Heinrich F</AU>
<TI>Prevention of venous thrombosis in recent ischaemic cerebrovascular accident: double-blind study with heparin-dihydroergotamine</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1981</YR>
<VL>106</VL>
<PG>1254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahan-1986" NAME="Dahan 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, et al</AU>
<TI>Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial</TI>
<SO>Haemostasis</SO>
<YR>1986</YR>
<VL>16</VL>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dan-2001" MODIFIED="2015-02-09 16:33:21 +0000" MODIFIED_BY="Hazel Fraser" NAME="Dan 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-02-09 16:33:21 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dan G, Gonta A, Serbanescu A, Ionete C</AU>
<TI>Improvement of outcome in patients with acute ischaemic stroke treated with fragmin</TI>
<SO>Haemostasis</SO>
<YR>2001</YR>
<VL>30 Suppl 2</VL>
<PG>168-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Dehen-1994" NAME="Dehen 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Dehen H on behalf of Laboratoire Houde. Etude en double aveugle, controlee contre placebo, du dermatane sulfate (RU 54 701) dans le traitement precoce de l'infarctus sylvien (Double blind placebo controlled study of dermatan sulphate in acute middle cerebral artery infarct). Unpublished work.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Dehen H, on behalf of Laboratoire Houde</AU>
<TI>Double blind placebo controlled study of dermatan sulphate in acute middle cerebral artery infarct</TI>
<TO>Etude en double aveugle, controlee contre placebo, du dermatane sulfate (RU 54 701) dans le traitement precoce de l'infarctus sylvien</TO>
<SO>Unpublished work</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enger-1965" NAME="Enger 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enger E, Boyesen S</AU>
<TI>Long term anticoagulant therapy in patients with cerebral infarction: a controlled clinical study</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1965</YR>
<VL>178 Suppl 438</VL>
<PG>7-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksson-1983" NAME="Eriksson 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson S-E, Link H</AU>
<TI>Evaluation of anticoagulants in patients with cerebral infarction with slight to moderate neurological deficit</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1983</YR>
<VL>68</VL>
<PG>96-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelmers-1980" NAME="Gelmers 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelmers HJ</AU>
<TI>Effects of low-dose subcutaneous heparin on the occurrence of deep vein thrombosis in patients with ischemic stroke</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1980</YR>
<VL>61</VL>
<PG>313-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2010" MODIFIED="2014-08-31 13:40:42 +0100" MODIFIED_BY="Eddie Kane" NAME="Kang 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-31 13:40:19 +0100" MODIFIED_BY="Eddie Kane" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kang K, Kim DW, Park H-K, Yoon B-W</AU>
<TI>Optimal dosing of intravenous unfractionated heparin bolus in transient ischaemic attack or stroke</TI>
<SO>Clinical and Applied Thrombosis/Haemostasis</SO>
<YR>2010</YR>
<VL>16(2)</VL>
<PG>126-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kario-1995" MODIFIED="2015-02-09 16:34:03 +0000" MODIFIED_BY="Hazel Fraser" NAME="Kario 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-02-09 16:34:03 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kario K, Kodama K, Koide M, Matsuo T</AU>
<TI>Thrombin inhibition in the acute phase of ischaemic stroke using argatroban</TI>
<SO>Blood Coagulation and Fibrinolysis</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>423-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayashi-1997" MODIFIED="2015-02-09 16:34:14 +0000" MODIFIED_BY="Hazel Fraser" NAME="Kobayashi 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-02-09 16:34:14 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi S, Tazaki Y</AU>
<TI>Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis</TI>
<SO>Seminars In Thrombosis and Hemostasis</SO>
<YR>1997</YR>
<VL>23</VL>
<PG>531-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1994" NAME="Lee 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee JH, Seo DC, Kim JS, Lee MC</AU>
<TI>Therapeutic efficacy of urokinase and heparin in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>268</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2008" MODIFIED="2015-02-18 12:36:12 +0000" MODIFIED_BY="Hazel Fraser" NAME="Lee 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-18 12:36:12 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC</AU>
<TI>Interaction between warfarin and panax ginseng in ischaemic stroke patients</TI>
<SO>Journal of Alternative and Complimentary Medicine</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>6</NO>
<PG>715-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2013" MODIFIED="2015-02-09 16:36:42 +0000" MODIFIED_BY="Hazel Fraser" NAME="Luo 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-02-09 16:36:42 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo W-L, He Y, Lee M, Ceng W</AU>
<TI>Safety and effects of using warfarin early in adult patients with cerebral venous and sinus thrombosis</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2013</YR>
<VL>36 Suppl 1</VL>
<PG>51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-McCarthy-1993" NAME="McCarthy 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>McCarthy S, McWalter R, Durkin CJ, Hallawi AH, Magnani HN, Pearson J, et al</AU>
<TI>Org 10172 for the prophylaxis of deep venous thrombosis in the legs (A protocol to establish the efficacy and safety of once or twice daily subcutaneous Org 10172 injections versus placebo in three groups of 60 non-haemorrhagic stroke victims)</TI>
<SO>Unpublished protocol</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDevitt-1959" MODIFIED="2008-04-16 10:59:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="McDevitt 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groch SN, McDevitt E, Wright IS</AU>
<TI>A long-term study of cerebral vascular disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1961</YR>
<VL>55</VL>
<PG>358-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McDevitt E, Groch SN, Wright IS</AU>
<TI>A cooperative study of cerebrovascular disease</TI>
<SO>Circulation</SO>
<YR>1959</YR>
<VL>20</VL>
<PG>215-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDowell F, McDevitt E, Wright IS</AU>
<TI>Anticoagulant therapy: five years' experience with the patient with an established cerebrovascular accident</TI>
<SO>Archives of Neurology</SO>
<YR>1963</YR>
<VL>8</VL>
<PG>209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-16 10:59:14 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>McDowell F, McDevitt E</AU>
<TI>Treatment of the completed stroke with long-term anticoagulant: six and one-half years experience</TI>
<SO>Cerebral Vascular Diseases</SO>
<YR>1965</YR>
<PG>185-99</PG>
<ED>Siekert RG, Whisnant JP</ED>
<PB>Grune &amp; Stratton Inc</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meredit-2009" MODIFIED="2015-02-09 16:37:29 +0000" MODIFIED_BY="Hazel Fraser" NAME="Meredit 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-09 16:37:29 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meredit T, Ahmad O, Harvey I, Hughes A, Lindley R, Neeman T, et al</AU>
<TI>The Acute Cardioembolic Stroke Trial</TI>
<SO>International Journal of Stroke</SO>
<YR>2009</YR>
<VL>4 Suppl 1</VL>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-08-31 13:16:04 +0100" MODIFIED_BY="Eddie Kane"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Rosin-1994" NAME="Rosin 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Rosin A, Abramovitz Z</AU>
<TI>Preventing deep venous thrombosis following acute strokes</TI>
<SO>Unpublished protocol</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2004" MODIFIED="2015-02-09 16:37:41 +0000" MODIFIED_BY="Hazel Fraser" NAME="Shi 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-02-09 16:37:41 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi J, Zhang Y</AU>
<TI>The clinical observation of low molecular weight heparin calcium in treating patients with acute cerebral infarction</TI>
<SO>Pharmaceutical Care and Research</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>258-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Stiekema-1988" NAME="Stiekema 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Stiekema JCJ, Egberts J, Voerman J</AU>
<TI>An open, randomised, rising dose, pilot two-centre study of Org 10172 administered for the purpose of deep vein thrombosis prophylaxis in patients with a non-haemorrhagic stroke on recent onset</TI>
<SO>Organon International, 1988 (SDG Release Report 2244)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-1998" MODIFIED="2015-02-09 16:39:42 +0000" MODIFIED_BY="Hazel Fraser" NAME="Tan 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-02-09 16:39:42 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan L, Li TS, Zhao RL</AU>
<TI>Nardoparin in treating cerebral embolism and thrombosis</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>325-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thygesen-1964" NAME="Thygesen 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thygesen P, Christensen E, Dyrbye M, Eiken M, Franzen E, Gormsen J, et al</AU>
<TI>Cerebral apoplexy: a clinical, radiological, electroencephalographic and pathological study with special reference to the prognosis of cerebral infarction and the result of long-term anticoagulant therapy</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1964</YR>
<VL>11</VL>
<PG>233-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomek-2011" MODIFIED="2015-02-10 13:27:03 +0000" MODIFIED_BY="Hazel Fraser" NAME="Tomek 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-02-10 13:27:03 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomek A, Matoska V, Kumstyrova T, Sramek M, Sarbochova I, Stovickova K, et al</AU>
<TI>Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2011</YR>
<VL>31 Suppl 2</VL>
<PG>31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuchiya-1989" NAME="Tsuchiya 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Tsuchiya T, Fujikake K, Oku K. Effects of urokinase and heparin on haemorrhagic infarction, recanalisation, recurrence - analysis of 111 cases with middle cerebral artery occlusion on a prospective controlled trial. [author's translation] Japanese Journal of Stroke 1989;11:500-510. (translated from Japanese)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuchiya T, Fujikake K, Oku K</AU>
<TI>Effects of urokinase and heparin on haemorrhagic infarction, recanalisation, recurrence - analysis of 111 cases with middle cerebral artery occlusion on a prospective controlled trial [author's translation]</TI>
<SO>Japanese Journal of Stroke</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>500-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuchiya-1990" NAME="Tsuchiya 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuchiya T, Fujikake K, Oku K</AU>
<TI>A study on clinical effects of urokinase and heparin for acute lacunar infarcts in a prospective controlled trial</TI>
<SO>Japanese Journal of Stroke</SO>
<YR>1990</YR>
<VL>11</VL>
<PG>177-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VA-Study-1961" NAME="VA Study 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker RN</AU>
<TI>An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section</TI>
<SO>Neurology</SO>
<YR>1961</YR>
<VL>11</VL>
<PG>132-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2015-02-09 16:39:47 +0000" MODIFIED_BY="Hazel Fraser" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-02-09 16:39:47 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang DJ, Zhu SW, Cui QX, Li YZ, Zhang HM, Xia ZL, et al</AU>
<TI>Clinical study of low molecular weight heparin calcium and aspirin therapy on acute cerebral infarction</TI>
<SO>Clinical Pharmacology</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>634-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2014" MODIFIED="2015-02-18 12:38:02 +0000" MODIFIED_BY="Hazel Fraser" NAME="Zhao 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-02-18 12:38:02 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<AU>Zhao G</AU>
<TI>Apixaban versus Dual-antiplatelet therapy (clopidogrel and aspirin) in Acute Non-disabling Cerebrovascular Events (ADANCE)</TI>
<SO>Clinicaltrials.gov</SO>
<YR>(accessed June 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2015-02-09 16:40:46 +0000" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="MIX" ID="STD-Nosal-2014" MODIFIED="2015-02-09 16:40:46 +0000" MODIFIED_BY="Hazel Fraser" NAME="Nosal 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-02-09 16:40:46 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Nosal V</AU>
<TI>Safety and efficacy of heparin and nadroparin in the acute phase of ischemic stroke (Heparinas)</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT01862978</SO>
<YR>(accessed June 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-02-09 10:38:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-02-09 10:38:18 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="NCT01862978"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-02-18 13:12:05 +0000" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2015-02-18 13:12:05 +0000" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-AHA-Guidelines-2012" MODIFIED="2015-02-10 13:32:14 +0000" MODIFIED_BY="Hazel Fraser" NAME="AHA Guidelines 2012" TYPE="JOURNAL_ARTICLE">
<AU>Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al</AU>
<TI>Guidelines for the early management of adults with ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2012</YR>
<VL>44</VL>
<PG>870-947</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Matthews JNS</AU>
<TI>Interaction 1: heterogeneity of effects</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>486</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andersen-2009" MODIFIED="2015-02-10 13:32:40 +0000" MODIFIED_BY="Hazel Fraser" NAME="Andersen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP</AU>
<TI>Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>6</NO>
<PG>2068-72</PG>
<IDENTIFIERS MODIFIED="2014-09-17 14:06:02 +0100" MODIFIED_BY="Eddie Kane"/>
</REFERENCE>
<REFERENCE ID="REF-APT-1994" NAME="APT 1994" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists' Collaboration</AU>
<TI>Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>81-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATC-2002" NAME="ATC 2002" TYPE="JOURNAL_ARTICLE">
<AU>Antithrombotic Trialists' Collaboration</AU>
<TI>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>324</VL>
<PG>71-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1990" MODIFIED="2015-02-10 13:33:06 +0000" MODIFIED_BY="Hazel Fraser" NAME="Bamford 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bamford J, Sandercock P, Dennis M, Burn J, Warlow C</AU>
<TI>A prospective study of acute cerebrovascular disease in the community: The Oxfordshire Community Stroke Project 1981-1986. 2. Incidence, case fatality and overall outcome at one year of cerebral infarction, primary intracerebral haemorrhage and subarachnoid haemorrhage</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1990</YR>
<VL>53</VL>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-2003" NAME="Bland 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bland M, Altman D</AU>
<TI>Tests for interaction</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CLOTS_x002d_3-2013" MODIFIED="2015-02-10 13:33:29 +0000" MODIFIED_BY="Hazel Fraser" NAME="CLOTS-3 2013" TYPE="JOURNAL_ARTICLE">
<AU>CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration</AU>
<TI>Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>382</VL>
<PG>516-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1988" NAME="Collins 1988" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Scrimgeour A, Yusuf S, Peto R</AU>
<TI>Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>1162-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coutinho-2011" MODIFIED="2015-02-10 13:33:41 +0000" MODIFIED_BY="Hazel Fraser" NAME="Coutinho 2011" TYPE="COCHRANE_REVIEW">
<AU>Coutinho J, de Bruijn SFTM, deVeber G, Stam J</AU>
<TI>Anticoagulation for cerebral venous sinus thrombosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2008-04-16 11:09:39 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-04-16 11:09:39 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD002005"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davenport-1996" NAME="Davenport 1996" TYPE="JOURNAL_ARTICLE">
<AU>Davenport R, Dennis M, Wellwood I, Warlow C</AU>
<TI>Complications after acute stroke</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>415-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feigin-2014" MODIFIED="2015-02-10 13:35:25 +0000" MODIFIED_BY="Hazel Fraser" NAME="Feigin 2014" TYPE="JOURNAL_ARTICLE">
<AU>Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al</AU>
<TI>Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010</TI>
<SO>Lancet</SO>
<YR>2014</YR>
<VL>383</VL>
<NO>9913</NO>
<PG>245-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hao-2012" MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser" NAME="Hao 2012" TYPE="COCHRANE_REVIEW">
<AU>Hao Z, Liu M, Counsell C, Wardlaw JM, Lin S, Zhao X</AU>
<TI>Fibrinogen depleting agents for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-04-16 11:09:48 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-04-16 11:09:48 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000091"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lederle-2011" MODIFIED="2015-02-10 13:36:14 +0000" MODIFIED_BY="Hazel Fraser" NAME="Lederle 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Zylla D, MacDonald R, Wilt T</AU>
<TI>Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2011</YR>
<VL>155</VL>
<PG>602-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindley-1993" NAME="Lindley 1993" TYPE="BOOK">
<AU>Lindley RI</AU>
<SO>Are very large trials of promising treatments for acute stroke feasible?</SO>
<YR>1993</YR>
<PB>University of Newcastle Upon Tyne</PB>
<CY>Newcastle Upon Tyne</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lozano-2012" MODIFIED="2015-02-10 13:37:32 +0000" MODIFIED_BY="Hazel Fraser" NAME="Lozano 2012" TYPE="JOURNAL_ARTICLE">
<AU>Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al</AU>
<TI>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</TI>
<SO>Lancet</SO>
<YR>2012</YR>
<VL>380</VL>
<NO>9859</NO>
<PG>2095-128</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lyrer-2010" MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser" NAME="Lyrer 2010" TYPE="COCHRANE_REVIEW">
<AU>Lyrer P, Engelter S</AU>
<TI>Antithrombotic drugs for carotid artery dissection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2008-04-16 11:08:30 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-04-16 11:08:30 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000255"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Murray-2012" MODIFIED="2015-02-10 13:38:59 +0000" MODIFIED_BY="Hazel Fraser" NAME="Murray 2012" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al</AU>
<TI>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010</TI>
<SO>Lancet</SO>
<YR>2012</YR>
<VL>380</VL>
<NO>9859</NO>
<PG>2197-223</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Odgaard_x002d_Jensen-2011" MODIFIED="2015-02-09 16:24:41 +0000" MODIFIED_BY="Hazel Fraser" NAME="Odgaard-Jensen 2011" TYPE="COCHRANE_REVIEW">
<AU>Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, Schünemann H, et al</AU>
<TI>Randomisation to protect against selection bias in healthcare trials</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>Issue 4</NO>
<IDENTIFIERS MODIFIED="2014-11-19 17:55:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-19 17:55:51 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000012.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-PREVAIL-2007" NAME="PREVAIL 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, et al</AU>
<TI>The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>1347-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-02-18 13:12:05 +0000" MODIFIED_BY="Hazel Fraser" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-2008" MODIFIED="2015-02-10 13:39:24 +0000" MODIFIED_BY="Hazel Fraser" NAME="Sandercock 2008" TYPE="COCHRANE_REVIEW">
<AU>Sandercock PAG, Counsell C, Tseng MC</AU>
<TI>Low molecular weight heparin or heparinoids versus standard unfractionated heparin for acute ischemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-11-19 17:52:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-19 17:52:38 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000119.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saxena-2001" MODIFIED="2015-02-10 13:40:23 +0000" MODIFIED_BY="Hazel Fraser" NAME="Saxena 2001" TYPE="JOURNAL_ARTICLE">
<AU>Saxena R, Lewis S, Berge E, Sandercock P, Koudstaal, P; the International Stroke Trial Collaborative Group</AU>
<TI>Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>2333-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2014" MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser" NAME="Wardlaw 2014" TYPE="COCHRANE_REVIEW">
<AU>Wardlaw JM, Murray V, Berge E, del Zoppo GJ</AU>
<TI>Thrombolysis for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2008-04-16 11:06:52 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-04-16 11:06:52 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000213"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Warlow-2008" NAME="Warlow 2008" TYPE="BOOK">
<AU>Warlow C, Bamford J, Dennis M, Rothwell P, Rinkel G, Sandercock P, et al</AU>
<SO>Stroke: Practical Management</SO>
<YR>2008</YR>
<EN>3rd</EN>
<PB>Blackwells Scientific</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whiteley-2013" MODIFIED="2015-02-10 13:40:44 +0000" MODIFIED_BY="Hazel Fraser" NAME="Whiteley 2013" TYPE="JOURNAL_ARTICLE">
<AU>Whiteley W, Adams HP, Bath PMW, Berge E, Sandset PM, Dennis M, et al</AU>
<TI>Targeted use of heparin, heparinoids, or low-molecular weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials</TI>
<SO>Lancet Neurology</SO>
<YR>2013</YR>
<VL>12</VL>
<PG>539&#8211;45</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-02-10 13:41:07 +0000" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Gubitz-2004" MODIFIED="2015-02-10 13:40:57 +0000" MODIFIED_BY="Hazel Fraser" NAME="Gubitz 2004" TYPE="COCHRANE_REVIEW">
<AU>Gubitz G, Sandercock P, Counsell C</AU>
<TI>Anticoagulants for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-11-19 17:53:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-19 17:53:53 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000024.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-1993" MODIFIED="2015-02-10 13:41:07 +0000" MODIFIED_BY="Hazel Fraser" NAME="Sandercock 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sandercock PAG, van den Belt AGM, Lindley RI, Slattery J</AU>
<TI>Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1993</YR>
<VL>56</VL>
<PG>17-25</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-03-09 10:45:10 +0000" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-03-09 10:45:10 +0000" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-05-05 11:14:54 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-ARGIS_x002d_1-2004">
<CHAR_METHODS>
<P>C = randomisation not described <BR/>Patient, doctor and assessments blinded<BR/>Exclusions during the trial: none<BR/>Losses to FU: 5 participants</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-05 11:14:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>North America<BR/>171 participants<BR/>Mean age 65 years<BR/>100% CT before entry<BR/>Mild to moderate ischaemic stroke NIHSS 7 to 22<BR/>Less than 12 hours since onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: argatroban 100 mcg/kg bolus, followed by low-dose arm 1 mcg/kg/min or high-dose arm 3 mcg/kg/min for 5 days versus placebo<BR/>Control: aspirin use in both arms</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death <BR/>Symptomatic ICH<BR/>Major extracranial ICH<BR/>Barthel, NIHSS, MRS at 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: age &gt; 85 <BR/>BP: &gt; 220/130<BR/>FU: 30 days, 90 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cazzato-1989">
<CHAR_METHODS>
<P>C = random number table controlled by doctor not involved in treatment<BR/>Outcome assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Italy <BR/>57 participants<BR/>Mean age 68 years<BR/>49% male<BR/>100% CT before entry<BR/>Ischaemic stroke<BR/>Less than 48 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: mesoglycan (heparinoid) 50 mg 8 hourly im for 5 days, then 144 mg/day orally for 25 days<BR/>Control: no treatment<BR/>All participants received dexamethasone iv<BR/>Duration: 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>Functional outcome (OHS 3, 4, 5 = dependent) <BR/>PE (symptomatic plus autopsy in 9/10 deaths)<BR/>Intracranial haemorrhage (symptomatic CT)<BR/>Recurrent stroke<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: none<BR/>FU: 30 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CESG-1983">
<CHAR_METHODS>
<P>C = sealed envelopes (opaque and sequentially numbered)<BR/>Non-blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>North America<BR/>45 participants<BR/>42 to 83 years<BR/>58% male<BR/>100% CT before entry<BR/>Cardioembolic stroke<BR/>Less than 48 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin iv (continuous, APTT 1.5 to 2.5) +/- coumadin<BR/>Control: no treatment<BR/>Duration: 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>Intracranial haemorrhage (systematic CT on day 4 to 10)<BR/>Recurrent stroke<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: BP &gt; 180/115, bleeding risk<BR/>FU: 14 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chaudhary-2002">
<CHAR_METHODS>
<P>C = randomisation not described<BR/>Assessment not blinded<BR/>Exclusions during trial: none <BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>India <BR/>30 participants<BR/>65 years<BR/>100% CT before entry<BR/>Acute stroke - time not otherwise defined</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: parnaparin 0.3 ml sc bid for 10 days versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death and Barthel Index at 3 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: CT with ICH, coagulopathy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-16 10:56:22 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Duke-1983">
<CHAR_METHODS>
<P>C = random number list controlled by pharmacy<BR/>Doctor, patient, and assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Canada<BR/>65 participants <BR/>? age<BR/>? sex<BR/>81% CT before entry<BR/>'Partial stable' ischaemic stroke &lt; 48 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-16 10:56:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: heparin 5000 IU sc 8 hourly<BR/>Control: placebo<BR/>Duration: 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death <BR/>DVT (systematic I-125 scan)<BR/>Intracranial haemorrhage (symptomatic)<BR/>Extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: BP &gt; 120 diastolic, bleeding risk<BR/>FU: 1 year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Duke-1986">
<CHAR_METHODS>
<P>C = random number list controlled by pharmacy<BR/>Doctor, patient, and assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: 3 participants (number in each group unknown)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Canada<BR/>225 participants<BR/>Mean age 67 years<BR/>63% male<BR/>100% CT before entry<BR/>'Partial stable' non-cardioembolic ischaemic stroke &lt; 48hrs since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin iv (continuous, APTT 50 to 70 seconds) <BR/>Control: placebo<BR/>Duration: 7 days<BR/>Antiplatelet therapy during follow up not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death but not cause of death<BR/>Functional outcome (measured but not reported)<BR/>Intracranial haemorrhage (symptomatic)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: BP &gt; 110 diastolic, coma<BR/>FU: 1 year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Elias-1990">
<CHAR_METHODS>
<P>C = sealed envelopes (? opaque and sequentially numbered)<BR/>Non-blind<BR/>Exclusions during trial: none<BR/>Losses to FU: 2 in Rx group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Europe<BR/>30 participants<BR/>Mean age 68 years<BR/>57% male<BR/>100% CT before entry<BR/>Ischaemic stroke with immobility <BR/>Less than 48 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: CY 222 (LMWH) 15,000 anti-Xa units sc 24 hourly<BR/>Control: no treatment <BR/>Duration: 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>DVT (systematic I-125 scan, venography 50%)<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: BP &gt; 220/120, coma<BR/>FU: 14 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-16 10:56:46 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-FISS-1995">
<CHAR_METHODS>
<P>C = sequentially numbered boxes containing identical syringes<BR/>Doctor, patient, and assessor blind<BR/>Exclusions during trial: 4 in Rx group (survival status known for all except one)<BR/>Losses to FU: 2 in Rx group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Hong Kong<BR/>312 participants<BR/>Mean age 67 years<BR/>58% male<BR/>100% CT before entry<BR/>Ischaemic stroke with motor deficit<BR/>Less than 48 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-16 10:56:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: nadroparin (LMWH) sc (randomised between 4100 anti-Xa units 12 hourly versus 24 hourly)<BR/>Control: placebo<BR/>Duration: 10 days<BR/>All surviving participants received aspirin 100 mg/day after 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>Functional outcome (dependency assessed using International Stroke Trial simple questions)<BR/>PE (symptomatic)<BR/>Intracranial haemorrhage (symptomatic and systematic CT)<BR/>Recurrent stroke<BR/>Major extracranial haemorrhage<BR/>Myocardial infarction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: over 80 years, BP &gt; 180/120 mmHg, previous disabling stroke, bleeding risk, imminent death<BR/>FU: 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-FISS_x002d_bis-1998">
<CHAR_METHODS>
<P>C = sequentially numbered boxes<BR/>Doctor, patient and assessor blind<BR/>Exclusions during trial: unknown<BR/>Losses to FU: unknown</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>International<BR/>766 participants<BR/>Mean age unknown<BR/>% male unknown<BR/>100% CT before entry<BR/>Ischaemic stroke with motor deficit &lt; 24 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: nadroparin (LMWH) 86 units/kg sc once daily versus 86 units/kg sc 12 hourly<BR/>Control: placebo<BR/>Duration: 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Functional Outcome (Barthel Index score &lt; 85 = dependent)<BR/>Intracerebral haemorrhage (symptomatic CT)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: mild stroke, coma<BR/>FU: 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-IST-1997">
<CHAR_METHODS>
<P>C = telephone randomisation<BR/>Unblinded; dependency assessment mainly blinded<BR/>Exclusions during trial: none<BR/>Losses to FU: data 99.99% complete for 14-day outcome and 99.2% complete for 6-month outcome</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>International<BR/>19,435 participants<BR/>61% &gt; 70 years<BR/>54% male<BR/>67% CT prior to randomisation, 29% CT after randomisation<BR/>Ischaemic stroke &lt; 48 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: sc heparin (5000 IU or 12,500 IU 12 hourly), aspirin 300 mg, both, or neither (factorial design)<BR/>Duration: 14 days or until discharge from hospital</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Functional outcome (validated simple questions)<BR/>Recurrent stroke<BR/>PE<BR/>Intracranial haemorrhage (symptomatic CT)<BR/>Extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: small likelihood of worthwhile benefit; high risk of adverse effect (e.g. hypersensitivity of aspirin, recent GI bleed or peptic ulcer disease, already on long-term anticoagulation)<BR/>FU: 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-09 10:45:10 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Kwiecinski-1995">
<CHAR_METHODS>
<P>C = unknown<BR/>Blinding not stated<BR/>Exclusions during trial: unknown<BR/>Losses to FU: unknown</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Poland<BR/>120 participants<BR/>Mean age 57 years<BR/>65% male<BR/>100% CT before entry<BR/>Enrolled less than 48 hours after ischaemic stroke</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-09 10:45:10 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: fraxiparin (LMWH)<BR/>0.6 ml 12 hourly for one week, then 0.3ml 12 hourly for one week<BR/>Control: placebo<BR/>Duration: 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Functional outcome<BR/>Intracerebral haemorrhage (symptomatic CT)<BR/>Symptomatic DVT and PE during treatment period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: &gt; 65 years, comatose, severe comorbidity, uncontrolled hypertension <BR/>FU: 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marshall-1960">
<CHAR_METHODS>
<P>C = unknown<BR/>Non-blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>United Kingdom<BR/>51 participants<BR/>30 to 70 years<BR/>47% male<BR/>No CT, 100% LP plus angiography<BR/>Non-cardioembolic ischaemic stroke &lt; 72 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin iv (3 doses of 12,500 IU), then phenindione orally 12 hourly (PT 2 to 3)<BR/>Control: no treatment <BR/>Duration: 21 days<BR/>No antiplatelet therapy during follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death but not cause of death<BR/>Fatal intracranial haemorrhage (autopsies in 8/9 deaths)<BR/>Recurrent stroke<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: bleeding risk<BR/>FU: 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McCarthy-1977">
<CHAR_METHODS>
<P>C = sealed envelopes (? opaque and sequentially numbered)<BR/>DVT assessment blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>United Kingdom<BR/>32 participants<BR/>Mean age 78 years<BR/>34% male<BR/>No CT, 100% LP before entry<BR/>Any stroke with no blood in CSF<BR/>Less than 48 hours since stroke onset<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin 5000 IU sc 8 hourly<BR/>Control: no treatment<BR/>Duration: 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death but not cause of death<BR/>DVT (systematic I-125 scan)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: BP &gt; 120 diastolic, bleeding risk<BR/>FU: 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McCarthy-1986">
<CHAR_METHODS>
<P>C = sealed envelopes (? opaque and sequentially numbered)<BR/>DVT assessment blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>United Kingdom<BR/>305 participants<BR/>Mean age 76 years<BR/>43% male<BR/>No CT before entry<BR/>All strokes (10% haemorrhagic on autopsy)<BR/>Less than 48 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin 5000 IU sc 8 hourly<BR/>Control: no treatment <BR/>Duration: 14 days<BR/>Antiplatelet therapy during follow up not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death but not cause of death<BR/>DVT (systematic I-125 scan)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: BP &gt; 120 diastolic, bleeding risk<BR/>FU: 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-NAT_x002d_COOP-1962">
<CHAR_METHODS>
<P>C = sealed envelopes (? opaque and sequentially numbered)<BR/>Patient only blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>30 participants<BR/>26 older than 55 years<BR/>53% male<BR/>No CT, 100% LP before entry<BR/>Cardioembolic stroke<BR/>Less than 2 weeks since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin 50 mg iv 4 hourly, then dicumarol (oral anticoagulant; PT 15 to 20%) <BR/>Control: placebo<BR/>Duration: 1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>Recurrent stroke<BR/>Extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: bleeding risk<BR/>FU: 1 year but only complete FU for all patients up to 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pambianco-1995">
<CHAR_METHODS>
<P>C = sealed, opaque but not sequentially numbered envelopes<BR/>Non-blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>131 participants<BR/>Mean age 71 years<BR/>50% male<BR/>100% CT before entry<BR/>Ischaemic stroke with severe leg weakness<BR/>Less than 14 days since stroke onset<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin 5000 IU sc 8 hourly, with dose adjustment to maintain PT 30 to 40 seconds<BR/>Control: no treatment<BR/>Duration: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>DVT (systematic B mode and Doppler ultrasound)<BR/>PE<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: bleeding risk, active cancer<BR/>FU: 28 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pince-1981">
<CHAR_METHODS>
<P>C = sealed envelopes (? opaque and sequentially numbered)<BR/>Non-blind<BR/>Exclusions during trial: Rx 0, control 4 participants (2 with intracranial haemorrhage)<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>France<BR/>80 participants<BR/>30 to 92 years<BR/>62% male<BR/>No CT, 100% LP before entry<BR/>Ischaemic stroke affecting the leg<BR/>Less than 7 days since stroke onset (89% &lt; 48 hours)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: heparin 5000 IU sc 8 hourly<BR/>Control: no treatment<BR/>Duration: 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death but not cause of death<BR/>DVT (systematic I-125 scan)<BR/>PE<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: bleeding risk<BR/>FU: 10 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Prins-1989">
<CHAR_METHODS>
<P>C = sequentially numbered identical syringes <BR/>Double-blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Netherlands<BR/>60 participants<BR/>78% &gt; 70 years<BR/>52% male<BR/>100% CT before entry<BR/>Ischaemic stroke less than 72 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: dalteparin (LMWH, Kabi 2165) 2500 anti-Xa units sc 12 hourly<BR/>Control: placebo<BR/>Duration: 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>DVT (systematic I-125 scan with venography)<BR/>PE<BR/>Intracranial haemorrhage (symptomatic plus systematic CT) <BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: coma<BR/>FU: 14 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sandset-1990">
<CHAR_METHODS>
<P>C = sequentially numbered identical ampoules <BR/>Doctor, patient and assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Norway<BR/>103 participants<BR/>47 to 90 years<BR/>45% male<BR/>100% CT before entry<BR/>Non-cardioembolic ischaemic stroke<BR/>Less than 72 hours since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: dalteparin (LMWH, Kabi 2165) 3000 to 5500 anti-Xa U sc 24 hourly<BR/>Control: placebo <BR/>Duration: 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>DVT (systematic venography or B mode ultrasound)<BR/>PE (symptomatic plus autopsy in 5/6 deaths) <BR/>Intracranial haemorrhage (systematic CT)<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: BP &gt; 120 diastolic, coma, bleeding risk <BR/>FU: 28 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-08 15:30:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tazaki-1986">
<CHAR_METHODS>
<P>C = numbered or coded containers administered sequentially to enrolled participants<BR/>Doctor, patient and assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Japanese<BR/>156 participants<BR/>68% &gt; 60 years<BR/>66% male <BR/>100% CT before entry<BR/>Ischaemic stroke within 7 to 10 days of stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-04-08 15:30:02 +0100" MODIFIED_BY="[Empty name]">
<P>Rx: MD805 (thrombin inhibitor) 60 mg/day versus 30 mg/day continuous iv for 2 days; then 20 mg 12 hourly iv for 5 days<BR/>Control: placebo<BR/>All patients received glycerol 500 mg/day<BR/>Duration: 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Functional outcome (graded on ADL-type scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: decreased level of consciousness, pregnancy, 'bleeding tendency', severe hepatic or renal damage<BR/>FU: 28 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tazaki-1992">
<CHAR_METHODS>
<P>C = numbered or coded containers administered sequentially to enrolled patients<BR/>Doctor, patient and assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Japanese<BR/>138 participants<BR/>Mean age 68 years <BR/>64% male<BR/>100% CT before entry<BR/>Ischaemic stroke within 5 to 7 days of stroke onset<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: MD805 (thrombin inhibitor) 60 mg/days for two days (continuous iv), then MD805 20 mg 12 hourly for 5 days (iv)<BR/>Control: placebo<BR/>All groups received glycerol 500 ml/day for 7 days<BR/>Duration: 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Functional outcome<BR/>Intracranial haemorrhage (symptomatic CT)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: decreased level of consciousness, bleeding risk, pregnancy, age &gt; 85 years, significant medical disease (cardiac, hepatic, renal)<BR/>FU: 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TOAST-1998">
<CHAR_METHODS>
<P>C = permuted blocks with randomly ordered sizes of 6, 6, and 4; randomisation lists pharmacy controlled<BR/>Doctor, patient and assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: 25 participants (11 treatment, 14 control)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>United States<BR/>1281 participants<BR/>Mean age 65 years<BR/>61% male<BR/>100% CT before entry<BR/>Ischaemic stroke &gt; 1 hour and &lt; 24 hours from symptom onset with estimated pre-stroke Barthel Index or 12 or more</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: danaparoid (heparinoid Org 10172) bolus followed by continuous infusion to maintain blood anti-Xa levels of 0.6 to 0.8<BR/>Control: placebo<BR/>Duration: 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Functional outcome: Barthel Index &lt; 85, NIHSS, Glasgow Outcome Scale<BR/>Recurrent stroke<BR/>Intracranial haemorrhage (symptomatic CT)<BR/>Extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: Age &lt; 18 or &gt; 85, women of childbearing potential, severe stroke (NIHSS score &gt; 15), weight less than 125 pounds<BR/>FU: 7 days and 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Turpie-1987">
<CHAR_METHODS>
<P>C = sequentially numbered identical containers <BR/>Double-blind<BR/>Exclusions during trial: none<BR/>Losses to FU: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Canada<BR/>75 participants<BR/>28 to 90 years <BR/>53% male<BR/>100% CT before entry<BR/>Non-cardioembolic ischaemic stroke with immobility<BR/>Less than 7 days since stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: danaparoid (heparinoid Org 10172) 750 anti-Xa units sc 12 hourly<BR/>Control: placebo <BR/>Duration: 14 days or prior discharge<BR/>Antiplatelet therapy during follow up not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death plus cause of death<BR/>DVT (systematic I-125 scan + plethysmography with venography) <BR/>PE (symptomatic)<BR/>Intracranial haemorrhage (symptomatic CT)<BR/>Extracranial haemorrhage<BR/>Recurrent stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ex: bleeding risk<BR/>FU: 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vissinger-1995">
<CHAR_METHODS>
<P>C = coded containers administered sequentially to enrolled participants<BR/>Doctor, patient and assessor blind<BR/>Exclusions during trial: none<BR/>Losses to FU: 31/50 participants lost to 6-month follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Denmark<BR/>50 participants<BR/>Mean age 71.8 years<BR/>58% male<BR/>66% CT before entry - haemorrhage excluded in remainder by cerebral scintigraphy<BR/>Non-embolic ischaemic stroke with motor deficit &lt; 24 hours since stroke onset<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: tinzaparin (LMWH) 3500 anti-Xa IU sc once daily<BR/>Control: placebo<BR/>Duration: 14 days or until full mobilisation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>DVT (venography) <BR/>PE (symptomatic)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Exclusion criteria: &lt; 50 years old, hypertension (BP &gt; 200/120 mmHg), coma, aphasia, bleeding risk, oral anticoagulant treatment, severe hepatic or renal disease, clinical suspicion of DVT or PE<BR/>FU: 12 to 14 days and 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living<BR/>APTT: activated partial thromboplastin time<BR/>bid: twice a day<BR/>BP: blood pressure<BR/>C: concealment of allocation<BR/>CSF: cerebrospinal fluid<BR/>CT: computerised tomography<BR/>DVT: Deep venous thrombosis<BR/>Ex: exclusion criteria<BR/>FU: follow up<BR/>GI: gastrointestinal<BR/>ICH: intracranial haemorrhage<BR/>im: intramuscularly<BR/>iv: intravenous, intravenously<BR/>LMWH: low-molecular-weight heparin<BR/>LP: lumbar puncture<BR/>MRS: modified Rankin Scale<BR/>NIHSS: National Institutes of Health Stroke Scale<BR/>OHS: Oxford Handicap Score<BR/>PE: pulmonary embolism<BR/>PT: prothrombin time<BR/>Rx: treatment<BR/>sc: subcutaneous, subcutaneously</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-02-18 12:03:45 +0000" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bradshaw-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-random: allocation by odd/even year of birth</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Camerlingo-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded by the use of low-dose unfractionated heparin in control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carter-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-random: alternate allocation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-10 13:45:38 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-COU-9116">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-10 13:45:38 +0000" MODIFIED_BY="Hazel Fraser">
<P>Participants randomised after 14 days of stroke onset</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Czechanowski-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded with dihydroergotamine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-10 13:45:45 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Dahan-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-10 13:45:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>Not all participants were stroke patients: individual patient data for stroke patients not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Methods of randomisation unclear; no clinically relevant outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dehen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control group received a low-molecular-weight heparin i.e. dermatan sulphate plus placebo versus low-molecular-weight heparin plus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Enger-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time from stroke to treatment unclear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eriksson-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-random: allocation by month of admission</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gelmers-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-random: alternate allocation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-31 14:07:55 +0100" MODIFIED_BY="Eddie Kane" STUDY_ID="STD-Kang-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-31 14:07:55 +0100" MODIFIED_BY="Eddie Kane">
<P>No clinical outcome data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kario-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinically relevant outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kobayashi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinically relevant outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded with urokinase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-18 12:03:18 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Lee-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-18 12:03:18 +0000" MODIFIED_BY="Hazel Fraser">
<P>Comparison of 2 anticoagulant regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-18 12:03:21 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Luo-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-18 12:03:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>Comparison of 2 anticoagulant regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCarthy-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data not available despite repeated contact with authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McDevitt-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Time from stroke to treatment unclear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-18 12:03:34 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Meredit-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-18 12:03:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>Comparison of 2 anticoagulant regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosin-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data not available despite repeated contact with authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shi-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinically relevant outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stiekema-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group: dose-finding trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tan-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised; no clinically relevant outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thygesen-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-random allocation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-18 12:03:45 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Tomek-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-18 12:03:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>Comparison of 2 anticoagulant regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsuchiya-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded with urokinase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsuchiya-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded with urokinase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-10 13:45:02 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-VA-Study-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-10 13:45:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment started acutely in only 50% and unable to get individual patient data for just these participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clearly randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-31 14:07:18 +0100" MODIFIED_BY="Eddie Kane" STUDY_ID="STD-Zhao-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-31 14:07:18 +0100" MODIFIED_BY="Eddie Kane">
<P>Anticoagulant versus antiplatelet regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-02-18 12:44:44 +0000" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-02-18 12:44:33 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Nosal-2014">
<CHAR_STUDY_NAME MODIFIED="2015-02-18 12:04:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>Safety and efficacy of heparin and nadroparin in the acute phase of ischemic stroke (Heparinas)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-02-18 12:05:17 +0000" MODIFIED_BY="Hazel Fraser">
<P>Double Blind (patient, caregiver, investigator, outcomes assessor)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-18 12:05:24 +0000" MODIFIED_BY="Hazel Fraser">
<P>18 to 80 years old</P>
<P>Estimated 150 participants</P>
<P>Slovakia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-18 12:05:56 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: heparin iv/nadroparin sc/placebo iv immediately</P>
<P>Followed by nadroparin sc at 24 hours</P>
<P>Duration of anticoagulation: 72 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-18 12:44:33 +0000" MODIFIED_BY="Hazel Fraser">
<P>Safety: incidence of intracranial haemorrhage</P>
<P>Efficacy: level of improvement measured by mRS, and NIHSS</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>May 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>Vladimir Nosal, MD, PhD, vnosal@gmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>ClinicalTrials.gov Identifier: NCT01862978</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>iv: intravenous<BR/>mRS: modified Rankin Scale<BR/>NIHSS: National Institutes of Health Stroke Scale<BR/>sc: subcutaneous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-11-10 10:29:10 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ARGIS_x002d_1-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-CESG-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cazzato-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chaudhary-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Duke-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Duke-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Elias-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-FISS-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-FISS_x002d_bis-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-IST-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kwiecinski-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marshall-1960">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McCarthy-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McCarthy-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-NAT_x002d_COOP-1962">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pambianco-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pince-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Prins-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sandset-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TOAST-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tazaki-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tazaki-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Turpie-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vissinger-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-02-09 11:22:21 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-02-09 11:22:21 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Anticoagulant versus control in acute presumed ischaemic stroke</NAME>
<DICH_OUTCOME CHI2="13.373979483807794" CI_END="1.0429943123696939" CI_START="0.9347009670710025" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9873640627557334" ESTIMABLE="YES" EVENTS_1="6698" EVENTS_2="6502" I2="47.659557811681466" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.018281940149261447" LOG_CI_START="-0.029327307975325328" LOG_EFFECT_SIZE="-0.005522683913031994" METHOD="PETO" MODIFIED="2015-02-09 11:22:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06350409780357935" P_Q="0.48492413849202776" P_Z="0.6493160445005184" Q="3.4538911714694445" RANDOM="NO" SCALE="37.8853334644617" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11269" TOTAL_2="10856" WEIGHT="99.99999999999999" Z="0.4547125608543875">
<NAME>Dead or dependent at end of follow up (if &gt; 1 month)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0605168818053556" CI_START="0.9442803285149433" DF="0" EFFECT_SIZE="1.0007123610442734" ESTIMABLE="YES" EVENTS_1="6063" EVENTS_2="6062" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.025517586210954703" LOG_CI_START="-0.02489905755136682" LOG_EFFECT_SIZE="3.092643297938891E-4" NO="1" P_CHI2="1.0" P_Z="0.9808163077019816" STUDIES="1" TAU2="0.0" TOTAL_1="9717" TOTAL_2="9718" WEIGHT="89.17328859254182" Z="0.024045509691463948">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="1.0605168818053556" CI_START="0.9442803285149431" EFFECT_SIZE="1.0007123610442734" ESTIMABLE="YES" EVENTS_1="6063" EVENTS_2="6062" LOG_CI_END="0.025517586210954703" LOG_CI_START="-0.02489905755136687" LOG_EFFECT_SIZE="3.092643297938891E-4" ORDER="4" O_E="0.8119372266528444" SE="0.029614986112399246" STUDY_ID="STD-IST-1997" TOTAL_1="9717" TOTAL_2="9718" VAR="1140.1892271964714" WEIGHT="89.17328859254182"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.92008831233835" CI_END="1.040201011644078" CI_START="0.6435110060161411" DF="3" EFFECT_SIZE="0.8181569528287884" ESTIMABLE="YES" EVENTS_1="420" EVENTS_2="237" I2="69.75833374115554" ID="CMP-001.01.02" LOG_CI_END="0.017117271810690952" LOG_CI_START="-0.19144402092555798" LOG_EFFECT_SIZE="-0.08716337455743355" MODIFIED="2015-02-09 09:06:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.019257805385660687" P_Z="0.10137094098430216" STUDIES="4" TAU2="0.0" TOTAL_1="800" TOTAL_2="428" WEIGHT="5.210929836773385" Z="1.6382433447954199">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="0.8714612552421224" CI_START="0.03127611413365115" EFFECT_SIZE="0.16509367547549333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.05975191665335179" LOG_CI_START="-1.504787210699978" LOG_EFFECT_SIZE="-0.7822695636766649" MODIFIED="2015-02-09 09:05:55 +0000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="-2.5" SE="0.8488208847630565" STUDY_ID="STD-Chaudhary-2002" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827585" WEIGHT="0.10854897742613856"/>
<DICH_DATA CI_END="0.8272792847057799" CI_START="0.3229699411846046" EFFECT_SIZE="0.51690070799397" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="68" LOG_CI_END="-0.08234785038628116" LOG_CI_START="-0.49083789557950225" LOG_EFFECT_SIZE="-0.2865928729828917" ORDER="5" O_E="-11.461538461538467" SE="0.23994907460483308" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="17.368481135485837" WEIGHT="1.358375034394107"/>
<DICH_DATA CI_END="1.4337949415221996" CI_START="0.778255497897375" EFFECT_SIZE="1.0563421775623167" ESTIMABLE="YES" EVENTS_1="300" EVENTS_2="142" LOG_CI_END="0.15648704384687118" LOG_CI_START="-0.10887780261067913" LOG_EFFECT_SIZE="0.02380462061809602" ORDER="6" O_E="2.2558746736292505" SE="0.15587662438634015" STUDY_ID="STD-FISS_x002d_bis-1998" TOTAL_1="516" TOTAL_2="250" VAR="41.156460266277634" WEIGHT="3.218813878636876"/>
<DICH_DATA CI_END="1.662211862007727" CI_START="0.36621523871213424" EFFECT_SIZE="0.7802097883488138" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.22068637723202705" LOG_CI_START="-0.43626358807666127" LOG_EFFECT_SIZE="-0.10778860542231711" MODIFIED="2015-02-09 09:06:34 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="-1.6666666666666679" SE="0.38589566157709865" STUDY_ID="STD-Kwiecinski-1995" TOTAL_1="62" TOTAL_2="58" VAR="6.715219421101776" WEIGHT="0.5251919463162628"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2737067523854777" CI_START="0.2900353343561051" DF="0" EFFECT_SIZE="0.8120685304553157" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.3567344515420327" LOG_CI_START="-0.5375490897524744" LOG_EFFECT_SIZE="-0.09040731910522083" MODIFIED="2015-02-09 11:22:21 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6918955963107285" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="0.28342109389603154" Z="0.39628391042187067">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="2.2737067523854777" CI_START="0.2900353343561051" EFFECT_SIZE="0.8120685304553157" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.3567344515420327" LOG_CI_START="-0.5375490897524744" LOG_EFFECT_SIZE="-0.09040731910522083" MODIFIED="2015-02-09 11:22:21 +0000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="-0.7543859649122808" SE="0.5253065789313169" STUDY_ID="STD-Cazzato-1989" TOTAL_1="28" TOTAL_2="29" VAR="3.623884272083718" WEIGHT="0.28342109389603154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.188893933500891" CI_START="0.7189160902692477" DF="0" EFFECT_SIZE="0.9245079655780623" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="167" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.075143111010611" LOG_CI_START="-0.1433217962090982" LOG_EFFECT_SIZE="-0.034089342599243615" NO="4" P_CHI2="1.0" P_Z="0.5407581238445682" STUDIES="1" TAU2="0.0" TOTAL_1="641" TOTAL_2="635" WEIGHT="4.749187066426847" Z="0.6116669684066932">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="1.188893933500891" CI_START="0.7189160902692477" EFFECT_SIZE="0.9245079655780623" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="167" LOG_CI_END="0.075143111010611" LOG_CI_START="-0.1433217962090982" LOG_EFFECT_SIZE="-0.034089342599243615" ORDER="10" O_E="-4.766457680250795" SE="0.12832736791958876" STUDY_ID="STD-TOAST-1998" TOTAL_1="641" TOTAL_2="635" VAR="60.72414751712538" WEIGHT="4.749187066426847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6170992042591172" CI_START="0.6228498151679577" DF="0" EFFECT_SIZE="1.2767379353841573" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="21" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.4178201854009559" LOG_CI_START="-0.20561666009335128" LOG_EFFECT_SIZE="0.10610176265380235" NO="5" P_CHI2="1.0" P_Z="0.5046913118108791" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="46" WEIGHT="0.583173410361895" Z="0.6671265421689564">
<NAME>Direct thrombin inhibitor versus control (intravenous)</NAME>
<DICH_DATA CI_END="2.6170992042591177" CI_START="0.6228498151679576" EFFECT_SIZE="1.2767379353841573" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="21" LOG_CI_END="0.41782018540095595" LOG_CI_START="-0.20561666009335136" LOG_EFFECT_SIZE="0.10610176265380235" ORDER="11" O_E="1.821705426356587" SE="0.36620988910551266" STUDY_ID="STD-ARGIS_x002d_1-2004" TOTAL_1="83" TOTAL_2="46" VAR="7.456583138032571" WEIGHT="0.583173410361895"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.382138508512554" CI_END="1.090363255421906" CI_START="0.9038061832414398" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9927119684125824" ESTIMABLE="YES" EVENTS_1="969" EVENTS_2="963" I2="15.81758768967881" I2_Q="14.463174152973474" ID="CMP-001.02" LOG_CI_END="0.037571207613493564" LOG_CI_START="-0.043924691840342735" LOG_EFFECT_SIZE="-0.0031767421134246136" METHOD="PETO" MODIFIED="2008-05-02 14:34:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2605739050386189" P_Q="0.31950643556274827" P_Z="0.8785557382058048" Q="7.014522622958162" RANDOM="NO" SCALE="807.8299071979499" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11403" TOTAL_2="11159" WEIGHT="100.0" Z="0.15280032915056732">
<NAME>Death from all causes during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.909947041979481" CI_END="1.0659979102857673" CI_START="0.8782416601266843" DF="3" EFFECT_SIZE="0.9675762370071664" ESTIMABLE="YES" EVENTS_1="889" EVENTS_2="916" I2="23.272618074100667" ID="CMP-001.02.01" LOG_CI_END="0.027756353328218027" LOG_CI_START="-0.05638596562151383" LOG_EFFECT_SIZE="-0.01431480614664794" NO="1" P_CHI2="0.27135391120380714" P_Z="0.504847429835332" STUDIES="5" TAU2="0.0" TOTAL_1="9872" TOTAL_2="9871" WEIGHT="93.80857973929187" Z="0.6668821312106694">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="5.841049241763352" CI_START="0.002246810152379241" EFFECT_SIZE="0.11455884399268773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7664908674853644" LOG_CI_START="-2.6484336223994553" LOG_EFFECT_SIZE="-0.9409713774570456" ORDER="12" O_E="-0.5384615384615384" SE="2.0059435495071947" STUDY_ID="STD-Duke-1983" TOTAL_1="35" TOTAL_2="30" VAR="0.2485207100591716" WEIGHT="0.05695204256168151"/>
<DICH_DATA CI_END="1.0636635456967518" CI_START="0.8752973983122491" EFFECT_SIZE="0.9648947788375419" ESTIMABLE="YES" EVENTS_1="876" EVENTS_2="905" LOG_CI_END="0.02680427518177586" LOG_CI_START="-0.057844362404568375" LOG_EFFECT_SIZE="-0.015520043611396245" ORDER="13" O_E="-14.454180602006659" SE="0.049723028735732526" STUDY_ID="STD-IST-1997" TOTAL_1="9717" TOTAL_2="9718" VAR="404.46863636872075" WEIGHT="92.68971985414039"/>
<DICH_DATA CI_END="2.5326529434200897" CI_START="0.10850771372898158" EFFECT_SIZE="0.5242255054454044" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.40357568126934346" LOG_CI_START="-0.9645393870610437" LOG_EFFECT_SIZE="-0.28048185289585015" ORDER="14" O_E="-1.0" SE="0.8036375634160796" STUDY_ID="STD-McCarthy-1977" TOTAL_1="16" TOTAL_2="16" VAR="1.5483870967741935" WEIGHT="0.3548348458220894"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-Pambianco-1995" TOTAL_1="64" TOTAL_2="67" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.862446660589681" CI_START="0.7367171738503064" EFFECT_SIZE="2.2484844472417644" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.8364789818513584" LOG_CI_START="-0.13269920604916555" LOG_EFFECT_SIZE="0.35188988790109643" ORDER="16" O_E="2.5" SE="0.569300065082171" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="40" VAR="3.085443037974683" WEIGHT="0.7070729967677117"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4292319044706554" CI_END="3.713746830277548" CI_START="0.10830619825491364" DF="1" EFFECT_SIZE="0.6342095871780852" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="58.83472474737211" ID="CMP-001.02.02" LOG_CI_END="0.5698122941369154" LOG_CI_START="-0.9653466884265863" LOG_EFFECT_SIZE="-0.1977671971448355" NO="2" P_CHI2="0.11909145380006614" P_Z="0.6135689576681593" STUDIES="2" TAU2="0.0" TOTAL_1="136" TOTAL_2="134" WEIGHT="0.2818154497834703" Z="0.5049855918897005">
<NAME>Unfractionated heparin (intravenous) versus control</NAME>
<DICH_DATA CI_END="1.8541258271909828" CI_START="0.006719138093306579" EFFECT_SIZE="0.11161598216770974" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2681392034872502" LOG_CI_START="-2.1726864330961946" LOG_EFFECT_SIZE="-0.9522736148044723" ORDER="17" O_E="-1.0666666666666667" SE="1.433753061210877" STUDY_ID="STD-CESG-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.4864646464646465" WEIGHT="0.11148026755440796"/>
<DICH_DATA CI_END="19.202118972602964" CI_START="0.20357711075717894" EFFECT_SIZE="1.9771474150548616" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.283349156168717" LOG_CI_START="-0.6912710535979122" LOG_EFFECT_SIZE="0.2960390512854024" ORDER="18" O_E="0.5066666666666666" SE="1.1599016857445978" STUDY_ID="STD-Duke-1986" TOTAL_1="112" TOTAL_2="113" VAR="0.7432888888888889" WEIGHT="0.17033518222906233"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.397288022159725" CI_END="2.9451387248064123" CI_START="0.8666686154868992" DF="4" EFFECT_SIZE="1.5976417937212413" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="16" I2="9.03484193342872" ID="CMP-001.02.03" LOG_CI_END="0.46910575616861766" LOG_CI_START="-0.062146930178550275" LOG_EFFECT_SIZE="0.2034794129950337" MODIFIED="2008-05-02 14:34:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.35490086611726457" P_Z="0.13325122944187817" STUDIES="6" TAU2="0.0" TOTAL_1="339" TOTAL_2="246" WEIGHT="2.3532563345965665" Z="1.5014034989933132">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="135" O_E="0.0" SE="0.0" STUDY_ID="STD-Chaudhary-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.807333480863482" CI_START="0.17219606955502612" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.763976765716537" LOG_CI_START="-0.7639767657165369" LOG_EFFECT_SIZE="0.0" ORDER="19" O_E="0.0" SE="0.8975274678557507" STUDY_ID="STD-Elias-1990" TOTAL_1="15" TOTAL_2="15" VAR="1.2413793103448276" WEIGHT="0.2844796608746062"/>
<DICH_DATA CI_END="2.3228618749572583" CI_START="0.38612120922242404" EFFECT_SIZE="0.947051337581635" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.36602338598303746" LOG_CI_START="-0.41327634239231165" LOG_EFFECT_SIZE="-0.023626478204637064" ORDER="20" O_E="-0.259615384615385" SE="0.45776451804355006" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="4.7721682418805536" WEIGHT="1.0936099802643227"/>
<DICH_DATA CI_END="8.879379166680522" CI_START="0.77687842210449" EFFECT_SIZE="2.6264420945983646" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.9483826015994921" LOG_CI_START="-0.10964694096800723" LOG_EFFECT_SIZE="0.4193678303157424" ORDER="21" O_E="2.5" SE="0.6214917906348514" STUDY_ID="STD-Prins-1989" TOTAL_1="30" TOTAL_2="30" VAR="2.5889830508474576" WEIGHT="0.5933021552539014"/>
<DICH_DATA CI_END="20.550426086567548" CI_START="0.7715651030172856" EFFECT_SIZE="3.981958264539145" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.312820830841126" LOG_CI_START="-0.11262742321290814" LOG_EFFECT_SIZE="0.6000967038141088" ORDER="22" O_E="1.970873786407767" SE="0.8373153605139961" STUDY_ID="STD-Sandset-1990" TOTAL_1="52" TOTAL_2="51" VAR="1.4263361297011967" WEIGHT="0.32686513710131243"/>
<DICH_DATA CI_END="665.6471532993894" CI_START="0.22296070578375105" EFFECT_SIZE="12.182493960703473" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.8232440790464643" LOG_CI_START="-0.6517716695302054" LOG_EFFECT_SIZE="1.0857362047581296" ORDER="23" O_E="0.6" SE="2.041241452319315" STUDY_ID="STD-Vissinger-1995" TOTAL_1="20" TOTAL_2="30" VAR="0.24" WEIGHT="0.05499940110242386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.102914638588829" CI_END="3.369142846302097" CI_START="0.3163915871492581" DF="1" EFFECT_SIZE="1.0324574821628683" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="52.44695235603786" ID="CMP-001.02.04" LOG_CI_END="0.5275194247672881" LOG_CI_START="-0.4997750729089666" LOG_EFFECT_SIZE="0.013872175929160785" MODIFIED="2008-05-02 14:34:43 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.14701870877528367" P_Z="0.9577851741061295" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="54" WEIGHT="0.6293345729851836" Z="0.05293314676533398">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="6.500306490036071" CI_START="0.43399366710710574" EFFECT_SIZE="1.6796106247969718" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.8129338341495284" LOG_CI_START="-0.362516607723676" LOG_EFFECT_SIZE="0.22520861321292618" ORDER="24" O_E="1.0877192982456139" SE="0.6904654081298482" STUDY_ID="STD-Cazzato-1989" TOTAL_1="28" TOTAL_2="29" VAR="2.0975684826100336" WEIGHT="0.4806875429786326"/>
<DICH_DATA CI_END="2.439761945804027" CI_START="0.018774911319278716" EFFECT_SIZE="0.2140240971774475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.3873474531144061" LOG_CI_START="-1.7264221056494324" LOG_EFFECT_SIZE="-0.6695373262675132" ORDER="26" O_E="-1.0" SE="1.241638702145945" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="0.6486486486486487" WEIGHT="0.14864703000655097"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1112208667894876" CI_START="0.5546769068032288" DF="0" EFFECT_SIZE="1.3136675252028014" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.4929308429386895" LOG_CI_START="-0.2559599149877612" LOG_EFFECT_SIZE="0.11848546397546408" NO="5" P_CHI2="1.0" P_Z="0.5351327738017428" STUDIES="1" TAU2="0.0" TOTAL_1="646" TOTAL_2="635" WEIGHT="1.1842259476527484" Z="0.6201898998631652">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="3.1112208667894876" CI_START="0.5546769068032288" EFFECT_SIZE="1.3136675252028014" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4929308429386895" LOG_CI_START="-0.2559599149877612" LOG_EFFECT_SIZE="0.11848546397546408" ORDER="27" O_E="1.4098360655737707" SE="0.43990213827503577" STUDY_ID="STD-TOAST-1998" TOTAL_1="646" TOTAL_2="635" VAR="5.167587678043536" WEIGHT="1.1842259476527484"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9670794743745543" CI_END="3.4780271022756537" CI_START="0.4649215418748468" DF="1" EFFECT_SIZE="1.2716169718403818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="0.541332961888345" LOG_CI_START="-0.3326203305632429" LOG_EFFECT_SIZE="0.10435631566255105" NO="6" P_CHI2="0.32540983129483536" P_Z="0.6397362331256835" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="0.8695510203180092" Z="0.46806762334892904">
<NAME>Oral vitamin K antagonist versus control</NAME>
<DICH_DATA CI_END="8.786275536054706" CI_START="0.5072834232518926" EFFECT_SIZE="2.1111920641107456" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9438048185413875" LOG_CI_START="-0.29474932910356055" LOG_EFFECT_SIZE="0.3245277447189136" ORDER="28" O_E="1.4117647058823533" SE="0.727532837268552" STUDY_ID="STD-Marshall-1960" TOTAL_1="26" TOTAL_2="25" VAR="1.889273356401384" WEIGHT="0.4329537630035096"/>
<DICH_DATA CI_END="3.1820714374170933" CI_START="0.18592363427886485" EFFECT_SIZE="0.7691698682212905" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.5027099253192958" LOG_CI_START="-0.730665399983446" LOG_EFFECT_SIZE="-0.11397773733207514" ORDER="29" O_E="-0.5" SE="0.724490771389156" STUDY_ID="STD-NAT_x002d_COOP-1962" TOTAL_1="15" TOTAL_2="15" VAR="1.9051724137931034" WEIGHT="0.4365972573144997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5611548039811437" CI_END="7.09462613476741" CI_START="0.9524071383799211" DF="2" EFFECT_SIZE="2.599417737665347" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" ID="CMP-001.02.07" LOG_CI_END="0.8509295143973612" LOG_CI_START="-0.021177358177498534" LOG_EFFECT_SIZE="0.4148760781099314" NO="7" P_CHI2="0.7553474976394946" P_Z="0.06221274810875141" STUDIES="3" TAU2="0.0" TOTAL_1="291" TOTAL_2="179" WEIGHT="0.8732369353721414" Z="1.864776432140531">
<NAME>Thrombin inhibitor versus control</NAME>
<DICH_DATA CI_END="11.925577033753324" CI_START="0.48249577182757314" EFFECT_SIZE="2.3987581152317112" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.076479402094708" LOG_CI_START="-0.31650648808184506" LOG_EFFECT_SIZE="0.37998645700643147" ORDER="30" O_E="1.3068181818181817" SE="0.818246807281071" STUDY_ID="STD-ARGIS_x002d_1-2004" TOTAL_1="118" TOTAL_2="58" VAR="1.4935898760330577" WEIGHT="0.34227728614359026"/>
<DICH_DATA CI_END="11.961244967342004" CI_START="0.17962764567973055" EFFECT_SIZE="1.4658002158828363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0777763848620714" LOG_CI_START="-0.7456268222222487" LOG_EFFECT_SIZE="0.16607478131991132" ORDER="31" O_E="0.3333333333333335" SE="1.071076069832774" STUDY_ID="STD-Tazaki-1986" TOTAL_1="104" TOTAL_2="52" VAR="0.8716845878136201" WEIGHT="0.1997588761665096"/>
<DICH_DATA CI_END="20.37216192281337" CI_START="0.7815371530057653" EFFECT_SIZE="3.9901881446528327" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3090371193942285" LOG_CI_START="-0.10705037150037985" LOG_EFFECT_SIZE="0.6009933739469243" ORDER="32" O_E="2.0" SE="0.8318168018976245" STUDY_ID="STD-Tazaki-1992" TOTAL_1="69" TOTAL_2="69" VAR="1.4452554744525548" WEIGHT="0.3312007730620415"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.582926532940691" CI_END="1.117977079581262" CI_START="0.9826758329070368" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0481455327617883" ESTIMABLE="YES" EVENTS_1="2469" EVENTS_2="2284" I2="28.474508879639334" I2_Q="0.08870391588035947" ID="CMP-001.03" LOG_CI_END="0.04843289987113866" LOG_CI_START="-0.007589724485451029" LOG_EFFECT_SIZE="0.02042158769284381" METHOD="PETO" MODIFIED="2008-05-02 14:35:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.18240418591619256" P_Q="0.42259374075144274" P_Z="0.1530307976165052" Q="6.005326960175094" RANDOM="NO" SCALE="28.74967859972762" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11613" TOTAL_2="11163" WEIGHT="100.0" Z="1.4289075831340368">
<NAME>Death from all causes at final follow up (if &gt; 1 month)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.796267066339368" CI_END="1.1163295352287694" CI_START="0.9754353260562022" DF="1" EFFECT_SIZE="1.0435071941208856" ESTIMABLE="YES" EVENTS_1="2196" EVENTS_2="2129" I2="82.74751683187107" ID="CMP-001.03.01" LOG_CI_END="0.04779241521614962" LOG_CI_START="-0.010801520188512582" LOG_EFFECT_SIZE="0.01849544751381855" NO="1" P_CHI2="0.01606026881424516" P_Z="0.2159596281556455" STUDIES="2" TAU2="0.0" TOTAL_1="9861" TOTAL_2="9879" WEIGHT="91.41586282979455" Z="1.2373434470541056">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="1.1296303504957752" CI_START="0.9858412276430837" EFFECT_SIZE="1.0552896149946904" ESTIMABLE="YES" EVENTS_1="2165" EVENTS_2="2076" LOG_CI_END="0.052936352330041535" LOG_CI_START="-0.006193023710714602" LOG_EFFECT_SIZE="0.02337166430966347" ORDER="33" O_E="44.60910728067938" SE="0.03473288818147206" STUDY_ID="STD-IST-1997" TOTAL_1="9717" TOTAL_2="9718" VAR="828.9306605614263" WEIGHT="89.76774306270592"/>
<DICH_DATA CI_END="0.9356121297027562" CI_START="0.3425402386779094" EFFECT_SIZE="0.5661137714438055" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="53" LOG_CI_END="-0.02890415643446803" LOG_CI_START="-0.465288403998408" LOG_EFFECT_SIZE="-0.247096280216438" ORDER="34" O_E="-8.65901639344262" SE="0.256334267155922" STUDY_ID="STD-McCarthy-1986" TOTAL_1="144" TOTAL_2="161" VAR="15.219019222336948" WEIGHT="1.648119767088634"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.186568178120623" CI_START="0.9867595578680409" DF="0" EFFECT_SIZE="2.2622766679375794" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.7148800911271593" LOG_CI_START="-0.005788658285124358" LOG_EFFECT_SIZE="0.3545457164210175" NO="2" P_CHI2="1.0" P_Z="0.053795725428958996" STUDIES="1" TAU2="0.0" TOTAL_1="112" TOTAL_2="113" WEIGHT="0.6043040690827591" Z="1.9284777801863742">
<NAME>Unfractionated heparin (intravenous) versus control</NAME>
<DICH_DATA CI_END="5.186568178120622" CI_START="0.986759557868041" EFFECT_SIZE="2.2622766679375794" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.7148800911271592" LOG_CI_START="-0.005788658285124308" LOG_EFFECT_SIZE="0.3545457164210175" ORDER="35" O_E="4.555555555555555" SE="0.42332439077261874" STUDY_ID="STD-Duke-1986" TOTAL_1="112" TOTAL_2="113" VAR="5.580246913580248" WEIGHT="0.6043040690827591"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7813325064262305" CI_END="1.3245599081311963" CI_START="0.7439305440467319" DF="2" EFFECT_SIZE="0.9926633734950282" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="93" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.12207160565508128" LOG_CI_START="-0.1284676098107339" LOG_EFFECT_SIZE="-0.003198002077826358" MODIFIED="2008-05-02 14:35:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6766061293762683" P_Z="0.9600938352303008" STUDIES="4" TAU2="0.0" TOTAL_1="800" TOTAL_2="428" WEIGHT="5.00006295292681" Z="0.05003583078497449">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Chaudhary-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4499598400622924" CI_START="0.41203386715611134" EFFECT_SIZE="0.7729376172252992" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="20" LOG_CI_END="0.16135597362747478" LOG_CI_START="-0.38506708563064057" LOG_EFFECT_SIZE="-0.11185555600158287" ORDER="36" O_E="-2.5" SE="0.32097160984598333" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="9.706591639871384" WEIGHT="1.0511600858779124"/>
<DICH_DATA CI_END="1.4779892694650318" CI_START="0.7542081140970665" EFFECT_SIZE="1.055798986350585" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="68" LOG_CI_END="0.16967128099450274" LOG_CI_START="-0.12250879957740783" LOG_EFFECT_SIZE="0.023581240708547484" ORDER="37" O_E="1.843342036553537" SE="0.17162802564266497" STUDY_ID="STD-FISS_x002d_bis-1998" TOTAL_1="516" TOTAL_2="250" VAR="33.9487342769597" WEIGHT="3.6764248216058912"/>
<DICH_DATA CI_END="3.901930066277005" CI_START="0.329638100495649" EFFECT_SIZE="1.1341185190774437" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5912794813316492" LOG_CI_START="-0.48196259710017514" LOG_EFFECT_SIZE="0.05465844211573706" ORDER="38" O_E="0.31666666666666643" SE="0.6304277095048229" STUDY_ID="STD-Kwiecinski-1995" TOTAL_1="62" TOTAL_2="58" VAR="2.5161087768440713" WEIGHT="0.27247804544300663"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0472493498032214" CI_START="0.0931808053684825" DF="0" EFFECT_SIZE="0.43676577613724077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.3111707418557323" LOG_CI_START="-1.0306735402327611" LOG_EFFECT_SIZE="-0.35975139918851445" MODIFIED="2008-05-02 14:35:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2932855667257249" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="25" WEIGHT="0.1743101428638621" Z="1.0509412980468025">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="2.0472493498032214" CI_START="0.0931808053684825" EFFECT_SIZE="0.43676577613724077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.3111707418557323" LOG_CI_START="-1.0306735402327611" LOG_EFFECT_SIZE="-0.35975139918851445" ORDER="40" O_E="-1.333333333333333" SE="0.788205973535102" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="1.6096096096096095" WEIGHT="0.1743101428638621"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7172824813626266" CI_START="0.6947648035287415" DF="0" EFFECT_SIZE="1.0922945691374901" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="0.23484173954440662" LOG_CI_START="-0.15816219083004138" LOG_EFFECT_SIZE="0.03833977435718267" NO="5" P_CHI2="1.0" P_Z="0.7021562921325144" STUDIES="1" TAU2="0.0" TOTAL_1="646" TOTAL_2="635" WEIGHT="2.0320440171653673" Z="0.38241132521943866">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="1.7172824813626266" CI_START="0.6947648035287415" EFFECT_SIZE="1.0922945691374901" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" LOG_CI_END="0.23484173954440662" LOG_CI_START="-0.15816219083004138" LOG_EFFECT_SIZE="0.03833977435718267" ORDER="41" O_E="1.656518345042933" SE="0.23085245410278113" STUDY_ID="STD-TOAST-1998" TOTAL_1="646" TOTAL_2="635" VAR="18.764241273863302" WEIGHT="2.0320440171653673"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.757653481033948" CI_START="0.3456750085909118" DF="0" EFFECT_SIZE="1.139704742175832" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="0.5749167283420658" LOG_CI_START="-0.46133201769044613" LOG_EFFECT_SIZE="0.05679235532580979" NO="6" P_CHI2="1.0" P_Z="0.8298963833550079" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.2922798411110077" Z="0.21483446221182967">
<NAME>Oral vitamin K antagonist versus control</NAME>
<DICH_DATA CI_END="3.757653481033948" CI_START="0.3456750085909118" EFFECT_SIZE="1.139704742175832" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5749167283420658" LOG_CI_START="-0.46133201769044613" LOG_EFFECT_SIZE="0.05679235532580979" ORDER="42" O_E="0.35294117647058787" SE="0.608697642933518" STUDY_ID="STD-Marshall-1960" TOTAL_1="26" TOTAL_2="25" VAR="2.6989619377162626" WEIGHT="0.2922798411110077"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.528791772137408" CI_START="0.7052136555147445" DF="0" EFFECT_SIZE="1.787111020808198" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" I2="0.0" ID="CMP-001.03.07" LOG_CI_END="0.6559823528554793" LOG_CI_START="-0.15167928676227532" LOG_EFFECT_SIZE="0.25215153304660204" NO="7" P_CHI2="1.0" P_Z="0.22102792582927455" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="58" WEIGHT="0.48113614705564967" Z="1.2237994208856993">
<NAME>Direct thrombin inhibitor (intravenous) versus control</NAME>
<DICH_DATA CI_END="4.528791772137408" CI_START="0.7052136555147445" EFFECT_SIZE="1.787111020808198" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.6559823528554793" LOG_CI_START="-0.15167928676227532" LOG_EFFECT_SIZE="0.25215153304660204" ORDER="43" O_E="2.579545454545455" SE="0.47442444510106396" STUDY_ID="STD-ARGIS_x002d_1-2004" TOTAL_1="118" TOTAL_2="58" VAR="4.442893299881936" WEIGHT="0.48113614705564967"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.60693450923793" CI_END="0.28641005760689997" CI_START="0.15498117351000346" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.21068499432324328" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="204" I2="71.52523602891789" I2_Q="74.6314872617929" ID="CMP-001.04" LOG_CI_END="-0.5430117353638888" LOG_CI_START="-0.8097210549736275" LOG_EFFECT_SIZE="-0.6763663951687581" METHOD="PETO" MODIFIED="2014-11-14 15:23:14 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.3279817885812903E-4" P_Q="0.019411446879021077" P_Z="2.765598663054208E-23" Q="7.883788934097946" RANDOM="NO" SCALE="146.5253845360764" SORT_BY="EFFECT_SIZE" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="456" TOTAL_2="460" WEIGHT="100.0" Z="9.940813293091598">
<NAME>Deep vein thrombosis during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.931073586232182" CI_END="0.2392642718629615" CI_START="0.11266833604680884" DF="4" EFFECT_SIZE="0.16418741543203358" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="149" I2="55.21255130887899" ID="CMP-001.04.01" LOG_CI_END="-0.6211221475679666" LOG_CI_START="-0.9481981195555034" LOG_EFFECT_SIZE="-0.7846601335617349" NO="1" P_CHI2="0.06284565332288683" P_Z="5.254445847019828E-21" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="310" WEIGHT="66.49348594703814" Z="9.403965644678971">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.33774744385758015" CI_START="0.021597492687434657" EFFECT_SIZE="0.08540783306532156" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.47140792912384055" LOG_CI_START="-1.665596664368351" LOG_EFFECT_SIZE="-1.0685022967460958" ORDER="45" O_E="-5.0" SE="0.7014723744122017" STUDY_ID="STD-McCarthy-1977" TOTAL_1="16" TOTAL_2="16" VAR="2.032258064516129" WEIGHT="4.988045916259886"/>
<DICH_DATA CI_END="1.0721421152760842" CI_START="0.010643808646172474" EFFECT_SIZE="0.1068254441437115" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.03025235605586501" LOG_CI_START="-1.9729029417736363" LOG_EFFECT_SIZE="-0.9713252928588857" ORDER="44" O_E="-1.6153846153846154" SE="1.176663337723693" STUDY_ID="STD-Duke-1983" TOTAL_1="35" TOTAL_2="30" VAR="0.7222633136094675" WEIGHT="1.7727485671323044"/>
<DICH_DATA CI_END="0.20942306825402304" CI_START="0.08531750831198695" EFFECT_SIZE="0.13366919752315573" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="117" LOG_CI_END="-0.6789754818566148" LOG_CI_START="-1.0689618365577733" LOG_EFFECT_SIZE="-0.873968659207194" ORDER="46" O_E="-38.347540983606564" SE="0.22907991521505036" STUDY_ID="STD-McCarthy-1986" TOTAL_1="144" TOTAL_2="161" VAR="19.05574675737988" WEIGHT="46.7710973591646"/>
<DICH_DATA CI_END="0.9462210868565075" CI_START="0.12798629630486644" EFFECT_SIZE="0.34799904079225524" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.02400737778039618" LOG_CI_START="-0.8928365284598021" LOG_EFFECT_SIZE="-0.45842195312009915" ORDER="48" O_E="-4.052631578947368" SE="0.5103545438827409" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="36" VAR="3.839335180055401" WEIGHT="9.423399764236127"/>
<DICH_DATA CI_END="5.3660005327602915" CI_START="0.20499582065327143" EFFECT_SIZE="1.0488125108135808" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7296507114546014" LOG_CI_START="-0.68825499302095" LOG_EFFECT_SIZE="0.02069785921682572" ORDER="47" O_E="0.06870229007633588" SE="0.8328848295553729" STUDY_ID="STD-Pambianco-1995" TOTAL_1="64" TOTAL_2="67" VAR="1.4415512813042093" WEIGHT="3.5381943402452176"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.792071988907797" CI_END="0.7288673168097499" CI_START="0.23360058112406407" DF="3" EFFECT_SIZE="0.41263037790387525" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="48" I2="79.7188656041586" ID="CMP-001.04.02" LOG_CI_END="-0.1373515235639924" LOG_CI_START="-0.6315260811715371" LOG_EFFECT_SIZE="-0.38443880236776473" NO="2" P_CHI2="0.002003252638659969" P_Z="0.0022924255371502226" STUDIES="4" TAU2="0.0" TOTAL_1="107" TOTAL_2="125" WEIGHT="29.128332180517525" Z="3.0494738966263086">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="0.16764518582173724" CI_START="0.009480303747860174" EFFECT_SIZE="0.039866367823724935" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.77560891346137" LOG_CI_START="-2.0231777476929196" LOG_EFFECT_SIZE="-1.3993933305771449" ORDER="49" O_E="-6.0" SE="0.73282810879294" STUDY_ID="STD-Elias-1990" TOTAL_1="15" TOTAL_2="15" VAR="1.8620689655172413" WEIGHT="4.570327785341571"/>
<DICH_DATA CI_END="0.9007842470589883" CI_START="0.1063319469675729" EFFECT_SIZE="0.3094869024490397" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.045379217380802056" LOG_CI_START="-0.9733362339971964" LOG_EFFECT_SIZE="-0.5093577256889992" ORDER="50" O_E="-3.947368421052632" SE="0.5450865450217847" STUDY_ID="STD-Prins-1989" TOTAL_1="27" TOTAL_2="30" VAR="3.365650969529085" WEIGHT="8.260772520596605"/>
<DICH_DATA CI_END="4.113460917462169" CI_START="0.13094844076173315" EFFECT_SIZE="0.7339286704278553" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.6142073753723332" LOG_CI_START="-0.882899668469042" LOG_EFFECT_SIZE="-0.1343461465483544" ORDER="52" O_E="-0.3999999999999999" SE="0.8794080883518106" STUDY_ID="STD-Vissinger-1995" TOTAL_1="20" TOTAL_2="30" VAR="1.2930612244897959" WEIGHT="3.173735104269847"/>
<DICH_DATA CI_END="2.266157094842036" CI_START="0.4159682541792524" EFFECT_SIZE="0.9709013391881629" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.3552900127904902" LOG_CI_START="-0.38093981254840037" LOG_EFFECT_SIZE="-0.012824899878955093" ORDER="51" O_E="-0.15789473684210442" SE="0.4324650438004758" STUDY_ID="STD-Sandset-1990" TOTAL_1="45" TOTAL_2="50" VAR="5.346849767195144" WEIGHT="13.123496770309503"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4607369332303074" CI_START="0.024479470726240814" DF="0" EFFECT_SIZE="0.10620073572960441" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-0.33654697278049733" LOG_CI_START="-1.6111979763613595" LOG_EFFECT_SIZE="-0.9738724745709284" NO="3" P_CHI2="1.0" P_Z="0.0027449411946500212" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="25" WEIGHT="4.378181872444328" Z="2.9949452365105063">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.4607369332303074" CI_START="0.024479470726240814" EFFECT_SIZE="0.10620073572960441" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-0.33654697278049733" LOG_CI_START="-1.6111979763613595" LOG_EFFECT_SIZE="-0.9738724745709284" ORDER="53" O_E="-4.0" SE="0.7487363091276265" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="1.7837837837837838" WEIGHT="4.378181872444328"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.434493703910594" CI_END="0.8117655053711197" CI_START="0.44369864567328554" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6001493608573253" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="104" I2="13.7476119552689" I2_Q="49.257907178888225" ID="CMP-001.05" LOG_CI_END="-0.0905694072503991" LOG_CI_START="-0.3529118969032703" LOG_EFFECT_SIZE="-0.2217406520768347" METHOD="PETO" MODIFIED="2008-05-02 14:36:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.31646829331629833" P_Q="0.11595856081390188" P_Z="9.221708890038526E-4" Q="5.912251216315261" RANDOM="NO" SCALE="758.2368826239217" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11470" TOTAL_2="11074" WEIGHT="100.0" Z="3.313254307787395">
<NAME>Symptomatic pulmonary embolism during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3703373005633517" CI_END="0.9575268093222328" CI_START="0.4901128376001557" DF="2" EFFECT_SIZE="0.685051955398379" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="82" I2="15.623822840544026" ID="CMP-001.05.01" LOG_CI_END="-0.018849057591493745" LOG_CI_START="-0.3097039217969183" LOG_EFFECT_SIZE="-0.16427648969420605" NO="1" P_CHI2="0.3056946746830528" P_Z="0.026828935679386396" STUDIES="3" TAU2="0.0" TOTAL_1="9820" TOTAL_2="9825" WEIGHT="81.35506734514311" Z="2.213997721419604">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.9223890988678225" CI_START="0.4674896396429138" EFFECT_SIZE="0.6566638009211946" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="81" LOG_CI_END="-0.0350858383342669" LOG_CI_START="-0.33022800938134655" LOG_EFFECT_SIZE="-0.18265692385780674" ORDER="54" O_E="-13.993104867757538" SE="0.17336797225036363" STUDY_ID="STD-IST-1997" TOTAL_1="9716" TOTAL_2="9718" VAR="33.27072470294914" WEIGHT="79.00866729365862"/>
<DICH_DATA CI_END="20.193534278633482" CI_START="0.21068269877750773" EFFECT_SIZE="2.0626265536152237" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3052123359510344" LOG_CI_START="-0.6763711271065039" LOG_EFFECT_SIZE="0.31442060442226527" ORDER="55" O_E="0.5343511450381679" SE="1.1639919351963375" STUDY_ID="STD-Pambianco-1995" TOTAL_1="64" TOTAL_2="67" VAR="0.7380742560277551" WEIGHT="1.752719961863124"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="56" O_E="0.5" SE="2.0" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="40" VAR="0.25" WEIGHT="0.5936800896213664"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Unfractionated heparin (intravenous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-CESG-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1519051870319847" CI_END="0.6442667395991757" CI_START="0.15177131564719698" DF="4" EFFECT_SIZE="0.3126998731958441" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="-0.19093428861546585" LOG_CI_START="-0.8188103011235246" LOG_EFFECT_SIZE="-0.5048722948694951" NO="3" P_CHI2="0.7078435683900244" P_Z="0.0016215818553187975" STUDIES="7" TAU2="0.0" TOTAL_1="902" TOTAL_2="539" WEIGHT="17.457798978989402" Z="3.151996556720174">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="58" O_E="-0.5" SE="2.0" STUDY_ID="STD-Elias-1990" TOTAL_1="15" TOTAL_2="15" VAR="0.25" WEIGHT="0.5936800896213664"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="59" O_E="0.0" SE="0.0" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6454770978704044" CI_START="0.11007551830295811" EFFECT_SIZE="0.2665543586227282" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="-0.19011916229757103" LOG_CI_START="-0.9583092609392091" LOG_EFFECT_SIZE="-0.57421421161839" ORDER="60" O_E="-6.493472584856397" SE="0.4512386665444141" STUDY_ID="STD-FISS_x002d_bis-1998" TOTAL_1="516" TOTAL_2="250" VAR="4.911197345751763" WEIGHT="11.662720321496494"/>
<DICH_DATA CI_END="2.010887946140083" CI_START="0.0076612920431726635" EFFECT_SIZE="0.12412090807545212" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.30338787083100893" LOG_CI_START="-2.1156979823384416" LOG_EFFECT_SIZE="-0.9061550557537164" ORDER="61" O_E="-1.0333333333333334" SE="1.4209830048198333" STUDY_ID="STD-Kwiecinski-1995" TOTAL_1="62" TOTAL_2="58" VAR="0.49524743230625595" WEIGHT="1.1760741599853186"/>
<DICH_DATA CI_END="5.0152107443983525" CI_START="0.05015724028530737" EFFECT_SIZE="0.5015467379898342" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7002891872480179" LOG_CI_START="-1.2996663669507513" LOG_EFFECT_SIZE="-0.29968858985136676" ORDER="62" O_E="-0.5" SE="1.1747837924760145" STUDY_ID="STD-Prins-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="1.7206660224619266"/>
<DICH_DATA CI_END="7.167269645905858" CI_START="0.13405028079756146" EFFECT_SIZE="0.9801910571850363" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8553537437364703" LOG_CI_START="-0.8727322719555981" LOG_EFFECT_SIZE="-0.00868926410956388" ORDER="63" O_E="-0.01941747572815533" SE="1.0150862797812585" STUDY_ID="STD-Sandset-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.9704967480441133" WEIGHT="2.3046583854242955"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="64" O_E="0.0" SE="0.0" STUDY_ID="STD-Vissinger-1995" TOTAL_1="20" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="386.1576267412401" CI_START="0.15185683543512074" DF="0" EFFECT_SIZE="7.657719972423989" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="2.586764616719195" LOG_CI_START="-0.8185656546845261" LOG_EFFECT_SIZE="0.8840994810173343" NO="4" P_CHI2="1.0" P_Z="0.3088203287788863" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="54" WEIGHT="0.5934973626008613" Z="1.017700489198215">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="386.1576267412401" CI_START="0.15185683543512074" EFFECT_SIZE="7.657719972423989" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.586764616719195" LOG_CI_START="-0.8185656546845261" LOG_EFFECT_SIZE="0.8840994810173343" ORDER="65" O_E="0.5087719298245614" SE="2.0003078580792497" STUDY_ID="STD-Cazzato-1989" TOTAL_1="28" TOTAL_2="29" VAR="0.24992305324715297" WEIGHT="0.5934973626008613"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="66" O_E="0.0" SE="0.0" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.704303709207294" CI_START="0.0026388941447867244" DF="0" EFFECT_SIZE="0.13301108150488455" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="0.8263536798831429" LOG_CI_START="-2.578578030491223" LOG_EFFECT_SIZE="-0.8761121753040402" NO="5" P_CHI2="1.0" P_Z="0.3131548967734452" STUDIES="1" TAU2="0.0" TOTAL_1="646" TOTAL_2="635" WEIGHT="0.5936363132666302" Z="1.0086242286628202">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="6.704303709207294" CI_START="0.0026388941447867244" EFFECT_SIZE="0.13301108150488455" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8263536798831429" LOG_CI_START="-2.578578030491223" LOG_EFFECT_SIZE="-0.8761121753040402" ORDER="67" O_E="-0.5042935206869633" SE="2.000073741357698" STUDY_ID="STD-TOAST-1998" TOTAL_1="646" TOTAL_2="635" VAR="0.24998156568011062" WEIGHT="0.5936363132666302"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.900600575911408" CI_END="0.8811063182472801" CI_START="0.6499556442719309" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7567562518727413" ESTIMABLE="YES" EVENTS_1="300" EVENTS_2="388" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.05497168450252565" LOG_CI_START="-0.1871162804421228" LOG_EFFECT_SIZE="-0.12104398247232424" METHOD="PETO" MODIFIED="2008-05-02 14:36:23 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.43930231495467875" P_Q="0.5897671680114218" P_Z="3.29866793951783E-4" Q="4.647376427230112" RANDOM="NO" SCALE="388.461690874322" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10866" TOTAL_2="10739" WEIGHT="100.00000000000001" Z="3.5906401545091646">
<NAME>Recurrent ischaemic or unknown stroke during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8873040807088648" CI_START="0.6494402297470759" DF="0" EFFECT_SIZE="0.7591119588249702" ESTIMABLE="YES" EVENTS_1="283" EVENTS_2="370" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.05192752115741751" LOG_CI_START="-0.18746081239001094" LOG_EFFECT_SIZE="-0.11969416677371421" NO="1" P_CHI2="1.0" P_Z="5.365262474831263E-4" STUDIES="2" TAU2="0.0" TOTAL_1="9781" TOTAL_2="9785" WEIGHT="95.06197771298463" Z="3.461824824033998">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.8873040807088648" CI_START="0.6494402297470759" EFFECT_SIZE="0.7591119588249702" ESTIMABLE="YES" EVENTS_1="283" EVENTS_2="370" LOG_CI_END="-0.05192752115741751" LOG_CI_START="-0.18746081239001094" LOG_EFFECT_SIZE="-0.11969416677371421" ORDER="68" O_E="-43.4832004116285" SE="0.07961292617063713" STUDY_ID="STD-IST-1997" TOTAL_1="9717" TOTAL_2="9718" VAR="157.77305196472327" WEIGHT="95.06197771298463"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="69" O_E="0.0" SE="0.0" STUDY_ID="STD-Pambianco-1995" TOTAL_1="64" TOTAL_2="67" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8541258271909828" CI_START="0.006719138093306579" DF="0" EFFECT_SIZE="0.11161598216770974" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.2681392034872502" LOG_CI_START="-2.1726864330961946" LOG_EFFECT_SIZE="-0.9522736148044723" NO="2" P_CHI2="1.0" P_Z="0.12618102108538956" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="0.29310640064639815" Z="1.5293365986249357">
<NAME>Unfractionated heparin (intravenous) versus control</NAME>
<DICH_DATA CI_END="1.8541258271909828" CI_START="0.006719138093306579" EFFECT_SIZE="0.11161598216770974" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2681392034872502" LOG_CI_START="-2.1726864330961946" LOG_EFFECT_SIZE="-0.9522736148044723" ORDER="70" O_E="-1.0666666666666667" SE="1.433753061210877" STUDY_ID="STD-CESG-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.4864646464646465" WEIGHT="0.29310640064639815"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.584391755316544" CI_START="0.13833604320530501" DF="0" EFFECT_SIZE="0.4681650203908858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.19986257380430392" LOG_CI_START="-0.8590646505069658" LOG_EFFECT_SIZE="-0.32960103835133087" NO="3" P_CHI2="1.0" P_Z="0.22242154256982127" STUDIES="2" TAU2="0.0" TOTAL_1="227" TOTAL_2="135" WEIGHT="1.5572795729308642" Z="1.2201143753873713">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="1.5843917553165436" CI_START="0.13833604320530507" EFFECT_SIZE="0.4681650203908858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.1998625738043038" LOG_CI_START="-0.8590646505069656" LOG_EFFECT_SIZE="-0.32960103835133087" ORDER="71" O_E="-1.9615384615384617" SE="0.6220190933347383" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="2.5845954070663444" WEIGHT="1.5572795729308642"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Vissinger-1995" TOTAL_1="20" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="286.4922465251166" CI_START="0.07010848344695701" DF="0" EFFECT_SIZE="4.481689070338065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="2.4571128729459137" LOG_CI_START="-1.1542294272361584" LOG_EFFECT_SIZE="0.6514417228548778" NO="4" P_CHI2="1.0" P_Z="0.4795001272643743" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="54" WEIGHT="0.13389411989661043" Z="0.7071067811865477">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="73" O_E="0.0" SE="0.0" STUDY_ID="STD-Cazzato-1989" TOTAL_1="28" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="286.4922465251166" CI_START="0.07010848344695701" EFFECT_SIZE="4.481689070338065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4571128729459137" LOG_CI_START="-1.1542294272361584" LOG_EFFECT_SIZE="0.6514417228548778" ORDER="74" O_E="0.33333333333333337" SE="2.1213203435596424" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="0.2222222222222222" WEIGHT="0.13389411989661043"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8170578014345606" CI_START="0.3428726581498337" DF="0" EFFECT_SIZE="0.9827980955107688" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="0.4497957580921061" LOG_CI_START="-0.4648671456464821" LOG_EFFECT_SIZE="-0.007535693777188027" NO="5" P_CHI2="1.0" P_Z="0.9742365015684394" STUDIES="1" TAU2="0.0" TOTAL_1="646" TOTAL_2="635" WEIGHT="2.0872606391562942" Z="0.03229536989297726">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="2.8170578014345606" CI_START="0.3428726581498337" EFFECT_SIZE="0.9827980955107688" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4497957580921061" LOG_CI_START="-0.4648671456464821" LOG_EFFECT_SIZE="-0.007535693777188027" ORDER="75" O_E="-0.060109289617486183" SE="0.5372775173104413" STUDY_ID="STD-TOAST-1998" TOTAL_1="646" TOTAL_2="635" VAR="3.4641976656514077" WEIGHT="2.0872606391562942"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2532241486812996" CI_END="3.8992859175296544" CI_START="0.10693974727622232" DF="1" EFFECT_SIZE="0.6457465838688998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="55.6191513132304" ID="CMP-001.06.06" LOG_CI_END="0.5909850812646177" LOG_CI_START="-0.9708608465744829" LOG_EFFECT_SIZE="-0.18993788265493253" NO="6" P_CHI2="0.1333364425256255" P_Z="0.6335708102502485" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="0.7158506695015282" Z="0.4767069563878439">
<NAME>Oral vitamin K antagonist versus control</NAME>
<DICH_DATA CI_END="2.0520807864766826" CI_START="0.007580928432846968" EFFECT_SIZE="0.12472641091885889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3121944541154169" LOG_CI_START="-2.120277603263649" LOG_EFFECT_SIZE="-0.9040415745741162" ORDER="76" O_E="-1.0196078431372548" SE="1.428846127435341" STUDY_ID="STD-Marshall-1960" TOTAL_1="26" TOTAL_2="25" VAR="0.48981161091887726" WEIGHT="0.2951230255160583"/>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="77" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-NAT_x002d_COOP-1962" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="0.4207276439854699"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="372.3848896839504" CI_START="0.1466175227450357" DF="0" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.06.07" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" NO="7" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="69" WEIGHT="0.15063088488368676" Z="1.0">
<NAME>Thrombin inhibitor versus control</NAME>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="78" O_E="0.5" SE="2.0" STUDY_ID="STD-Tazaki-1992" TOTAL_1="69" TOTAL_2="69" VAR="0.25" WEIGHT="0.15063088488368676"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.8813718851134515" CI_END="3.3324157099728677" CI_START="1.9507540130743597" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.549651607467501" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.5227591731926865" LOG_CI_START="0.29020250901536065" LOG_EFFECT_SIZE="0.40648084110402355" METHOD="PETO" MODIFIED="2008-05-02 14:36:45 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7517299576402642" P_Q="0.8554619486456756" P_Z="7.304965058351896E-12" Q="2.6143071807373497" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11701" TOTAL_2="11242" WEIGHT="100.0" Z="6.8515586236819725">
<NAME>Symptomatic intracranial haemorrhage during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.668673353927917" CI_START="1.972700951369211" DF="0" EFFECT_SIZE="2.690203601134397" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="41" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.564509045388588" LOG_CI_START="0.29506125402371153" LOG_EFFECT_SIZE="0.4297851497061498" NO="1" P_CHI2="1.0" P_Z="4.0389040783546754E-10" STUDIES="3" TAU2="0.0" TOTAL_1="9816" TOTAL_2="9815" WEIGHT="74.49177491022215" Z="6.252516750998422">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="79" O_E="0.0" SE="0.0" STUDY_ID="STD-Duke-1983" TOTAL_1="35" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.668673353927917" CI_START="1.972700951369211" EFFECT_SIZE="2.690203601134397" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="41" LOG_CI_END="0.564509045388588" LOG_CI_START="0.29506125402371153" LOG_EFFECT_SIZE="0.4297851497061498" ORDER="80" O_E="39.50414201183432" SE="0.15827496643580677" STUDY_ID="STD-IST-1997" TOTAL_1="9717" TOTAL_2="9718" VAR="39.918621896992406" WEIGHT="74.49177491022215"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-Pambianco-1995" TOTAL_1="64" TOTAL_2="67" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="136" TOTAL_2="134" WEIGHT="0.0" Z="0.0">
<NAME>Unfractionated heparin (intravenous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-CESG-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="83" O_E="0.0" SE="0.0" STUDY_ID="STD-Duke-1986" TOTAL_1="112" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2670647043760965" CI_END="3.215296278910109" CI_START="0.8012558564770704" DF="3" EFFECT_SIZE="1.6050778715643852" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="9" I2="8.174454090804339" ID="CMP-001.07.03" LOG_CI_END="0.5072209979032329" LOG_CI_START="-0.09622878315003111" LOG_EFFECT_SIZE="0.20549610737660093" MODIFIED="2008-05-02 14:36:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3522530530572362" P_Z="0.1819173088585455" STUDIES="6" TAU2="0.0" TOTAL_1="840" TOTAL_2="481" WEIGHT="14.851670670138878" Z="1.334874854766956">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="137" O_E="0.0" SE="0.0" STUDY_ID="STD-Chaudhary-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.2427434401649253" CI_START="8.093518181372383E-4" EFFECT_SIZE="0.051230072213984665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5109125894598041" LOG_CI_START="-3.0918626533419857" LOG_EFFECT_SIZE="-1.290475031941091" ORDER="84" O_E="-0.6634615384615384" SE="2.116288011646847" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="0.223280325443787" WEIGHT="0.41666137142106296"/>
<DICH_DATA CI_END="3.5415554814663177" CI_START="0.7833369348079806" EFFECT_SIZE="1.665602358098783" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="7" LOG_CI_END="0.5491940497786076" LOG_CI_START="-0.10605139572838941" LOG_EFFECT_SIZE="0.22157132702510907" ORDER="85" O_E="3.443864229765012" SE="0.3848944182080761" STUDY_ID="STD-FISS_x002d_bis-1998" TOTAL_1="516" TOTAL_2="250" VAR="6.750202074844485" WEIGHT="12.596490301077129"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="86" O_E="0.5" SE="2.0" STUDY_ID="STD-Prins-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="0.46652271152072633"/>
<DICH_DATA CI_END="19.03073462197957" CI_START="0.19680488679198588" EFFECT_SIZE="1.9352884986086736" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2794555531905474" LOG_CI_START="-0.70596412195933" LOG_EFFECT_SIZE="0.28674571561560863" ORDER="87" O_E="0.4854368932038835" SE="1.1662453451689336" STUDY_ID="STD-Sandset-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.7352248091243283" WEIGHT="1.3719962861199604"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="88" O_E="0.0" SE="0.0" STUDY_ID="STD-Vissinger-1995" TOTAL_1="20" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="286.4922465251166" CI_START="0.07010848344695701" DF="0" EFFECT_SIZE="4.481689070338065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="2.4571128729459137" LOG_CI_START="-1.1542294272361584" LOG_EFFECT_SIZE="0.6514417228548778" MODIFIED="2008-05-02 14:36:39 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4795001272643743" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="25" WEIGHT="0.41468685468509003" Z="0.7071067811865477">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="286.4922465251166" CI_START="0.07010848344695701" EFFECT_SIZE="4.481689070338065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4571128729459137" LOG_CI_START="-1.1542294272361584" LOG_EFFECT_SIZE="0.6514417228548778" ORDER="90" O_E="0.33333333333333337" SE="2.1213203435596424" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="0.2222222222222222" WEIGHT="0.41468685468509003"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.690426902699768" CI_START="0.9777434561024996" DF="0" EFFECT_SIZE="2.914962784471152" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.07.05" LOG_CI_END="0.9390411109633932" LOG_CI_START="-0.009775082037130631" LOG_EFFECT_SIZE="0.46463301446313127" NO="5" P_CHI2="1.0" P_Z="0.05491105745377877" STUDIES="1" TAU2="0.0" TOTAL_1="646" TOTAL_2="635" WEIGHT="6.007494785314151" Z="1.9195793265208592">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="8.690426902699768" CI_START="0.9777434561024996" EFFECT_SIZE="2.914962784471152" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9390411109633932" LOG_CI_START="-0.009775082037130631" LOG_EFFECT_SIZE="0.46463301446313127" ORDER="91" O_E="3.4441842310694772" SE="0.5573393284844107" STUDY_ID="STD-TOAST-1998" TOTAL_1="646" TOTAL_2="635" VAR="3.2192938505241746" WEIGHT="6.007494785314151"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.99829636932249" CI_START="0.36808804163420505" DF="0" EFFECT_SIZE="2.7801477997111146" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.07.06" LOG_CI_END="1.3221840610474695" LOG_CI_START="-0.4340482915906555" LOG_EFFECT_SIZE="0.44406788472840697" NO="6" P_CHI2="1.0" P_Z="0.3216055642270742" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="1.7534509910905882" Z="0.9911639077268505">
<NAME>Oral vitamin K antagonist versus control</NAME>
<DICH_DATA CI_END="20.99829636932249" CI_START="0.36808804163420505" EFFECT_SIZE="2.7801477997111146" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3221840610474695" LOG_CI_START="-0.4340482915906555" LOG_EFFECT_SIZE="0.44406788472840697" ORDER="92" O_E="0.9607843137254903" SE="1.031619577429987" STUDY_ID="STD-Marshall-1960" TOTAL_1="26" TOTAL_2="25" VAR="0.9396386005382544" WEIGHT="1.7534509910905882"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="372.3848896839504" CI_START="0.1466175227450357" DF="0" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.07.07" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" NO="7" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="69" WEIGHT="0.46652271152072633" Z="1.0">
<NAME>Thrombin inhibitor versus control</NAME>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="93" O_E="0.5" SE="2.0" STUDY_ID="STD-Tazaki-1992" TOTAL_1="69" TOTAL_2="69" VAR="0.25" WEIGHT="0.46652271152072633"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.351604585816848" CI_START="0.6976626720909652" DF="0" EFFECT_SIZE="4.60164987342468" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.07.08" LOG_CI_END="1.4821816556862448" LOG_CI_START="-0.15635451299418834" LOG_EFFECT_SIZE="0.6629135713460282" NO="8" P_CHI2="1.0" P_Z="0.11275937338747404" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="58" WEIGHT="2.0143990770284184" Z="1.5859115587877408">
<NAME>Direct thrombin inhibitor (intravenous) versus control</NAME>
<DICH_DATA CI_END="30.351604585816848" CI_START="0.6976626720909651" EFFECT_SIZE="4.60164987342468" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.4821816556862448" LOG_CI_START="-0.1563545129941884" LOG_EFFECT_SIZE="0.6629135713460282" ORDER="94" O_E="1.647727272727273" SE="0.9624842563677322" STUDY_ID="STD-ARGIS_x002d_1-2004" TOTAL_1="118" TOTAL_2="58" VAR="1.0794753541912632" WEIGHT="2.0143990770284184"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.190731051602114" CI_END="1.112344285364261" CI_START="0.8467791089970926" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9705204288724462" ESTIMABLE="YES" EVENTS_1="428" EVENTS_2="435" I2="31.310129130534655" I2_Q="39.54776276055453" ID="CMP-001.08" LOG_CI_END="0.04623922797634872" LOG_CI_START="-0.0722298650588631" LOG_EFFECT_SIZE="-0.01299531854125718" METHOD="PETO" MODIFIED="2008-05-02 14:36:57 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.17802017073532772" P_Q="0.1278380185166188" P_Z="0.6672017665929771" Q="9.925190983808555" RANDOM="NO" SCALE="279.5938417612857" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10866" TOTAL_2="10739" WEIGHT="100.0" Z="0.42999158102644225">
<NAME>Any recurrent stroke or symptomatic intracranial haemorrhage during treatment period or follow up (&gt; 1 month)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1076778422719291" CI_START="0.83558978049118" DF="0" EFFECT_SIZE="0.9620625162009718" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="411" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.044413468273655846" LOG_CI_START="-0.07800688020851801" LOG_EFFECT_SIZE="-0.016796705967431085" NO="1" P_CHI2="1.0" P_Z="0.5906913668920559" STUDIES="2" TAU2="0.0" TOTAL_1="9781" TOTAL_2="9785" WEIGHT="93.64894828018281" Z="0.5378344231697347">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="1.1076778422719291" CI_START="0.83558978049118" EFFECT_SIZE="0.9620625162009718" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="411" LOG_CI_END="0.044413468273655846" LOG_CI_START="-0.07800688020851801" LOG_EFFECT_SIZE="-0.016796705967431085" ORDER="95" O_E="-7.479238487265263" SE="0.0719103186889272" STUDY_ID="STD-IST-1997" TOTAL_1="9717" TOTAL_2="9718" VAR="193.38267932748192" WEIGHT="93.64894828018281"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="96" O_E="0.0" SE="0.0" STUDY_ID="STD-Pambianco-1995" TOTAL_1="64" TOTAL_2="67" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8541258271909828" CI_START="0.006719138093306579" DF="0" EFFECT_SIZE="0.11161598216770974" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.2681392034872502" LOG_CI_START="-2.1726864330961946" LOG_EFFECT_SIZE="-0.9522736148044723" NO="2" P_CHI2="1.0" P_Z="0.12618102108538956" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="0.23557902225440377" Z="1.5293365986249357">
<NAME>Unfractionated heparin (intravenous) versus control</NAME>
<DICH_DATA CI_END="1.8541258271909828" CI_START="0.006719138093306579" EFFECT_SIZE="0.11161598216770974" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2681392034872502" LOG_CI_START="-2.1726864330961946" LOG_EFFECT_SIZE="-0.9522736148044723" ORDER="97" O_E="-1.0666666666666667" SE="1.433753061210877" STUDY_ID="STD-CESG-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.4864646464646465" WEIGHT="0.23557902225440377"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2619036206579644" CI_START="0.12076523373407125" DF="0" EFFECT_SIZE="0.39037685087442087" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.10102618643361966" LOG_CI_START="-0.9180580737495292" LOG_EFFECT_SIZE="-0.4085159436579548" NO="3" P_CHI2="1.0" P_Z="0.11609795130024586" STUDIES="2" TAU2="0.0" TOTAL_1="227" TOTAL_2="135" WEIGHT="1.3514187476141346" Z="1.5713647398225707">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="1.2619036206579644" CI_START="0.12076523373407125" EFFECT_SIZE="0.39037685087442087" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.10102618643361966" LOG_CI_START="-0.9180580737495292" LOG_EFFECT_SIZE="-0.4085159436579548" ORDER="98" O_E="-2.625" SE="0.5986151389800269" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="2.790645096463023" WEIGHT="1.3514187476141346"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="99" O_E="0.0" SE="0.0" STUDY_ID="STD-Vissinger-1995" TOTAL_1="20" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="88.28427852519691" CI_START="0.23705427510122676" DF="0" EFFECT_SIZE="4.574731210533068" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="1.9458833722338111" LOG_CI_START="-0.6251522080896752" LOG_EFFECT_SIZE="0.6603655820720679" NO="4" P_CHI2="1.0" P_Z="0.31401840298416595" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="54" WEIGHT="0.2123214901570062" Z="1.0068260178089292">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="100" O_E="0.0" SE="0.0" STUDY_ID="STD-Cazzato-1989" TOTAL_1="28" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="88.28427852519684" CI_START="0.23705427510122687" EFFECT_SIZE="4.574731210533068" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9458833722338107" LOG_CI_START="-0.625152208089675" LOG_EFFECT_SIZE="0.6603655820720679" ORDER="101" O_E="0.6666666666666667" SE="1.5102390267133938" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="0.43843843843843844" WEIGHT="0.2123214901570062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0732788648930107" CI_START="0.6692128010439728" DF="0" EFFECT_SIZE="1.434112114712198" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="0.487601969299468" LOG_CI_START="-0.17443576022370774" LOG_EFFECT_SIZE="0.15658310453788007" NO="5" P_CHI2="1.0" P_Z="0.35385948321440586" STUDIES="1" TAU2="0.0" TOTAL_1="646" TOTAL_2="635" WEIGHT="3.2021719292451696" Z="0.9271291704258431">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="3.0732788648930107" CI_START="0.6692128010439728" EFFECT_SIZE="1.434112114712198" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.487601969299468" LOG_CI_START="-0.17443576022370774" LOG_EFFECT_SIZE="0.15658310453788007" ORDER="102" O_E="2.38407494145199" SE="0.38888423946152756" STUDY_ID="STD-TOAST-1998" TOTAL_1="646" TOTAL_2="635" VAR="6.612403008435302" WEIGHT="3.2021719292451696"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.26554006779356004" CI_END="4.879738165354201" CI_START="0.31530842085967936" DF="1" EFFECT_SIZE="1.2404122440247605" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.08.06" LOG_CI_END="0.6883965194632485" LOG_CI_START="-0.501264430507864" LOG_EFFECT_SIZE="0.09356604447769226" NO="6" P_CHI2="0.6063393930916237" P_Z="0.7578542686999704" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="0.9916620982644022" Z="0.3082997342336953">
<NAME>Oral vitamin K antagonist versus control</NAME>
<DICH_DATA CI_END="5.173777290350381" CI_START="0.17714573457209598" EFFECT_SIZE="0.9573466345120489" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7138077302070424" LOG_CI_START="-0.7516693004242487" LOG_EFFECT_SIZE="-0.01893078510860323" ORDER="103" O_E="-0.0588235294117645" SE="0.8608284620211167" STUDY_ID="STD-Marshall-1960" TOTAL_1="26" TOTAL_2="25" VAR="1.3494809688581313" WEIGHT="0.6535097863840923"/>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="104" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-NAT_x002d_COOP-1962" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="0.33815231188030986"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="74.40355305664032" CI_START="0.7786104381595896" DF="0" EFFECT_SIZE="7.611266848958917" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.08.07" LOG_CI_END="1.8715936752777114" LOG_CI_START="-0.108679778366734" LOG_EFFECT_SIZE="0.8814569484554887" NO="7" P_CHI2="1.0" P_Z="0.0810138306187798" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="69" WEIGHT="0.3578984322820798" Z="1.7448336437736531">
<NAME>Thrombin inhibitor versus stroke</NAME>
<DICH_DATA CI_END="74.40355305664032" CI_START="0.7786104381595896" EFFECT_SIZE="7.611266848958917" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8715936752777114" LOG_CI_START="-0.108679778366734" LOG_EFFECT_SIZE="0.8814569484554887" ORDER="105" O_E="1.5" SE="1.1632224291824356" STUDY_ID="STD-Tazaki-1992" TOTAL_1="69" TOTAL_2="69" VAR="0.739051094890511" WEIGHT="0.3578984322820798"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.165340417766588" CI_END="3.9905681670828894" CI_START="2.236070646029951" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.9871712939494435" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="42" I2="3.9694334960320443" I2_Q="3.9694334960321673" ID="CMP-001.09" LOG_CI_END="0.6010347338476784" LOG_CI_START="0.3494855204560239" LOG_EFFECT_SIZE="0.47526012715185106" METHOD="PETO" MODIFIED="2008-05-02 14:37:46 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.3840917157072148" P_Q="0.3840917157072141" P_Z="1.3011908007362144E-13" Q="4.165340417766593" RANDOM="NO" SCALE="489.7215368275362" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11255" TOTAL_2="11000" WEIGHT="100.00000000000001" Z="7.406047667143758">
<NAME>Major extracranial haemorrhage during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.151934129126429" CI_START="2.253498181697342" DF="0" EFFECT_SIZE="3.058819381806246" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="37" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.6182504547672227" LOG_CI_START="0.35285721198359743" LOG_EFFECT_SIZE="0.48555383337541" NO="1" P_CHI2="1.0" P_Z="7.4040863333549E-13" STUDIES="4" TAU2="0.0" TOTAL_1="9856" TOTAL_2="9855" WEIGHT="89.83926809275926" Z="7.171757773403898">
<NAME>Unfractionated heparin (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="106" O_E="0.0" SE="0.0" STUDY_ID="STD-Duke-1983" TOTAL_1="35" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.151934129126429" CI_START="2.253498181697342" EFFECT_SIZE="3.058819381806246" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="37" LOG_CI_END="0.6182504547672227" LOG_CI_START="0.35285721198359743" LOG_EFFECT_SIZE="0.48555383337541" ORDER="107" O_E="46.004270645742224" SE="0.15589330452884065" STUDY_ID="STD-IST-1997" TOTAL_1="9717" TOTAL_2="9718" VAR="41.14765348785199" WEIGHT="89.83926809275926"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="108" O_E="0.0" SE="0.0" STUDY_ID="STD-Pambianco-1995" TOTAL_1="64" TOTAL_2="67" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="109" O_E="0.0" SE="0.0" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Unfractionated heparin (intravenous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="110" O_E="0.0" SE="0.0" STUDY_ID="STD-CESG-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.05435409831097" CI_START="0.025421725883036952" DF="0" EFFECT_SIZE="0.4797679730194728" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.9568574749102153" LOG_CI_START="-1.594794968493436" LOG_EFFECT_SIZE="-0.31896874679161047" MODIFIED="2008-05-02 14:37:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6241270190357134" STUDIES="5" TAU2="0.0" TOTAL_1="319" TOTAL_2="216" WEIGHT="0.971858166079099" Z="0.4900097248914678">
<NAME>Low-molecular-weight heparin versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="140" O_E="0.0" SE="0.0" STUDY_ID="STD-Chaudhary-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="111" O_E="0.0" SE="0.0" STUDY_ID="STD-Elias-1990" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.054354098310963" CI_START="0.025421725883036952" EFFECT_SIZE="0.4797679730194728" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9568574749102149" LOG_CI_START="-1.594794968493436" LOG_EFFECT_SIZE="-0.31896874679161047" ORDER="112" O_E="-0.32692307692307687" SE="1.4988532761386077" STUDY_ID="STD-FISS-1995" TOTAL_1="207" TOTAL_2="105" VAR="0.4451247645503149" WEIGHT="0.971858166079099"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="113" O_E="0.0" SE="0.0" STUDY_ID="STD-Prins-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandset-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="386.1576267412401" CI_START="0.15185683543512074" DF="0" EFFECT_SIZE="7.657719972423989" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="2.586764616719195" LOG_CI_START="-0.8185656546845261" LOG_EFFECT_SIZE="0.8840994810173343" MODIFIED="2008-05-02 14:37:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3088203287788863" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="54" WEIGHT="0.5456666973697707" Z="1.017700489198215">
<NAME>Heparinoid (subcutaneous) versus control</NAME>
<DICH_DATA CI_END="386.1576267412401" CI_START="0.15185683543512074" EFFECT_SIZE="7.657719972423989" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.586764616719195" LOG_CI_START="-0.8185656546845261" LOG_EFFECT_SIZE="0.8840994810173343" ORDER="139" O_E="0.5087719298245614" SE="2.0003078580792497" STUDY_ID="STD-Cazzato-1989" TOTAL_1="28" TOTAL_2="29" VAR="0.24992305324715297" WEIGHT="0.5456666973697707"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="117" O_E="0.0" SE="0.0" STUDY_ID="STD-Turpie-1987" TOTAL_1="50" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.14981593172131" CI_START="1.1951299183212893" DF="0" EFFECT_SIZE="3.306844230854081" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-001.09.05" LOG_CI_END="0.9614123573842839" LOG_CI_START="0.07741511845835021" LOG_EFFECT_SIZE="0.519413737921317" NO="5" P_CHI2="1.0" P_Z="0.021264921134532874" STUDIES="1" TAU2="0.0" TOTAL_1="646" TOTAL_2="635" WEIGHT="8.09737234559165" Z="2.303247509320342">
<NAME>Heparinoid (intravenous) versus control</NAME>
<DICH_DATA CI_END="9.14981593172131" CI_START="1.1951299183212893" EFFECT_SIZE="3.306844230854081" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.9614123573842839" LOG_CI_START="0.07741511845835021" LOG_EFFECT_SIZE="0.519413737921317" ORDER="118" O_E="4.43559718969555" SE="0.519264354001999" STUDY_ID="STD-TOAST-1998" TOTAL_1="646" TOTAL_2="635" VAR="3.708710884582266" WEIGHT="8.09737234559165"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.820467167072353" CI_START="0.0026853936013588454" DF="0" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.09.06" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" NO="6" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="0.5458346982002417" Z="1.0">
<NAME>Oral vitamin K antagonist versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="119" O_E="0.0" SE="0.0" STUDY_ID="STD-Marshall-1960" TOTAL_1="26" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="120" O_E="-0.5" SE="2.0" STUDY_ID="STD-NAT_x002d_COOP-1962" TOTAL_1="15" TOTAL_2="15" VAR="0.25" WEIGHT="0.5458346982002417"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="173" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Thrombin inhibitor versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="121" O_E="0.0" SE="0.0" STUDY_ID="STD-Tazaki-1986" TOTAL_1="104" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="122" O_E="0.0" SE="0.0" STUDY_ID="STD-Tazaki-1992" TOTAL_1="69" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Direct thrombin inhibitor (intravenous) versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="123" O_E="0.0" SE="0.0" STUDY_ID="STD-ARGIS_x002d_1-2004" TOTAL_1="118" TOTAL_2="58" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.166685349252115" CI_END="1.0418734772079234" CI_START="0.9336650188148081" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9862863781377016" ESTIMABLE="YES" EVENTS_1="6713" EVENTS_2="6511" I2="29.411857795458708" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.0178149824119805" LOG_CI_START="-0.029808912394059993" LOG_EFFECT_SIZE="-0.005996964991039773" METHOD="PETO" NO="10" P_CHI2="0.16552358317472438" P_Q="0.9167257456941139" P_Z="0.6215810443580048" Q="0.17389394246909762" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11272" TOTAL_2="10855" WEIGHT="100.0" Z="0.4936108416523163">
<NAME>Subgroup analysis by anticoagulant dose: effect on death or dependency</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3507585254214207" CI_END="1.2021741671944663" CI_START="0.7462408641562415" DF="1" EFFECT_SIZE="0.9471596958240509" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="197" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.07996739143709455" LOG_CI_START="-0.12712097267439185" LOG_EFFECT_SIZE="-0.023576790618648605" NO="1" P_CHI2="0.5536842691359339" P_Z="0.6553952613521967" STUDIES="2" TAU2="0.0" TOTAL_1="727" TOTAL_2="682" WEIGHT="5.288572052733825" Z="0.44627964185101276">
<NAME>Adjusted full-dose intravenous anticoagulant</NAME>
<DICH_DATA CI_END="2.481144517363475" CI_START="0.5551874583340274" EFFECT_SIZE="1.1736695950540914" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="30" LOG_CI_END="0.39465206103383893" LOG_CI_START="-0.25556035314010095" LOG_EFFECT_SIZE="0.069545853946869" ORDER="124" O_E="1.0977443609022544" SE="0.3819379906891314" STUDY_ID="STD-ARGIS_x002d_1-2004" TOTAL_1="86" TOTAL_2="47" VAR="6.855107694047147" WEIGHT="0.5364624226167074"/>
<DICH_DATA CI_END="1.188893933500891" CI_START="0.7189160902692477" EFFECT_SIZE="0.9245079655780623" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="167" LOG_CI_END="0.075143111010611" LOG_CI_START="-0.1433217962090982" LOG_EFFECT_SIZE="-0.034089342599243615" ORDER="125" O_E="-4.766457680250795" SE="0.12832736791958876" STUDY_ID="STD-TOAST-1998" TOTAL_1="641" TOTAL_2="635" VAR="60.72414751712538" WEIGHT="4.7521096301171175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.7925970111333065" CI_END="1.0631328883962863" CI_START="0.9066303274831626" DF="3" EFFECT_SIZE="0.9817680575191096" ESTIMABLE="YES" EVENTS_1="3232" EVENTS_2="3157" I2="55.83427082332584" ID="CMP-001.10.02" LOG_CI_END="0.026587553413333905" LOG_CI_START="-0.04256975754923254" LOG_EFFECT_SIZE="-0.00799110206794932" NO="2" P_CHI2="0.07881064158773232" P_Z="0.6505874492498817" STUDIES="4" TAU2="0.0" TOTAL_1="5268" TOTAL_2="5093" WEIGHT="47.42131839093973" Z="0.4529462476770359">
<NAME>Medium fixed-dose anticoagulant</NAME>
<DICH_DATA CI_END="0.8227439213511052" CI_START="0.21859604521706483" EFFECT_SIZE="0.42408556617000237" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" LOG_CI_END="-0.08473531770381021" LOG_CI_START="-0.6603576994583308" LOG_EFFECT_SIZE="-0.3725465085810704" ORDER="126" O_E="-7.503184713375795" SE="0.33812343641934917" STUDY_ID="STD-FISS-1995" TOTAL_1="105" TOTAL_2="52" VAR="8.746805144224918" WEIGHT="0.6845016135781375"/>
<DICH_DATA CI_END="1.6769531768310129" CI_START="0.6985597112853124" EFFECT_SIZE="1.0823363280635367" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="71" LOG_CI_END="0.224520936590697" LOG_CI_START="-0.1557964654648016" LOG_EFFECT_SIZE="0.03436223556294773" ORDER="127" O_E="1.5853658536585442" SE="0.22340032456890227" STUDY_ID="STD-FISS_x002d_bis-1998" TOTAL_1="245" TOTAL_2="124" VAR="20.03698626593901" WEIGHT="1.5680410394569952"/>
<DICH_DATA CI_END="1.0787578364943857" CI_START="0.9154768499138406" EFFECT_SIZE="0.9937695034432029" ESTIMABLE="YES" EVENTS_1="3022" EVENTS_2="3031" LOG_CI_END="0.03292396360985472" LOG_CI_START="-0.03835263342868892" LOG_EFFECT_SIZE="-0.0027143349094171125" ORDER="128" O_E="-3.5654143077713343" SE="0.04186822592528615" STUDY_ID="STD-IST-1997" TOTAL_1="4856" TOTAL_2="4859" VAR="570.4674667049493" WEIGHT="44.643260597978305"/>
<DICH_DATA CI_END="1.662211862007727" CI_START="0.36621523871213424" EFFECT_SIZE="0.7802097883488138" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.22068637723202705" LOG_CI_START="-0.43626358807666127" LOG_EFFECT_SIZE="-0.10778860542231711" ORDER="129" O_E="-1.6666666666666679" SE="0.38589566157709865" STUDY_ID="STD-Kwiecinski-1995" TOTAL_1="62" TOTAL_2="58" VAR="6.715219421101776" WEIGHT="0.5255151399262971"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.849435870228291" CI_END="1.0779417511692484" CI_START="0.9190562836878532" DF="4" EFFECT_SIZE="0.9953336826720907" ESTIMABLE="YES" EVENTS_1="3264" EVENTS_2="3157" I2="41.60102998574859" ID="CMP-001.10.03" LOG_CI_END="0.032595293476645276" LOG_CI_START="-0.03665789128356716" LOG_EFFECT_SIZE="-0.0020312989034609306" NO="3" P_CHI2="0.14406215472608275" P_Z="0.90846310112905" STUDIES="5" TAU2="0.0" TOTAL_1="5277" TOTAL_2="5080" WEIGHT="47.290109556326435" Z="0.11497731711268384">
<NAME>Low fixed-dose anticoagulant</NAME>
<DICH_DATA CI_END="2.2737067523854777" CI_START="0.2900353343561051" EFFECT_SIZE="0.8120685304553157" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.3567344515420327" LOG_CI_START="-0.5375490897524744" LOG_EFFECT_SIZE="-0.09040731910522083" ORDER="130" O_E="-0.7543859649122808" SE="0.5253065789313169" STUDY_ID="STD-Cazzato-1989" TOTAL_1="28" TOTAL_2="29" VAR="3.623884272083718" WEIGHT="0.28359550610310863"/>
<DICH_DATA CI_END="0.8714612552421224" CI_START="0.03127611413365115" EFFECT_SIZE="0.16509367547549333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.05975191665335179" LOG_CI_START="-1.504787210699978" LOG_EFFECT_SIZE="-0.7822695636766649" ORDER="131" O_E="-2.5" SE="0.8488208847630565" STUDY_ID="STD-Chaudhary-2002" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827585" WEIGHT="0.10861577650050737"/>
<DICH_DATA CI_END="1.1827689892802595" CI_START="0.30805600589755366" EFFECT_SIZE="0.6036216453517578" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="34" LOG_CI_END="0.0728999293466267" LOG_CI_START="-0.5113703197297175" LOG_EFFECT_SIZE="-0.21923519519154536" ORDER="132" O_E="-4.285714285714285" SE="0.34320323649182205" STUDY_ID="STD-FISS-1995" TOTAL_1="102" TOTAL_2="52" VAR="8.489795918367346" WEIGHT="0.6643887578664576"/>
<DICH_DATA CI_END="1.5584488560736447" CI_START="0.6626680937918084" EFFECT_SIZE="1.0162353726998221" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="71" LOG_CI_END="0.19269255451824524" LOG_CI_START="-0.17870393935871004" LOG_EFFECT_SIZE="0.006994307579767585" ORDER="133" O_E="0.3383838383838338" SE="0.21816013894561823" STUDY_ID="STD-FISS_x002d_bis-1998" TOTAL_1="271" TOTAL_2="125" VAR="21.011119699746477" WEIGHT="1.6442741207120264"/>
<DICH_DATA CI_END="1.093943323005203" CI_START="0.9282715875867663" EFFECT_SIZE="1.0077085417798057" ESTIMABLE="YES" EVENTS_1="3041" EVENTS_2="3031" LOG_CI_END="0.038994821866043916" LOG_CI_START="-0.03232494217097229" LOG_EFFECT_SIZE="0.0033349398475358283" ORDER="134" O_E="4.375308641975153" SE="0.041893582433869" STUDY_ID="STD-IST-1997" TOTAL_1="4861" TOTAL_2="4859" VAR="569.7771134425285" WEIGHT="44.589235395144335"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-02-10 13:42:40 +0000" MODIFIED_BY="Hazel Fraser">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-02-10 13:42:40 +0000" MODIFIED_BY="Hazel Fraser" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for 2014 update</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAL4CAYAAADvSZayAABmCElEQVR42uydD0Rf7f//v8xtMjNj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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-11-19 17:49:31 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Death from all causes during the treatment period</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-11-19 17:49:44 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Death from all causes during final follow up</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-02-09 16:25:21 +0000" MODIFIED_BY="Hazel Fraser" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of deep vein thrombosis during follow-up showing asymmetry</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-02-18 12:42:04 +0000" MODIFIED_BY="Hazel Fraser">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-02-18 12:42:04 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2009-01-09 16:42:23 +0000" MODIFIED_BY="[Empty name]">Conclusions too weak</TITLE>
<DATE_SUBMITTED>
<DATE DAY="25" MONTH="6" YEAR="2007"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-01-09 16:43:02 +0000" MODIFIED_BY="[Empty name]">
<P>This review of anticoagulant trials, including over 22,000 patients with acute ischemic stroke, found no net benefit with the use of any anticoagulant. Consequently, the implications for practice and implications for research are too timid. The implication for practice should say that anticoagulants should be contraindicated in patients with acute ischemic stroke. The implications for research should say that further trials of anticoagulants in acute ischemic stroke would be unethical.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-02-18 12:42:04 +0000" MODIFIED_BY="Hazel Fraser">
<P>This comment was submitted before the 2008 update was performed. The wording of the <LINK TAG="CONCLUSIONS" TYPE="SECTION">Authors' conclusions</LINK> section has been modified to be more in keeping with this comment.<BR/>Note: the response to this feedback was delayed by a number of unavoidable administrative factors.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-02-18 12:41:42 +0000" MODIFIED_BY="Hazel Fraser">
<P>Commenter: David A Cundiff MD<BR/>Reply: Peter Sandercock</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-02-09 16:26:34 +0000" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2015-02-09 16:25:55 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2015-02-09 16:25:21 +0000" MODIFIED_BY="Hazel Fraser">Cochrane Library Databases (CENTRAL, CDSR, DARE, HTA)</TITLE>
<APPENDIX_BODY MODIFIED="2015-02-09 16:25:55 +0000" MODIFIED_BY="Hazel Fraser">
<P>#1 [mh ^"cerebrovascular disorders"] or [mh ^"basal ganglia cerebrovascular disease"] or [mh ^"brain ischemia"] or [mh "brain infarction"] or [mh ^"hypoxia-ischemia, brain"] or [mh ^"carotid artery diseases"] or [mh ^"carotid artery thrombosis"] or [mh ^"carotid artery, internal, dissection"] or [mh ^"intracranial arterial diseases"] or [mh ^"cerebral arterial diseases"] or [mh ^"infarction, anterior cerebral artery"] or [mh ^"infarction, middle cerebral artery"] or [mh ^"infarction, posterior cerebral artery"] or [mh "intracranial embolism and thrombosis"] or [mh stroke] or [mh ^"vertebral artery dissection"]<BR/>#2 isch*mi* near/5 (stroke* or apoplex* or cerebral next vasc* or cerebrovasc* or cva):ti,ab<BR/>#3 (brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle next cerebr* or mca* or "anterior circulation" or "basilar artery" or "vertebral artery") near/5 (isch*mi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*):ti,ab<BR/>#4 #1 or #2 or #3<BR/>#5 [mh anticoagulants]<BR/>#6 [mh "Blood coagulation factors"/AI,DE] or [mh "Blood coagulation"/AI,DE]<BR/>#7 (anticoagul* or antithromb*):ti,ab<BR/>#8 [mh ^Warfarin] or [mh ^4-hydroxycoumarins] or [mh ^acenocoumarol] or [mh ^coumarins] or [mh ^dicumarol] or [mh ^"ethyl biscoumacetate"] or [mh ^phenindione] or [mh ^phenprocoumon]<BR/>#9 [mh "Vitamin K"/AI]<BR/>#10 (warfarin* or coumadin* or coumarin* or cumarin* or phenprocoum* or phenprocum* or dicoumar* or dicumar* or acenocoumar* or acenocumar* or fluindione or phenindione or clorindione or diphenadione or "ethyl biscoumacetate"):ti,ab<BR/>#11 (Vitamin next K next antagonist* or VKA or VKAs or "antivitamin K"):ti,ab<BR/>#12 [mh antithrombins] or [mh ^"hirudin therapy"] or [mh ^thrombin/AI]<BR/>#13 ((direct* near/5 thrombin near/5 inhib*) or DTI or DTIs):ti,ab<BR/>#14 (argatroban or MD805 or "MD-805" or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin* or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil):ti,ab<BR/>#15 [mh ^"factor Xa"/AI]<BR/>#16 (("factor Xa" or "factor 10a" or fXa or "autoprothrombin c" or thrombokinase) near/5 inhib*):ti,ab<BR/>#17 (activated near/5 ("factor X" or "factor 10") near/5 inhib*):ti,ab<BR/>#18 xabans:ti,ab<BR/>#19 (antistasin or apixaban or betrixaban or "du 176b" or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or "ym 150" or ym150 or LY517717 or darexaban or edoxaban or SSR126517E or fidexaban or idrabiotaparinux or letaxaban or tanogitran or taxexaban):ti,ab<BR/>#20 [mh ^heparin] or [mh "heparin, low-molecular-weight"] or [mh ^heparinoids]<BR/>#21 (heparin* or lmwh* or enoxaparin* or glycosaminoglycan* or nadroparin* or mesoglycan* or tedelparin* or certoparin or tinzaparin or parnaparin or dalteparin or reviparin or fraxiparin* or danaparoid or lomoparan or "org 10172" or mesoglycan or pentosan next polysul* or sp54 or "sp-54" or cy222 or "cy-222" or cy216 or "cy-216" or dermatan next sul* or heparan next sul*):ti,ab<BR/>#22 {or #5-#21}<BR/>#23 #4 and #22<BR/>#24 atrial fibrillation:ti<BR/>#25 #23 not #24<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-02-09 16:26:16 +0000" MODIFIED_BY="Hazel Fraser" NO="2">
<TITLE MODIFIED="2015-02-09 16:25:21 +0000" MODIFIED_BY="Hazel Fraser">MEDLINE (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2015-02-09 16:26:16 +0000" MODIFIED_BY="Hazel Fraser">
<P>1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or brain ischemia/ or exp brain infarction/ or hypoxia-ischemia, brain/ or carotid artery diseases/ or carotid artery thrombosis/ or carotid artery, internal, dissection/ or intracranial arterial diseases/ or cerebral arterial diseases/ or infarction, anterior cerebral artery/ or infarction, middle cerebral artery/ or infarction, posterior cerebral artery/ or exp "intracranial embolism and thrombosis"/ or exp stroke/ or vertebral artery dissection/<BR/>2. (isch?emi$ adj5 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. exp anticoagulants/<BR/>6. exp Blood coagulation factors/ai, de or exp Blood coagulation/ai, de<BR/>7. (anticoagul$ or antithromb$).tw.<BR/>8. Warfarin/ or 4-hydroxycoumarins/ or acenocoumarol/ or coumarins/ or dicumarol/ or ethyl biscoumacetate/ or phenindione/ or phenprocoumon/<BR/>9. exp Vitamin K/ai<BR/>10. (warfarin$ or coumadin$ or coumarin$ or cumarin$ or phenprocoum$ or phenprocum$ or dicoumar$ or dicumar$ or acenocoumar$ or acenocumar$ or fluindione or phenindione or clorindione or diphenadione or ethyl biscoumacetate).tw,nm.<BR/>11. (Vitamin K antagonist$ or VKA or VKAs or antivitamin K).tw.<BR/>12. exp antithrombins/ or hirudin therapy/ or thrombin/ai<BR/>13. ((direct$ adj5 thrombin adj5 inhib$) or DTI$1).tw.<BR/>14. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil).tw,nm.<BR/>15. factor Xa/ai<BR/>16. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5 inhib$).tw.<BR/>17. (activated adj5 (factor X or factor 10) adj5 inhib$).tw.<BR/>18. xabans.tw.<BR/>19. (antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or ym 150 or ym150 or LY517717 or darexaban or edoxaban or SSR126517E or fidexaban or idrabiotaparinux or letaxaban or tanogitran or taxexaban).tw,nm.<BR/>20. heparin/ or exp heparin, low-molecular-weight/ or heparinoids/<BR/>21. (heparin$ or lmwh$ or enoxaparin$ or glycosaminoglycan$ or nadroparin$ or mesoglycan$ or tedelparin$ or certoparin or tinzaparin or parnaparin or dalteparin or reviparin or fraxiparin$ or danaparoid or lomoparan or org 10172 or mesoglycan or pentosan polysul$ or sp54 or sp-54 or cy222 or cy-222 or cy216 or cy-216 or dermatan sul$ or heparan sul$).tw,nm.<BR/>22. or/5-21<BR/>23. Randomized Controlled Trials as Topic/<BR/>24. random allocation/<BR/>25. Controlled Clinical Trials as Topic/<BR/>26. control groups/<BR/>27. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/<BR/>28. double-blind method/<BR/>29. single-blind method/<BR/>30. Placebos/<BR/>31. placebo effect/<BR/>32. Research Design/<BR/>33. randomized controlled trial.pt.<BR/>34. controlled clinical trial.pt.<BR/>35. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.<BR/>36. (random$ or RCT or RCTs).tw.<BR/>37. (controlled adj5 (trial$ or stud$)).tw.<BR/>38. (clinical$ adj5 trial$).tw.<BR/>39. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>40. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>41. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.<BR/>42. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>43. (placebo$ or sham).tw.<BR/>44. trial.ti.<BR/>45. (assign$ or allocat$).tw.<BR/>46. controls.tw.<BR/>47. or/23-46<BR/>48. 4 and 22 and 47<BR/>49. exp animals/ not humans.sh.<BR/>50. 48 not 49<BR/>51. atrial fibrillation.ti.<BR/>52. 50 not 51<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-02-09 16:26:23 +0000" MODIFIED_BY="Hazel Fraser" NO="3">
<TITLE MODIFIED="2015-02-09 16:25:21 +0000" MODIFIED_BY="Hazel Fraser">EMBASE (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2015-02-09 16:26:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>1. brain infarction/ or brain stem infarction/ or cerebellum infarction/ or exp brain ischemia/ or carotid artery disease/ or exp carotid artery obstruction/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp occlusive cerebrovascular disease/ or stroke patient/<BR/>2. (isch?emi$ adj5 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. exp anticoagulant agent/<BR/>6. anticoagul$.tw.<BR/>7. antithromb$.tw.<BR/>8. coumarin derivative/ or 4 hydroxycoumarin/ or 4 hydroxycoumarin derivative/ or acenocoumarol/ or coumarin/ or dicoumarol/ or ethyl biscoumacetate/ or phenprocoumon/ or warfarin/ or phenindione/<BR/>9. antivitamin k/<BR/>10. (warfarin$ or coumadin$ or coumarin$ or cumarin$ or phenprocoum$ or phenprocum$ or dicoumar$ or dicumar$ or acenocoumar$ or acenocumar$ or fluindione or phenindione or clorindione or diphenadione or ethyl biscoumacetate).tw.<BR/>11. (Vitamin K antagonist$ or VKA or VKAs or antivitamin K).tw.<BR/>12. exp thrombin inhibitor/<BR/>13. ((direct$ adj5 thrombin adj5 inhib$) or DTI$1).tw.<BR/>14. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil).tw.<BR/>15. blood clotting factor 10a inhibitor/<BR/>16. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5 inhib$).tw.<BR/>17. (activated adj5 (factor X or factor 10) adj5 inhib$).tw.<BR/>18. xabans.tw.<BR/>19. (antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or ym 150 or ym150 or LY517717 or darexaban or edoxaban or SSR126517E or fidexaban or idrabiotaparinux or letaxaban or tanogitran or taxexaban).tw.<BR/>20. heparin derivative/ or heparin/ or heparinoid/ or exp low molecular weight heparin/<BR/>21. (heparin$ or lmwh$ or enoxaparin$ or glycosaminoglycan$ or nadroparin$ or mesoglycan$ or tedelparin$ or certoparin or tinzaparin or parnaparin or dalteparin or reviparin or fraxiparin$ or danaparoid or lomoparan or org 10172 or mesoglycan or pentosan polysul$ or sp54 or sp-54 or cy222 or cy-222 or cy216 or cy-216 or dermatan sul$ or heparan sul$).tw.<BR/>22. or/5-21<BR/>23. Randomized Controlled Trial/<BR/>24. Randomization/<BR/>25. Controlled Study/<BR/>26. control group/<BR/>27. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical trial/<BR/>28. Double Blind Procedure/<BR/>29. Single Blind Procedure/ or triple blind procedure/<BR/>30. placebo/<BR/>31. (random$ or RCT or RCTs).tw.<BR/>32. (controlled adj5 (trial$ or stud$)).tw.<BR/>33. (clinical$ adj5 trial$).tw.<BR/>34. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>35. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>36. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.<BR/>37. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>38. placebo$.tw.<BR/>39. trial.ti.<BR/>40. (assign$ or allocat$).tw.<BR/>41. controls.tw.<BR/>42. or/23-41<BR/>43. 4 and 22 and 42<BR/>44. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not (human/ or normal human/ or human cell/)<BR/>45. 43 not 44<BR/>46. (atrial fibrillation or myocardial or coronary or cardiac or heart or renal or subarachnoid or arteritis or hypertens$ or aortic or cancer or pregnan$ or dementia or diabetes or sickle cell or aneurysm$ or cardiopulmonary or migrain$).ti.<BR/>47. 45 not 46<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2015-02-09 16:26:34 +0000" MODIFIED_BY="Hazel Fraser" NO="4">
<TITLE MODIFIED="2014-11-20 10:52:47 +0000" MODIFIED_BY="Hazel Fraser">Ongoing trials registries search</TITLE>
<APPENDIX_BODY MODIFIED="2015-02-09 16:26:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>ClinicalTrials.gov<BR/>"stroke" AND "anticoagulants"<BR/>"stroke" AND "heparin"<BR/>
<BR/>Internet Stroke Center Stroke Trials Registry<BR/>"stroke" AND "anticoagulants"<BR/>"stroke" AND "heparin"<BR/>
<BR/>ISRCTN Registry<BR/>"stroke" AND "anticoagulants"<BR/>"stroke" AND "heparin"<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;24 studies included in this review&lt;/p&gt;" WIDTH="220">
<FLOWCHARTBOX TEXT="&lt;p&gt;24 studies included&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified in previous versions of this review&lt;/p&gt;"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8913 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8913 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;9041 records identified through database searching in 2014 update&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;8907 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>